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Abstract 
This thesis describes the development of new pathways towards the synthesis of novel 
antimicrobial (and anticancer) agents. Two synthetic protocols based on free radical chemistry 
are studied, which are used to access polycyclic heterocyclic compounds of potential biological 
importance. Both these procedures involve the generation of radicals using BU3SnH and AmN 
initiators, and the subsequent intramolecular radical cyclisation onto the imidazole ring. Radical 
cyclisations onto benzimidazoles and pyrroles are also described. 
Chapter One provides a general introduction to the research. It includes a description of the 
initial aims and objectives of the work, and a review of the literature in the areas of 
"bioreductive antimicrobial and anticancer agents," and "homolytic aromatic substitution 
reactions." The former outlines the current understanding of this biological activity, while the 
latter review's the basis of the free radical methodology used in this project. 
Chapter Two describes the possibility of incorporating various ring systems onto 
nitroimidazoles by adapting synthetic procedures, which had already been used to synthesise 
mitomycin analogues. It describes the synthetic problems, and limitations of using 
nitroimidazole substrates with this methodology. 
Chapter Three describes the first reported radical cyclisations onto irnidazoles and 
benzimidazoles using" ipso" substitution at the C-2 position. This provides a new synthetic route 
to biologically important [1,2-a]fused benzimidazoles and imidazoles, and the potential 
synthesis of the targets given in Chapter Two. A mechanistic investigation into these 
intramolecular radical cyclisations using isotopic labelling studies is also described. 
Chapter Four describes "oxidative radical cyclisations onto imidazoles and pyrroles using 
BU3SnH." The mechanism for such a transformation has been the subject of a great deal of 
literature speculation. A "pseudo SRN 1 mechanism" is offered in this section. This synthetic 
protocol yielded a series of novel five, six and seven membered [l,2-c]fused imidazoles, which 
may be elaborated further to form new antimicrobial (and anticancer) agents. A description of 
the versatility and limitations of this methodology to access polycyclic heterocyclic systems is 
given. 
Chapter Five provides a detailed description of all the experiments performed. All novel 
compounds reported in this chapter are fully characterised by IR, lH and 13C NMR, mass 
spectra and combustion analysis or accurate mass. 
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1.0 General Introduction 
1.1 Aims and Objectives of the Project 
The long tenn aim of this research is the synthesis of novel antimicrobial (and anticancer) agents 
containing the combined structural features of mitomycins and nitroirnidazoles necessary for 
biological activity. This objective can only be achieved by the development of new synthetic 
methodology to access such polycyclic heterocyclic systems. Thus, two synthetic protocols 
based on free radical chemistry had to be developed, which involved radical cyclisations onto 
several nitrogen containing heteroaromatic systems (imidazoles, benzimidazoles and pyrroles). 
The first synthetic protocol was an intramolecular aromatic "ipso-substitution" pathway, and the 
second involved "oxidative radical cyclisations" using BU3SnH. An understanding of the 
versatility and limitations of the two reaction protocols was essential. An assessment of the 
advantages of the two developed radical pathways against conventional syntheses of such 
heterocyclic systems, and an understanding of the mechanisms of these two radical protocols had 
also to be achieved. 
1.2 Bioreductive Antimicrobial and Anticancer Agents 
Bioreductive agents are compounds that require in vivo reduction in order to induce biological 
activity. 1 This may be antibiotic activity, which is the treatment of disease caused by micro-
organisms. The most widely used bioreductive antibiotics are nitroimidazoles, which are 
discussed in section 1.2.1. However, the tenn "bioreductive" was first applied to quinone 
compounds such as the anticancer drug mitomycin C, and so mitomycins are the subject of 
section 1.2.2. 
1.2.1 Nitroimidazoles 
Nitroimidazoles are antibiotics used clinically for treatment against anaerobic (without oxygen) 
bacteria, protozoal infection and in anticancer chemotherapy. 1,2 The specific mechanisms for 
these biological activities have not been clearly proven, nevertheless nitroimidazoles are an 
important group of antimicrobial and anticancer agents, which require reductive activation in 
vivo prior to reaction between the drugs and DNA (scheme 1). The initial stage in reductive 
acti vation often proceeds by a discrete one-electron transfer process that can be reversed by 
oxygen. This implies, that bioreductive drugs should be less potent in oxygenated cells. This is 
often the case and is the basis for the selectivity observed in experimental tumours. 
1 
-e 
Scheme 1. Reductive activation and oxidative deactivation 
There are three possible isomeric structures with the nitro group at C-2 (1), C-4 (2) or C-S (3) in 
the heterocyc1ic ring (figure 1). However, only 2- and 5-nitroimidazoles are biologically active. 
R2 3 XN}-N0 2 02NXN R N I }-R2 XN}--R2 3 N 3 N 
R 1 R 1 02 N 11 RI RI R 
2-Nitro (1) 4-Nitro (2) 5-Nitro (3) 
Figure 1 . Nitroimidazole structural isomers 
The antibiotic azomycin (4) was the first nitroimidazole which was reported to be active against 
T. vagina lis. 3 Nevertheless, the greatest advance in the chemotherapy of protozoan infections was 
made in about 1960 with the introduction of metronidazole (5).2,4 The latter was the first orally 
effective treatment of trichomoniasis and at higher dosage levels it proved to be most efficacious 
and tolerated treatment of amoebiasis. Metronidazole is still the market leader among 
nitroimidazole antibiotics because of its effectiveness, short duration of therapy, and low 
toxicity. However, several other S-nitroimidazole analogues are commercially available 
(figure 2), the leading ones being tinidazole (6), ornidazole (7), nimorazole (8), and 
dimetridazole (9) .1,2 There are less 2-nitroimidazoles in production, but misonidazole (10) is 
used as a substitute for metronidazole. Generally, S-nitroimidazoles possess greater therapeutic 
advantage over 2-nitroimidazoles. 
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Figure 2. The market leading nitroimidazole antibiotics 
2 
The in vivo reduction of nitroimidazoles does not require a nitroreductase enzyme, but is 
achieved by ferredoxin oxireductase (an Fe-S-protein acting as an electron transfer agent), which 
has a reduction potential of around -430 mY. This should be compared to the lowest reduction 
potential discovered in aerobic cells at -350 mY. Therefore, aerobic cells clearly possess 
insufficient reduction potential, and this would explain the lack of activity towards aerobes. 
Furthermore, the inactivity of 4-nitroimidazoles is explained, since it has a higher reduction 
potential than 2- or 5-nitroimidazoles. Therefore, nitroimidazoles act as electron acceptors from 
ferridoxin oxireductase, so interfering with the metabolic pathways of anaerobes without 
affecting the human host. 
These bioreductive drugs can function as either hypoxic (oxygen depleted) cell radiation 
sensitizers or as hypoxic-cytotoxins. Most biologically active nitroimidazoles exhibit both types 
of behaviour to varying degrees. 
a) Radiosensitization 
This represents an increase in the efficiency of radiation-induced DNA damage. This 
sensitisation is usually not observed in oxygenated cells, so this is the basis for tumour 
selectivity. It was suggested that a redox process was involved in which the efficiency of 
mammalian cell radiosensitization increases with the electron affinic properties of the nitro 
compounds used.5 Therefore, there is a clear dependence between the efficiency of sensitisation 
and one-electron reduction potentials. 
b) Hypoxic Cytotoxicity 
A vast array of compounds have been used to kill hypoxic mammalian cells. However, despite 
the efficiency of these hypoxic cytotoxins being directly related to the electron affinities of the 
compounds, the mechanisms involved are quite different from those of radiosensitization. 1,6 
This is because the critical step in hypoxic toxicity is enzyme-mediated reductive activation. 
This explains the process being much slower, highly temperature-dependent, and showing a 
much greater cell-line variability than is observed in hypoxic cell radiosensitization. 
The only defined part of the mode of action of nitroimidazoles is the requirement that the 
nitroimidazole is reduced prior to any observable activity. The initial nitro radical anion (12) 
formed undergoes a reduction sequence (scheme 2) similar to that observed in many other 
aromatic nitro compounds. This consists of a series of single electron transfer (SET), protonation 
and dehydration reactions. There is no clear evidence published to date to which of the possible 
reduced species is the reactive intermediate in the mode of action of nitroimidazoles, although 
several proposals have been put forward. For instance, the nitro radical anion (12) is a likely 
reactive intermediate, since it is well known that many electrophiles and radicals readily react 
with DNA. Studies using electron paramagnetic resonance (EPR) spectroscopy have detected the 
presence of nitro radical anions in protozoal and anaerobic bacterial cells),7 This suggests that 
they are relatively stable, and may survive long enough to react with some intracellular species. 
Furthermore, EPR spectroscopy work by Bowman and Symons 8 has suggested that the nitro 
radical anion is more stable than might otherwise have been expected (scheme 3). 
3 
-. X-N02 .. X-N02 • X-NO • X-NHOH • X-NH2 
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- H+ R-N-OH + • R-NHOH .. (14) 
R-NHOH + 2H+ + 2e- • R-NH2 + H2 O (14) (15) 
Overall 
+ 
-R-N02 + 6H + 6e • R-NH2 + 2H20 
(11) (15) 
Scheme 2. Nitroimidazole reduction sequence 
-"~}-R2 • -~:X}-R2 - J:>=-- 2 .·~~}-R2 ,,+ . R
• N::-- N .. • N=-- N • 
rf 11 rf 11 rf 11 rf 1 1 
- R - R - R - R 
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Scheme 3. EPR spectroscopic evidence for the resonance stabilized 5-nitroimidazole radical anion 
There have been only a few reports in the literature9 claiming that the nitroso derivative (13) is 
the reactive intermediate, probably because it has never been isolated in reduction studies. This 
is due to the fact that the nitroso species is rapidly reduced to the hydroxyl amino compound (14) 
in reduction studies, and this reactivity has led to it not being considered as a serious reactive 
intermediate. Nevertheless, it has been shown that hydroxyl amino derivatives require oxidation 
prior to becoming active, which supports the case for the nitroso species (13) being the reactive 
4 
intermediate. 9 Furthermore, nitroso analogues of 4- and 5-nitroimidazoles have been synthesised 
and proved to have a much greater biological activity against a number of anaerobic micro-
organisms. These results provide further evidence for the reductive potential being the primary 
factor in determining the activity of nitroimidazoles, and suggests that the nitroso species is the 
reactive intermediate. There is however good evidence to eliminate the amino derivative (15) 
from suspicion of being an active intermediate, since Sullivan et al lO have prepared the amine. 
derivative of metronidazole (5, figure 2), and found it to be biologically inactive. 
1.2.2 Mitomycins 
Mitomycins, I,ll exemplified by mitomycin C (16a) and A (16b in figure 3) are a class of potent 
anti-tumour antibiotics. These bioreductive drugs are useful as chemotherapeutic agents for the 
treatment of various tumours. Once reductive activation has taken place, mitomycin reacts 
covalently with DNA, so exerting its cytotoxic action. Therefore, like nitroimidazoles, these 
compounds are selectively toxic to hypoxic cells because the oxygen in aerobic cells oxidises the 
reductively activated intermediates back to the neutral drugs, before they are able to react with 
DNA. There has been intense research into the synthesis of mitomycin analogues and other 
structurally related compounds as part of the quest for new therapeutically useful drug 
formulations with improved tumour specificity and cytoxicity. 
o 
x = NH2 , Mitomycin C (16a) 
X = OCH3, Mitomycin A (16b) 
Figure 3. Mitomycins 
The proposed mechanism for mitomycin antitumour activity is shown in scheme 4. Activation 
occurs at the quinone group in a single electron reduction process, and subsequent loss of 
methanol, and opening of the aziridine ring provides electrophilic species (19). It is particularly 
noteworthy that all these steps occur at the radical anion stage, and that the intennediate 
aziridinomitosene semiquinone (17) can be reoxidised on exposure to air to aziridinomitosene 
(18). Isolation of mono DNA adducts such as (21) proved that nucleophilic moieties in DNA 
firstly alkylate position 1 in the electrophilic species (19), prior to the alkylation of position 10 to 
give the cross-linked DNA adduct (22). The latter occurs at the iminium species (20), which is 
formed by virtue of the push of the indole nitrogen electron pair causing the loss of the urethane 
group (OCONH2). 
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Scheme 4. Proposed mechanism for the activation-alkylation cascade of the mitomycins 
6 
1.3 Homolytic Aromatic Substitution 
Homolytic aromatic substitution is an addition-elimination reaction, which can be represented by 
the general reaction given in scheme 5. The mechanism is based on studies performed by Hey et 
al12 in the 1930s on arylation (Rad - = Ar -, and various X) reactions. The synthetic interest of 
these reactions was however limited until the extensive work of the last twenty five years 
improved the reactivity and regioselectivity of these processes. 
Summary: 
• Rad- + x-< ) [- H-] 
Scheme 5. Homolytic aromatic substitution 
A general mechanism for the addition of a radical to an aromatic system is given in scheme 6, 
which probably proceeds via several transition states and intermediates with reactivity and 
regioselectivity being determined by polar effects in the radical and substrate. 13 
+0 OH Rad - , ( . i\:- x-i~-- Rad 
ArH ArHRad -
OH [- H - ] Q-Rad , ( . • x-i~-- Rad xy-
ArHRad- ArRad 
Scheme 6. Radical addition followed by substitution 
Unlike, aromatic electrophilic substitution, which proceeds via a rapid extrusion of a proton to 
regain aromaticity, the expulsion of a hydrogen atom from a cycIohexadienyl radical requires the 
participation of a new reactant. Scheme 7 shows the two possible elimination processes; 
disproportionation or oxidation, where the oxidant can be e.g. oxygen, a nitro derivative, a 
peroxide or a metal salt. A good oxidant wiII enhance the yield of the substitution product. 
Oxidative radical cycIisations are the subject of section 1.3.2. 
The two synthetic protocols used in this project are aromatic homolytic substitution 
(ipso-substitution), which is the subject of the next section, and 'oxidative radical cyclisations' 
using BU3SnH, which is reviewed for the first time in section 1.3.3. The latter may proceed via a 
"pseudo SRN I mechanism" consequently the mechanism of SRN I reactions is briefly discussed 
in section 1.3.4. 
7 
l:- + (:-~'H ====='~ 0-' Rad + L-H x-'\~-- Rad x/(-
disproportionation with a radical of the medium 
(. .' Or-- "H x-'\~-- Rad 
or by oxidation 
oxidant 
• 0-, Rad + W Xy -
Scheme 7. Elimination 
1.3.1 Aromatic Homolytic 'ipso-Substitution' 
'Ipso-substitution' is substitution at a position already carrying a substituent. In the 1970s, Tiecco 
et al 14 extensively studied intermolecular aromatic ipso-substitution reactions, and provided the 
following conclusions; 
1. Electroneutral radicals only give selective ipso attack in those cases in which addition affords 
a a-complex intermediate of considerably greater stability than those derived from the addition 
at un substituted positions. 2. Ipso attack is particularly facilitated by polar effects that can 
intervene and stabilise the transition state of the addition. 3. Many examples have been reported 
of nucleophilic radicals easily undergoing ipso-substitution onto aromatic compounds containing 
electron withdrawing groups. 4. Fewer literature examples exist of polar effects facilitating the 
addition of electrophilic radicals at the ipso position of aromatic compounds holding electron-
releasing substituents. 
For example, the nucleophilic l-adamantyl (Ad -) radical reacts with several2-substituted 
benzothiazoles (23) to afford 2-(1-adamantyl)-benzothiazole (24), as a result of homolytic ipso-
substitution (scheme 8))5 The greatest yields were obtained with the strongest electron 
withdrawing leaving groups i.e. nitro (X= N02) and phenylsulfonyl (X = PhS02). The 
l-adamantyl radical was generated via a redox reaction with silver nitrate in a solution of 
aqueous ammonia and ammonium sulfate in acetonitrile. 
(]C}-X + Ad-
23 
X = N02, S02Ph, SOPh, COMe, F, Cl, Br, I, SMe, OMe 
• (]Cl }-Ad + X-~ S 
24 
Scheme 8./pso-substitution in 2·substituted benzothiazole 
Therefore, on the basis of these results an addition-elimination sequence was proposed 
(scheme 9) in which radical anion (25) may be formed by the transfer of an electron from the 
8 
adamantyl radical to the benzothiazole, and this may play an important role in determining the 
ease of formation of the a-complex intermediate (26) .15 The subsequent formation of substituted 
benzothiazole (24) will be thus greatly facilitated by the superior leaving group ability of e.g. the 
PhS02 group. 
(JC)-X + Ad- [ (JC)-' F An' 
23 25 
x- + (JCI }-Ad _.---
~ S 
24 
Scheme 9. Tiecco et at, 'addition-elimination' mechanism 
Watanabe et al l6 reacted electron deficient 2-(alkylsulfonyl)benzothiazoles (27) directly with 
BU3Sn - to give 2-(tributylstannyl)benzothiazole (28) in 67-79% yield (scheme 10). This 
synthetic methodology is important in overcoming the steric factors in carbon-tin bond 
formation between a bulky tin atom and a sterically hindered internal carbon atom. 
2 BU3SnH, AIBN, reflux 
• (JCI }-snBU3 + BU3SnOSOR ~ S 
28 
Scheme 10. Intermolecular 'ipso-substitution' using Bu 3Sn • 
Intramolecular ipso-substitution reactions have received greater attention in the last fifteen years. 
For example, ipso-substitution reactions were proposed for the formation of unexpected 
productsI7,18,19 such as the phenanthrene (31) via the postulated spiro intermediate (30) instead 
of the 'oxidative biaryl coupling reaction product' (29) in scheme 1117 (also see scheme 44 in 
section 1.3.3).19 
The synthetic utility of intramolecular ipso-substitution reactions was first demonstrated by 
Speckamp et a120 (scheme 12), when a 1,4-aryl rearrangement was observed to quantitatively 
give the phenanthridine analogue (32). 
9 
OH 
MeO 
o -----x------ MeO 
MeO 
MeO OMe 
OMe 
o OH 
OMe OMe 
30 31 
Scheme 11. Unexpected ipso-substitution product. 
MeO MeO 
32 
Scheme 12. 1 A-aryl rearrangement 
A further example from Speckamp et a121 is illustrated in scheme 13, which can be adapted to 
the aryl shift depicted in scheme 12. The a-halomethyl substituted piperidine sulfonamides (33) 
gave a mixture of the 1,6-addition products (35), the ipso-substitution, desulfonylation products 
(36), and the reduction compounds (34). Furthermore, it was found that if the ortho positions 
were blocked, as in compound (33e) the 'ipso-attack product' (36e) was the only compound 
obtained, and the 1,6-adduct (35e) and reduction compound (34e) were not formed. The absence 
of the latter may be due to an interaction of the radical intermediate with the aromatic substituent 
in such a way that steric factors prevent effective hydrogen transfer by the bulky tributyl tin 
hydride molecule. 
10 
~CH3 
I 
B~ 
O2 
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Scheme 13. Intramolecular radical reactions 01 o:-iodomethyl substituted piperidine sullonamides 
This methodology has been extended by Motherwell et aZ22,23 in the area of biaryl couplings 
(scheme 14) in which competition is observed between [1,5] ipso-substitution and [1,6]addition 
of aryl radicals (37). When X = 0 or CH2 only the direct addition products (39) were observed, 
and a mixture of (39) and (41) were obtained when X = NCH3. These results may be compared 
to the decarboxylation of carbamoyloxyl radicals (R2NC02 .) which are known to be faster than 
the analogous oxygen case (ROC02 .). Given the possibility of the interconversion of radical 
intermediates (38) and (40), and a similar rate difference for the extrusion of sulfur dioxide, the 
mechanisms shown in scheme 14 provide a reasonable explanation. 
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X 
• 
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• • 
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Scheme 14. Ipso-substitution route to biaryl couplings 
Attention was then shifted to the effect of incorporation of substituents on the aromatic acceptor 
ring,22,23 which proved that this strategy is of great synthetic value, since it encourages the 
formation of sterically congested products with both electron releasing and I or electron 
withdrawing groups sited either ortha and/or para to the sulfonyl substituted acceptor ring. 
These are both beneficial, and tolerant to the synthetic process. The formation of such molecules 
could prove difficult by non- radical metal mediated methods. Some of the results are shown in 
scheme 15. Particularly noteworthy was the location of methoxy substituent at the otho position 
in biaryl compound (42), which yielded solely the ipso-substitution product (43). In contrast 
sulfonamide (44) with a meta carbomethoxy group yielded a mixture of the [1,5] ipso-
substitution product (45), and [1,6]addition products (46) and (47). In the latter, there are two 
possible sites for [1,6]attack, but only one set of the possible rearomatised regioisomeric 
products was recovered. The dihydroaromatic compound (47) was isolated from the second set, 
since rearomatisation would lead to the introduction of a severe peri interaction from the 
carbomethoxy group. The formation of 'oxidative radical cyclisation' products using the 
reductive conditions of BU3SnH mediated reactions is the subject of section 1.3.3. 
Furthermore, this strategy was extended to the synthesis of heterobiaryls by appropriate 
positioning of the heteroatom. 23 A couple of representative examples are shown in scheme 16, 
and serve to reinforce the previously established reactivity pattern, i.e. hetero atoms positioned 
ortho and/or para to the sulfonyl group yield largely or selectively the [1,5] ipso-substitution 
product. 
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Scheme 15.The influence of substituents on ipso-substitution during biaryl coupling 
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Scheme 16. Heterobiaryl couplings 
13 
Grimshaw etaZ24 have carried out radical hiaryl couplings electrochemically. The reduction of 
compounds (48) and (49), as shown in scheme 17 occurs at a mercury cathode in aprotic 
solvents and can lead to the formation of compounds (51), (52) and (53). The intermediate 0'-
radical (50) is derived from the radical anions (48) or (49). In the case of the amide (49), a halide 
anion is lost to give syn and anti radicals of (50). The formation of carbanions was considered 
unlikely, since nucleophilic substitution on an unactivated benzene ring is highly improbable. 
There was however, a considerable quantity of reduced amide (51) observed in these processes, 
which may be due to the rotation about the amide bonds adjoining the two benzene rings during 
radical cyclisation to give the anti amide. The cis conformation of the amide would give the 
greatest access to the [1 ,6] addition product (53). It is however particularly noteworthy, that these 
electrochemical biaryl coupling experiments give relatively large quantities of products formed 
as a consequence of ipso-substitution, such as the biaryl (52), when there are substituents ortho 
or para in the starting compound. Such findings are in agreement with the biaryl couplings of 
Motherwell et a1.22•23 
OMe 
OMe 
OMe 
o 
[ -Ho] 
• CONHMe 
53 
52 OMe OMe 
OMe 
Scheme 17. Electrochemical biaryl couplings 
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More recent work by Lee at al on radical isomerisations by intramolecular ipso-substitution of 
aryl ethers25 and N-arylamides26, also proposed that the efficiency of ipso attack was greatly 
dependent upon the stability of the intermediate spiro cycIohexadienyl radical. The 
3-aryloxypropyl radicals (54) can abstract hydrogen from BU3SnH to form aryl propyl ethers 
(55), or attack ortho or ipso aryl positions intramolecularIy to form the fused (56) or spiro (57) 
cycIohexadienyl radicals (scheme IS). In agreement with the findings of MotherweII22.23 and 
Grimshaw24 both electron-withdrawing and -donating substituents on the aryl ring facilitate the 
ipso attack. Furthermore, captodative stabiIisation can be achieved, when the spiro 
cycIohexadienyl radical intermediate (57) is strategicaIIy substituted by two groups with 
opposing electron demand (e.g. compound SS). This leads to the isolation of only the rearranged 
product (59) in high yield.25 
54 
• ,
, 
, 
• 
ortho: 
• ,
, 
• 
• t 
I'\n 
56 
e.g. 
• 
--------<.- ~ 
57 
-. -
--- ................ 
OHC'O~ OMe OHC~OMe 
BU3SnH, AIBN I ~ O~ Br--=..::::..:~.:..;....:;~~·~ ~ OH 
58 59 (90%) 
Scheme 18. Radicallsimerisation via ipso-substitution 
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A similar aryl shift to that first observed by Speckamp et a120•21 (schemes 12 and 13) may also 
be induced photochemically, and has proved to be an effective method for the arylation of 
1.2-diketones.27 Scheme 19 shows the irradiation of2-{(arylsulfonyl)oxy}cyclohexanones (60) 
provided an excited triplet state (61), subsequent addition to the ipso position provided 
intermediate (62), which can either revert to the starting material or eliminate sulfur dioxide and 
rearomatise to the enolisable diketone (63). Sensitisation and quenching experiments 
unambiguously proved the radical process and the formation of the excited lowest triplet state. 
&~Jva 
Ar U Ar 
63 
• 
Scheme 19. Photochemical arylation of 1.2-diketones 
Vinyl radicals, generated by the regioselective addition of stannyl radicals to an appropriate 
alkyne, and subsequent intramolecular radical cyclisation onto a benzene ring have been the 
subject of detailed research. 28•29 Such a process was carried out by Nanni et a129, with aryl 
alkynyl sulfides and selenides. The latter is depicted in scheme 20, and it was concluded that a 
5-exo cyclisation of (Z-) vinyl radicals (64) to form spiro cyclohexadienyl radical (65) was a 
highly favoured process due to the heteroatom (selenium or sulfur) possessing empty low energy 
orbitals, which interact with the radical centre to facilitate such a ring closure. It can then be 
assumed that both 5- and 6-membered rings can be derived from the initial 5-exo cyclisation, and 
the virtual absence of the selenopyran (66) suggests that radical (65) was not subject to a 
competing ring expansion, presumably owing to the fairly low energy of the C-Se bond. On the 
contrary, nitrogen- and oxygen-containing vinyl radicals give only reduction products, while the 
hydrogen abstraction product (67) was absent. This can again be attributed to the powerful 
carbon radical and selenium atom interaction. 
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Scheme 20. BU3Sn • radical addition to alkynyl selenides 
The free radical ipso-substitution of 2-substituted indoles carried out by Caddick et aPO,31 is 
shown in scheme 21. The iodides (68) gave better yields of cyclised compounds (69) than 
analogous bromide radical precursors. The electron withdrawing SPh, SOPh and S02TOl groups 
enhanced the electrophilicity at the indole-2-position thereby facilitating attack by the 
nucleophilic alkyl radicals. Therefore, this radical 'addition-elimination' sequence enabled the 
formation offive, six and seven membered fused [l,2-a] indole systems (69). Generally, for any 
one substituent the yields of the six membered rings were greater than the five membered 
compounds. These findings reinforce the reactivity patterns found in other radical cyclisations 
onto indole systems.32,33 An explanation by Jones et a133 proposed that there is considerable 
strain and distortion in the five membered ring product, and hence presumably the transition 
state. However, the favourability of such a cyclisation protocol was highlighted by the formation 
of the seven membered ring in moderate yields, when L = SOPh or S02Tol. However, the 
attempted formation of the seven membered ring with L = SPh (68c) failed. The authors believe 
that this is due to the aryl sulfide moiety not being as strongly electron withdrawing as the higher 
valence sulfur forms (i.e. SOPh and S02Tol), consequently the rate of cyclisation would be Iow. 
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b) L = SPh, n = 2 
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Scheme 21. The formation of [1 ,2-a) indoles by intramolecular ipso-substitution 
The generality of this protocol was tested with the radical cyclisations detailed in scheme 22.31 
Despite the formation of the tricycle (70) in good yield, only the reduced compound (72) was 
formed from the attempted cyclisation of amide (71). The reason for this anomaly is the 
restricted rotation about an amide bond, which forces the alkyl radical generated from (71) to 
take up a disfavoured trans conformation for radical cyclisation onto the aromatic ring.34 
~ BU3SnH, AIBN 
Yf · TSO~Br 
CD D. o 
70 (57%) 
~~~ Br BU3SnH, AIBN •. ~~ 
Th H Th H 
71 72 
Scheme 22. Testing the generality of aromatic ipso-substitution 
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1.3.2 Oxidative Radical Cyclisations onto Heteroaromatic Systems 
The intermolecular and intramolecular addition of a radical onto an aromatic nucleus followed 
by oxidation of the new resonance stabilised It-radical intermediate back to the aromatic system 
(i.e. oxidative radical cyclisation ) is a process which has considerable synthetic utility. 
Numerous methods have been employed to affect such cyclisations, and many of these methods 
will be discussed in this section. 
Much of the basic understanding of intermolecular homolytic radical substitution reactions has 
been due to the extensive work of Minisci et al.35 In 1968 a preliminary report36 by this group 
proposed that regioselective reactions could only be achieved if a polar antagonism was created 
by allowing nucleophilic carbon centred radicals to attack electron deficient substrates. 
Therefore, olefins conjugated with electron withdrawing groups, protonated heteroaromatic 
bases, quinones and many other electron deficient heterocycles were thus employed as 
substrates. Intermolecular radical additions onto heteroaromatic rings have proved to be very 
facile, and most importantly it reproduces the Friedel-Crafts reaction, but with opposite 
reactivity and selectivity owing to the nucleophilic character of the reacting radicals. 
Furthermore, the similarity of such a process with the classical Friedel-Crafts reaction can be 
related by the fact that generally the more stable the carbonium ion the more nucleophilic the 
corresponding radical. Hence, it may be inferred the electrophilic species useful in the Friedel-
Crafts reactions can be utilised, as corresponding radicals, for the selective substitution on to 
heteroaromatic bases (with exception to carbon centred radicals conjugated with electron 
withdrawing groups). The rates for alkyl and acyl radicals are usually extremely high, and this is 
coupled with high substrate and positional selectivity. A general oxidative homolytic 
substitution process with a protonated pyridine as the substrate is outlined in scheme 23. The 
pyridyllt-radical intermediate (73) is highly nucleophilic, and so only a mild oxidant is required 
to achieve selective rearomatisation. 
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A -H+ l+~R-----• 
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Scheme 23. The general outline of an oxidative radical substitution onto protonated pyridines 
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Such a system can be mediated by Ti(III) and hydroxylamine in acid medium (scheme 24), 
which can generate alkyl radicals (74), and selectively rearomatise the quinoline intermediate 
(75).37 
+NH30H Ti3+ H+ 
+. Ti4+ + H2O + + • NH3 + 
oc5 ~ h N+ 
1 
H 
Overall reaction; 
+. 
NH3 + R-H 
+ R-
74 
aCt,:: + Ti4+ ~ . R 
I 
H 75 
• NH: + R-
74 
c& -H+ • ~ +. H R 
I 
H 
74 = 'CH20H, CH3CHOH, 
• ~+ U~R 1+ 
H 
Scheme 24. Hydroxylamine I Ti{llI) system. 
cO • ~ . 
1 
H 
+ Ti3+ 
Moreover, the low oxidising character of this system allows the use of strongly nucleophilic 
radicals. This is advantageous because, often a marked increase in the nucleophilicity of radicals 
can cause synthetic limitations due to an increase in the stability of the radical, and consequently 
its oxidisability.38 The latter is particularly prevalent in radicals with oxygen and nitrogen atoms 
in the a-position, as depicted in figure 4. 
'\.. '\. - + • 
...... C-OR -'I-~'~ ...... C-OR 
Figure 4 
20 
R 
Furthermore, radicals that are too nucleophilic can be involved in electron transfer processes 
with heteroaromatic compounds of high electron affinity (schemes 9 and 25), which limits the 
substitution process. 15,37 
+ R·------... 
I 
H 
Scheme 25. Electron transfer process 
+ 
Another method for the effective substitution of protonated heteroaromatic bases uses alkyl 
iodides in Fenton's reagent type conditions (scheme 26).39 This method may be also applied to 
complex alkyl iodides, such as iodo sugars that lead to C-nucleosides with interesting biological 
activities. The reaction depicted in scheme 26 proceeds through a complex pathway. Normally, a 
Fenton's reagent reaction as shown in scheme 27 (eq. 1) would produce highly reactive and none 
selective hydroxyl radicals (HO .) by the Fe(II) catalysed decomposition of hydrogen peroxide. 
The hydroxyl radical can thus react with substrates, such as the alkyl iodides. However, this 
reaction was minimised by using DMSO as the reaction solvent. Scheme 27 (eq. 2) shows the 
reaction of DMSO with the hydroxyl radical leads to fast ~-scission, and the generation of a 
methyl radical (Me .). The methyl radicals generated are much more reactive than the alkyl 
radicals (R .), and consequently the abstraction of iodine from the alkyl iodides is fast. 
However, in the studies of Minisci et al35 the alkyl radical was always selectively introduced 
into the heteroaromatic ring because of its superior nUcleophilicity over that of the methyl 
radical. Fe(III) compounds also serves as oxidants for the pyridyl radical intermediates (73, in 
scheme 23).39 
+ R-I 
Fe2+ A 
----, l~ + Me-I + MeS02H 
1+ R 
+ MeSOMe + H2O:! 
H 
Scheme 26. Fenton's conditions for intermolecular radical cyclisations. 
• HO· + HO- + Fe 3f. (equation 1) 
HO. + MeSOMe • 
.0-. /OH 
Me-S-Me (equation 2) 
! 
MeS02H + Me· 
Scheme 27. The generation of methyl radicals using Fenton's type conditions 
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Scheme 28. Intramolecular radical cyclisations onto indoles and pyrroles using Fenton's conditions. 
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Muchowski et a140 extended the use of the Fe(Il) IDMSO IH 202 system to intramolecular 
radical cyclisation reactions. This allowed the synthesis of a wide range of bicyclic indoles and 
pyrroles. A selection of the reactions carried out are shown in scheme 28. The regioselectivity of 
these reactions was in agreement with Frontier Molecular Orbital (FMO) calculations, which 
showed that indole compounds (76 and 78) possess a large LUMO coefficient at C-2. Therefore, 
the expected addition of the nucleophilic alkyl radical at this position was observed providing 
cyclised products (77) and (79) respectively. There was however, no correlation observed 
between the isolated yields and the magnitude of LUMO coefficients. Furthermore, indoles (80) 
and (82) possess a methyl and hydrogen substituent at the 3-position respectively, which results 
in the LUMO coefficient at C-2 and C-7 being almost identical. However, indoles (81) and (83) 
resulting from radical addition at C-2 were the only observed products, because the disruption of 
the heterocyclic system is always more favourable than the more resonance stabilised benzoid 
ring. Secondary radicals could also be cyclised under these conditions, but tertiary radicals (e.g. 
generated from compound 84) gave the expected cyclised compounds (e.g. 85) in poor yield due 
to the formation of the tertiary carbonium ion providing alkenes (86) and (87). The pyrrole (88) 
has similar LUMO coefficients at C-3 and C-5, but for steric reasons only the cyclised indole 
(89) was produced. 
Manganese (Ill) based oxidative radical cyclisations have also been used to carry out 
intramolecular radical cyclisations onto pyrroles. 41 The almost quantitative conversion of 
alkylmalonate (90) into cyclic diester (92) using manganese(III) acetate in acetic acid is shown 
in scheme 29. Cyclised diester (92) can also be obtained by bromine abstraction (Br 0) from the 
bromomalonate (91) using a triethylborane/oxygen mediated oxidation process. 
2 Mn(OAc)a, HOAC,/ 
NaH, THF, NBS 
92 E~ 
Scheme 29. Intramolecular oxidative radical cyclisations of pyrroles 
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The mechanism for triethylborane oxidative radical cyclisations is not fully understood.42 
However, the most probable pathway is autoxidation. The ethyl radical generated (scheme 30) 
probably undergoes bromine abstraction from bromomalonate (91). The initiation process for 
such a mechanism remains largely unknown. 
slow 
ROO· + EIsB ----I.~ ROO-BEt2 + Et. 
Et· + 
fast -"':":::':"--I'~ EtOO. 
Scheme 30. Triethylborane autoxidation 
The synthesis of indolo[2,3-a jisoquinolines via the Mn(ill) mediated oxidative addition of 
dimethyl malonate radicals across the C-2 position of indole is shown in scheme 31,43 the 
cyclisation is again activated by the electron-withdrawing group (EWG) at C-3. The great 
advantage of these transition metal catalysed processes is that the reaction products are free of 
unwanted tin hydride reduction compounds, as is observed in the analogous BU3SnH mediated 
radical cyclisations. 
EWG EWG 
~ ~1a Mn(OAcb, CH2(C02Me)2 • 
Scheme 31. Synthesis of indolo[2,3-ajisoquinolones 
Minisci et al44 have also cyclohexylated a variety of heteroaromatic bases (e.g. quinoline, 
benzothiazole, isoquinoline) (scheme 32) using cyclohexyldithiocarbonate (94), and benzoyl 
peroxide (93). Cyclohexyldithiocarbonate (94) was conveniently prepared in situ from the 
reaction of cyclohexanol and dithiocarbonate under acidic conditions. The mechanism was 
proposed by Barton44 in which the rate of phenyl radical addition to the dithiocarbonate (94) is 
very high, since no phenylation of the heteroaromatic bases was observed. The nucleophilic 
cyclohexyl radical (R .) generated now adds to the heteroaromatic base, which subsequently 
looses a proton. The final step of the mechanism involves a single electron transfer (SET) with 
the oxidising benzoyl peroxide (93) to regain the aromaticity of the heteroaromatic system. It 
may be speculated that this will lead to the formation of a benzoyl peroxide radical anion (95) 
which will then disintegrate to a phenyl radical and peroxy anion (PhCOO-) in a process 
identical to that earlier proposed by Bowman et al,45 i.e. the "pseudo aromatic SRN I" 
mechanism (see section 1.3.3). 
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Scheme 32. Use of alkyl xanthates for selective substitution onto heteroaromatic bases 
1.3.3 'Oxidative Radical Cyclisations' using BU3SnH 
The last section describes the wide variety of systems reported to perform radical cyclisations 
with oxidative rearomatisation. The conditions employed in most cases were oxidative, which is 
useful in regenerating the final aromaticity of the product. However, this project is concerned 
with 'oxidation' during 'reductive cyclisations' with BU3SnH. 
The use ofBu3SnH for the reductive cyclisations of a wide range of substrates has been widely 
reported, and is well used in synthetic organic chemistry. 46 These reactions involve radical 
abstraction of a labile group (e.g. iodine, bromine and benzeneselanyl) by BU3Sn· radicals to 
yield an intermediate radical, cyclisation of the radical onto an unsaturated bond, and reduction 
of the new intermediate radical by abstraction from BU3SnH. Nevertheless, there has been an 
increasing number of reported BU3SnH mediated 'oxidative radical cyclisations'. This type of 
radical cyclisation has been shown to be synthetically very useful, and an understanding of the 
common aspects of its mechanism is of great interest. 
The earliest literature example47 (scheme 33) is of radicals generated from 5'-deoxy-5'-
iodoadenosine derivatives undergoing 5'-8-cyclisation to give mainly the reduction compounds 
(96) and (97), and a small amount of 'oxidative rearomatisation product' (98) in 16% yield. This 
was improved by Ueda et a148 with their stereospecific radical cyclisations of adenosine 
5'-aldehyde (99) to yield the corresponding rearomatised 8,5'-cycIoadenosine derivative (100) in 
good yield. An understanding of these reactions is important since radicals are effective 
nucIeobase damaging agents. 
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Scheme 33. Radical cyclisations onto adenosines 
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The synthetic utility of these intramolecular radical cyclisations onto heteroaromatic systems was 
first demonstrated by Murphy and Sherbum49 reporting the efficient formation of [6,5], [6,6], 
[6,7]-bicyclic pyridinium salts (scheme 34). 
O~ BU3SnH, AIBN • ~ n= 1 (65%) 
le n·~±I n = 2 (60%) 
n = 3 (58%) 
n I 
Scheme 34. Radical cyclisations onto pyridinium salts 
Most recently, pyridinium radicals have been generated from 2-bromo-N-alkylpyridinium salts 
(101) (scheme 35), and shown to add to a benzene ring to give the fused tricyclic system (102) in 
good yield. 50 
BU3SnH, AIBN 
• 
OTI e ("'::l OTI e 
+t) 62% 
Ratio 1: 2 
Scheme 35. Pyridinium radical cyclisation onto arene 
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The first proposed mechanism for oxidative radical cyclisations using BU3SnH was the "pseudo 
SRN I mechanism" given by Bowman et al.45 It was first described for the addition of aryl 
radicals onto thioamides (scheme 36) to yield benzothiazoles (104) with no dihydro product 
being observed. This almost quantitative formation of the 'oxidised' product was carried out 
under conditions, which rigorously excluded oxygen. 
H 
I (XyPh ::::".. I s 
I 
103 
-----. I ~ Ph BU3SnH 0:>-AIBN ::::".. S 
104 
Scheme 36. Cyclisation of thloamide 
The proposed mechanism (scheme 37) begins with SH2 abstraction of halogen by BU3Sn' to 
yield a very reactive a-aryl radical (105), which undergoes addition to the sulfur in the C=S 
bond. It is proposed that a proton is lost from radical intermediate (106) to BU3SnH to evolve 
hydrogen gas, and yield a highly stable radical anion (107). The normal steps of SRN I reactions 
are followed, that is the radical anion (107) undergoes a SET (single electron transfer) with a 
another molecule of substrate (103) to form the benzothiazole product (104), and a new radical 
anion of the substrate (103'-). The latter loses halide anion rapidly to reform a-aryl radical (105), 
and so completing the mechanistic cycle. The role of Bu 3SnH is only catalytic to the radical 
chain, and it is the only substance that can act both as a base and radical initiator. This was 
supported by the formation of benzothiazole (104) in good yield using only a catalytic amount of 
BU3SnH (0.1 equiv.), and DABCO (1.1 equiv.). It should be noted that in "normal" BU3SnH 
reductive cyclisations an acidic hydrogen is not present. 
104 
Scheme 37. pseudo SRN 1 mechanism 
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Support for the "pseudo SRN 1 mechanism" has been offered by Beckwith and StoreyS! 
(scheme 38) to explain the formation of oxindoles (111) from suitable o-bromo-N-
methylanilides (108) using tandem translocation of the initially formed aryl radical (109), and 
subsequent intramolecular homolytic substitution. It was first shown that the intramolecular 
homolytic substitution was the rate determining step as opposed to the prior aryl radical 
translocation (or 1,5-hydrogen transfer). The reactions used di-tert-butyl peroxide as initiator, 
which would be a doubtful oxidant for intermediate cyclised radical (110). Therefore, on this 
evidence initiators such as AIBN may also not be involved in abstraction of hydrogen (H 0). 
• 
108 ~ 
Me 
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Scheme 38. Radical synthesis of oxindoles 
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Scheme 39. The fate of radicals generated next to carbonyls in o·iodoanilides 
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The generation of radicals adjacent to carbonyls (113) via a highly favoured I,S-hydrogen 
transfer reaction of o-iodoanilides (112), which undergo tandem I,S-exo and 1,7-cyclisation to 
give the radical intermediates (114) is shown in scheme 39.52 Contrary to the "pseudo SRN I 
mechanism" AffiN was proposed as a possible oxidant of the intermediate cyclised radical (114), 
since the reaction only reached completion with an excess of AffiN and prolonged heating. Other 
reactions involving oxidative rearomatisations do not occur in the absence of BU3SnH or AffiN 
and are low yielding in the presence of catalytic amounts of AffiN. 52,53 Furthermore, AffiN has 
been shown to abstract hydrogens in radical reactions. 54 
The work of Minisci et al35 in the area of oxidative intermolecular homolytic aromatic 
substitution reactions has proved to be fundamental. Section 1.3.2 discussed many of these 
reactions, however the alkyl radicals generated prior to aromatic substitution were always 
selectively derived from the respective alkyl iodides. 39 Such reactions are not suitable for alkyl 
bromides, because bromine abstraction by aryl radical (e.g. from benzoyl peroxide) or methyl 
radical (e.g. from DMSO + H202) is slower than iodine abstraction. Therefore, these reactions 
are not selective, and compete with hydrogen abstraction from acidic C-H bonds or addition to 
double bonds and aromatic rings. This difference in behaviour would appear to be due more to a 
different mechanism of atom transfer than to bond strengths. A classical transition state was 
proposed for bromine atom transfer, while iodine abstraction was said to proceed by a much 
faster and more selective addition-elimination process (scheme 40).55 
* --~.~ [R" 'X' • 'Br] -,..----;.~ R 0 + BrX (1) RBr + oX 
(2) RI + oX ===='~ R-i-x ----;.~ R 0 + IX 
Scheme 40. Mechanisms for bromine and iodine abstractions 
Therefore, it follows that Minisci et al56 were obliged to use the standard radical conditions of 
BU3SnH and AffiN in order to achieve successful intermolecular homolytic aromatic substitution 
with alkyl bromides. Since, tin (and silicon) radicals can be utilised to achieve a high rate of 
bromide abstraction. However, the authors stressed the use of stoichiometric amounts of AffiN 
(scheme 41, also see scheme 32) in order to achieve hydrogen abstraction from the intermediate 
cyclohexadienyl radical ion (116) by the a-cyanoisopropyl radical (115) to yield the 
rearomatised products (117). This result is in contradiction with the "pseudo SRN I mechanism" 
and in agreement with the findings of Curran et al.52 The a-cyanoisopropyl radical (115) is 
deemed electrophilic by virtue of the proximity of the cyano group to the radical centre, and so it 
does not react with protonated heteroaromatic bases. Therefore, this is an important example of a 
regioselective "oxidative intermolecular radical substitution using BU3SnH." 
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Scheme 41. The role of AIBN in 'oxidative rearomatisation'. 
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Scheme 42. A mechanistic study of the synthesis of phenanthridines by radical Caryl- Caryl coupling 
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Most recently however, Lobo and Prabhakar et al57 gave evidence of the non-participation of 
ABCN in oxidative rearomatisation during the synthesis ofphenanthridines by radical Caryl-
Caryl coupling. The reaction (scheme 42) used was the radical cyclisation of a-bromobenzyl 
aniline (118), in which the aniline is substituted with deuterium, and employing l,l-azobiscyclo-
hexy1carbonitrile (ABCN, 120) as initiator. It was shown (scheme 42) that cleaved ABCN 
radical (121) was not implicated in the abstraction of deuterium from the intermediate radical 
(119), since (123), as opposed to (122) was given. Therefore, the carbon centred radical (121) 
was not the oxidising agent. Analogous initiators such as AIBN, are therefore unlikely to be 
taking part in such a process. 
Castedo et al have also used intramolecular radical Caryl- C aryl couplings to generate various 
isoquinoline alkaloids58 and a wide range of phenanthrene ring systems (126).59 The free radical 
reaction of the haloketoester (124) gives the intermediate phenanthrolic methyl ester (125), and 
subsequent lactonisation yields phenanthrene ring systems (126). There is now also the potential 
for the synthesis of a wide range of pyrrolophenanthridone alkaloids by oxidative biaryl 
couplings using Bu 3SnH mediated intramolecular radical cyclisations. 33 
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Scheme 43. C aryl- CaryI coupling to generate phenanthrenes 
Hoshino et al 19 used this synthetic methodology to yield novel polycyclic organosilicon 
compounds (scheme 44), and provided a mechanistic explanation for the formation of the three 
products (128), (130) and (131). An ipso-substitution pathway is predicted to yield compound 
(130), but no explanation is given for the loss of hydrogen (H 0) to regenerate aromaticity from 
compound (127) to yield (128). Early work 17 into BU3SnH mediated biaryl couplings also 
yielded unexpected products derived from speculative ipso attack, and possible spiro 
intermediates such as (129). Later, rather than radical oxidative addition reactions, biraryl 
couplings were promoted via ipso substitution pathways (see section 1.3.1).22.23 
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Scheme 44. The synthesis of novel polycyclic organosilicon compounds 
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A most innovative radical reaction, which was developed by Curran etal,60 is shown in scheme 
45 and is the tandem or cascade cyclisation to form camptothecins (135). These antitumor agents 
were synthesised via the initial formation of the pyridone radical (132), intermolecular reaction 
with phenyl isocyanide, and subsequent 5-exo radical cyclisation onto the N-propagyl group 
creates the vinyl radical (133). The latter cyclises onto the arene to form the radical (134), which 
undergoes rapid oxidative rearomatisation via an unknown pathway to yield the pentacyclic 
product (135). Vinyl29 (and iminyl)61 radicals are widely studied intermediates that have been 
employed in other synthetically useful oxidative annulations. Initiation for this cascade reaction 
is provided by hexamethylditin, and UV light. Therefore, there is no BU3SnH or AllN to be 
implicated in the final oxidation step. 
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Scheme 45. The synthesis of camptothecin 
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Selenoimidates (scheme 46) have been used as radical precursors to generate imidoyl radicals, 
which undergo 6-exo radical cyclisation onto double bonds, followed by oxidative addition onto 
arenes to yield tetracycle (136).62 
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Scheme 46. Imidoyl radicals undergo 6-exo cyclisation 
Oxidativc radical cycIisations mediated by BU3SnH have also found increasing use in the 
synthesis of indole based polycyclic systems (scheme 47). Most notably, intramolecular radical 
cycIisations of haloarylindole-3-carbaldehyde (137)63 and haloalkylindole-3-carbaldehydes 
(139)32 to form isoindolo[I,2-a]indole (138) and tricyclic [1,2-a]fused indoles respectively 
(140). In both these examples homolytic radical cycIisation is followed by highly favoured 
oxidative rearomatisation, which may be explained using the "pseudo SRN 1 mechanism". Since, 
the intermediate radical anion formed will be highly stabilised as the ketyl radical anion, and the 
profound stability of such aromatic ketyl radicals has been proven by EPR spectroscopy.64 
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Scheme 47. Oxidative radical cyclisations onto. indoles using BU3SnH 
This is in contrast to reductive radical cyclisations carried out by Ziegler et al with allyl, 65 
dioxolanyl,66 and carbon centred oxiranyl67 and aziridinyl68 radicals onto the indole-2-position, 
which invariably gave predominantly dihydroindole products. Three such examples are shown in 
scheme 48. BU3SnH mediated radical cyclisation of N-allylindole-3-carboxylate (141) yielded 
the dihydropyrrolo[I,2-a]indole (142).65 Furthermore, E and Z isomeric mixtures of 
bromoaziridine (143) were heated at reflux in toluene in the presence of BU3SnH and 1,1-
azobiscycIohexylcarbonitrile (ABCN, 120) as initiator, the dimer (144), dihydroindole (145), and 
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uncycIised aziridine (146) were produced. 68 The tendency for the cycIised benzylic radical to 
dimerize may be due to an additional captodative stability created by the nitrile group. Chiral 
carbon-centred epoxy radicals 67 have been generated via photolysis of degassed solutions of 
Barton's ester (147), which along with the biproduct 2, 2'-dipyridinyl disulfide give symmetrical 
dimer (148), unsymmetrical dimer (149) and a trace of epoxyindole (150). Therefore, it can be 
inferred that oxidative radical cyclisations are far more favoured in the indole-3-carbaldehyde 
reactions (scheme 47), while 'reductive cycIisations' with BU3SnH occur with the poorer radical 
stabilising groups (i.e. COOMe, and CN in scheme 48). Nevertheless, the potential for the 
incorporation of three membered rings may be adapted to form a wide range of mitomycin 
analogues. 
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Scheme 48. Reductive cyclisations onto indoles 
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Muchowski etaZ69 have used the "pseudo SRNl mechanism" to explain oxidative radical 
cyclisations onto pyrroles. The radical cycIisation of 1-(2-bromobenzyl)-2-
alkanesulfonylpyrroles (151) and 1-(4-bromobutyl)~2-methylsulfonylpyrroles (153) yielded the 
partial or complete reductive desulfonylation pyrroIizidine derivatives (152) and (154) 
respectively as the major products (scheme 49). The authors stress that the radical cycIisations 
occurred with no apparent oxidant nor were products indicative of disproportionation processes 
observed. Radical addition was proposed to occur at the a-position of the pyrrole nucleus not 
bearing the sulfonyl group, and that sulfonyl group is lost via reduction in a second process after 
the oxidative radical cycIisation is complete. The "pseudo SRN 1 mechanism" would again 
suggest that the driving force of such radical cycIisations would be the thennodynamic stability 
of the intennediate ketyl radical anion. 
R-Q 
R = S02Me, 
R = S02CeH4Me 
• U #traces + 152 
4
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154 
R = H (24%), S02Me (40%) trace 
Scheme 49. Oxidative radical cyclisations onto pyrroles using BU3SnH 
1.3.4 The Aromatic SRNl Mechanism 
Before the introduction of the aromatic SRN 1 mechanism by Bunnett and Kim 70 in 1970, there 
were three commonly known mechanistic pathways that nucleophilic aromatic substitution 
reactions could follow (scheme 50). These routes are shown in general, e.g. intennediates (156), 
(157) and (158) after one or several reaction steps give the nucleophilic substitution product 
(160). Aryl cations (156) are generally intennediates, when the aromatic substrates (155) has 
nitrogen as a leaving group (i.e. X = N2+). Nucleophilic addition with the fonnation of (j-
complex (157) only occurs, if aromatic substrate (155) possesses one or more electron 
withdrawing groups activating such an ipso-attack. Finally, the removal of a proton, and the 
fonnation of a aryl carbanion (158) can only occur in strongly basic conditions. Consequently, 
the benzyne intennediate (159) is fonned, which on nucleophilic substitution leads the fonnation 
of more than one regioisomer of (160). 
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Scheme 50. Nucleophilic Aromatic Substitution Pathways. 
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However, intense research by Bunnett et a171 provided many reactions that could not be 
explained by the above processes. One such reaction is the nucleophilic substitution of 
unactivated aryl halides, which was not carried out under strongly basic conditions in a process 
conducive to any of the mechanism depicted in scheme 50. These reactions are explained by the 
SRN 1 mechanisms (scheme 51), which represents a Substitution, Radical, 
Nucleophilic, Unimolecular process, similar to SN 1. Since, the overall reaction is a nucleophilic 
aromatic substitution that involves radicals and radical anions, it follows that such reactions are 
suppressed by radical scavengers (e.g. di-tert-butyl nitroxide and 02) and strong electron 
acceptors (p-dinitrobenzene and ° 2)' 
Initiation can occur chemically, photochemically, electrochemically or simply by heating. A 
common initiation process is the solvation of potassium or sodium metal in liquid ammonia, 
which furnishes metal cations and solvated electrons. Combination of the solvated electrons with 
aryl halide molecules is represented in scheme 52. Therefore, generation of radical (R e), radical 
anion (RX"') or radical anion (RNu"') allows entry to the propagation cycle. If the subsequent 
radical chain is long, then most of the reaction occurs in the propagation steps. 
-. ArX + e
NH3 ----. (ArX) 
Scheme 52. Initiation using metal in ammonia 
A useful example of aromatic SRN 1 is illustrated in scheme 53, and is the photostimulated 
reaction of dihalobenzenes, such as m-chloroiodobenzene (161) with thiophenyl anion (PhS-) to 
give predominantly the disubstituted product (165).72 The radical anions are formed either by a 
single electron transfer (SET) process or the combination of an aromatic radical with PhS-. The 
favourability of such a process depends on the relative energies of the radical anions formed. 
Therefore, this depends on the energy, and the location of the extra electron in the radical anions, 
which may either undergo a SET process or fragment by loss of a leaving group. Both these 
processes have been studied extensively, 73 and depend on factors such as reduction potentials, 
solvent and temperature. Molecular orbital74 calculations and EPR spectroscopy75 have shown 
that this extra electron can either occupy a It" or cr" orbital. The extra electron in halobenzene 
radical anions (162) and (163) is said to undergo an intramolecular electron transfer process from 
the It" orbitals of the aromatic moiety to the cr" orbital of the C-X (X = I or Cl) bond. This leads 
to the rupture of the C-X bond, since the location of an electron in the cr" orbital is a repulsive 
state. The probability for such an electron transfer will depend on the relative energies of these 
molecular orbitals. If the energy of the cr" orbital is lower than that of the It* orbital, the radical 
anion will probably be a cr' radical anion. Therefore it follows that the disubstituted radical anion 
(164) is a It'-radical anion, since the SET process is much more favoured than the fragmentation 
process. 
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2.0 Syntheses of Target 4(5)-Nitroimidazoles (168) and (170) 
2.1 Introduction 
The modes of action of bioreductive antimicrobial and anticancer agents were discussed in 
section 1.2.1 and 1.2.2. The design of more potent and selective antimicrobial (and anticancer) 
drugs could be feasible by understanding the common aspects of the molecular mechanisms. It 
was apparent that these mechanisms are dependent on certain structural features, and therefore 
an analysis of common structural features should provide a direction for designing the synthesis 
of new drugs. In particular, an oxidising group is essential, e.g. a nitro group in the 
nitroimidazoles and a quinone group in the indolequinones. Likewise, a strained three membered 
ring is present in mitomycins. If these features are central to the mode of action there is every 
possibility that they can be combined or are interchangeable. Therefore, the synthetic targets 
which are proposed in this chapter are based on this concept. In particular, the structures of the 
synthetic targets will combine the strained three membered moieties from mitomycins and 
mitosenes, and the oxidising moiety of nitroimidazoles. If these compounds prove to be equally 
potent and selective, they in turn provide evidence for the mechanism of bioreductive 
antimicrobial (and anticancer) drugs. 
Aziridinomitosene (18) is formed by the reoxidation of reductively activated intermediate 
aziridinomitosene semiquinone (17, scheme 4, section 1.2.2). Interestingly, the 
aziridinomitosene (18) has been found to exhibit antitumour activity upon reductive activation.76 
Therefore, a postulated nitroimidazole target will combine aziridinomitosene structural features 
that were necessary to its activity with those of nitroimidazole (Figure 5). Such a nitroimidazole 
target (166) has the quinone group replaced by the nitro-moiety (N=C-N02). The 5-nitro target 
(167) also has the same structural features. The nitroimine (N=C-N02) and nitroalkene 
(CH=C-N02) moieties of 2- and 5-nitroimidazoles have been shown to readily accept electrons 
to form radical anions,8 and thus it should prove viable to replace the oxidising function of the 
quinone group. Analogues (166) and (167) have three potential sites for reaction with DNA 
(nitro-group, aziridine and benzylic carbon). Therefore, in order to simplify synthetic studies, the 
initial target did not contain the benzylic side chain, e.g. (168). This target still has two potential 
DNA alkylating sites. Once the synthetic methodology for adding the aziridine ring moiety is 
proven the syntheses can be repeated with a suitable protected benzylic side chain incorporated 
into the starting material. 
40 
0 OCONH2 OCONH2 H2NOCyN X I I N-I '-':: I~ ~' I~ NH 02N ;. NH 02N NH Me I I 
I 
0 
18 aziridinomitosene 166 2-nitro analogue 167 5-nitro analogue 
168 simplified structure 
Figure 5. Aziridinomitosene-based synthetic targets. 
Aziridinomitosene analogues in which the aziridine is replaced by a cyclopropane ring (i.e. so 
called cyclopropamitosene 169, figure 6) have proven to be especially potent bioreductive 
anticancer agents. 77 Thus, using the same principles as outlined above, a second simplified 
target (170) was also considered for synthesis. 
169 Cycloopropamitosene 170 simplified structure 
Figure 6. Cyclopropamitosene-based target 
Therefore, initial synthetic studies aimed to synthesise nitroimidazole targets (168) and (170) by 
adapting methods that had already been successfully used by to make analogues of 
aziridiniomitosene (18) and cyc\opropamitosene (169). 
2.2 Attempted Synthesis of Nitroimidazole (168) 
~N-C'\ ll./ N 
I 
H 
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Scheme 54. Putative synthesis of nitroimidazole 168 
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The proposed synthesis of nitroimidazole (168) is shown in scheme 54. The first step in the 
synthesis involves the alkylation of 4(5)-nitro-IH-imidazole (171), which proved problematic. 
This should not have been too suprising, since the regioselectiveN-alkylation of 4(5)-nitro-IH-
imidazoles has always been a problem of great significance, because of the chemotherapeutic 
and pharmacological advantage of l-alkyl-5-nitro-IH-imidazoles over l-alkyl-4-nitro-IH-
imidazoles (see section 1.2.1). The reason for this, is the existence of 4(5)-nitro-IH-imidazole 
(171) as two tautomers (scheme 55) in acidic or neutral conditions by virtue of a 1,3-shift of the 
NH proton. The tautomeric system in which the NH bond is strongest predominates, and the two 
tautomers exist in an approximate ratio of 400: I in favour of the 4-nitro isomer (l71a).78 
Alkylations under basic conditions gives l-alkyl-4-nitro-1H -imidazoles, since they proceed 
largely via the conjugate base of (1713), while under neutral or acidic conditions the formation 
of l-alkyl-5-nitro-1 H-imidazole occurs via a more favoured substitution at the basic imine 
nitrogen (3-N) of (1713).79 
~"l? ...... ~---~):? 
H H 
171a 400: 1 171b 
Scheme 55. Tautomers of 4{5}-nitro-1 H-imidazole 
The first step in the synthesis involved the formation of 2-(5-nitro-IH-I-imidazolyl)-I-ethanol 
(175), which according to a literature procedure 80 could be simply made by refluxing 4(5)-nitro-
IH-imidazole (171) in 2-chloroethanol. However, we discovered that this alkylation process 
only took place, when small amounts of potassium iodide were added to the refluxing solution 
(scheme 56). The iodide probably displaces the chlorine in 2-chloroethanol, and the resulting 
2-iodoethanol was in turn undergoing an intramolecular displacement reaction to form ethylene 
oxide, since Giraldi et al 81 have reported ethylene oxide as a successful alkylating agent of 
(171) to yield (175), as shown in scheme 57. Alternatively, the more reactive 2-iodoethanol 
undergoes SN2 attack by the basic N-imine in 4(5)-nitroimidazole (171). 
Scheme 56. Alkylation of 4{5}-nitro-1 H-imidazole using 2-chloroethanol 
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Scheme 57. Alkylation of 4(5)-nitro-1 H·imidazole using ethylene oxide 
1-(2-Chloroethyl)-5-nitro-1H-imidazole (172) was made in moderate yield according to the 
method of Welch and Vatne.82 An attempt at increasing this yield by increasing the time the 
reaction was heated under reflux from 3 h to 54 h is shown in scheme 58. However, this led to 
the unexpected chlorination of the heteroaromatic ring to yield 2(4)-chloro-l-(2-chloroethyl)-5-
nitro-l H-imidazole (176), as the sole product in 45% yield. The exact position of the new 
heteroaromatic chlorine substituent could not be deduced by relative chemical shifts in the 'H 
NMR and 13C NMR spectra. Consequently, this synthetic route was not pursued further, because 
these first steps proved fairly low yielding and capricious. 
J \ SOCI2, reflux, 54h. Jrt.o I '} • I J O2 N O2 N 
175 ~ > 176 (45%) 
HO 0 
Scheme 58. Attempted preparations of 1-(2-chloroethyl)-5·nitro-1 H·imidazole 
The next step in the synthesis was the hydroxymethylation of chloride (172), as shown in 
scheme 54, and is discussed in the next section. Simple oxidation of the resulting alcohol should 
form the the aldehyde (173), which would facilitate the formation of the unsaturated pyrrolo[ 1,2-
a]imidazole (174) via a proposed intramolecular Wittig reaction. "One-pot" alkylation-
intramolecular Wittig reactions have been used to form similar fused heterocyclic systems. For 
example,83 the preparation of pyrrolizidine (178) from readily available pyrrole-2-carbaldehyde 
(177) by reaction with vinyltriphenylphosphonium bromide in the presence of sodium hydride is 
illustrated in scheme 59. More recently, this Schweizer-Light reaction has been extended to the 
formation of the biologicaIIy important pyrrolo[ l,2-a ]indole system (180).84 The initiaIIy 
formed 3H-isomer (179) isomerises to the more stable 9H-isomer (180). 
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Moreover, the fonnation of SH-pyrrolo[l ,2-a]imidazole (182) has been reported85 using the 
Schweizer-Light reaction, as shown in scheme 60. The latter literature procedure was repeated, 
and used as a guide to the fonnation of nitroimidazole (174) in scheme 54. Imidazole-2-
carbaldehyde (181) was reacted with sodium hydride, and vinyltriphenylphosphonium bromide. 
Unfortunately, pyrrolizidine (182) could not be isolated, and the reaction gave unidentifiable 
products even under conditions which rigorously excluded air. Furthennore, it was suggested 
that pyrrolzidine (182) was air sensitive, and for this reason was rapidly catalytically 
hydrogenated to the stable heterocycle (183).85 Thus, the analogous nitroirnidazole (174) was 
also likely to be highly unstable, and so difficult to handle. It was hoped that unsaturated 
pyrrolo[I,2-a]imidazole (174) could be converted to the proposed nitroimidazole target (168) by 
addition of the aziridine ring using standard methods 86 (scheme 54), examples of which have 
been used in aziridinomitosene synthesis. 87 
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183 
Scheme 60. Schweizer-Light reaction used to synthesise 5H-pyrrolo[l,2-alimidazole (182) 
Therefore, we have obtained circumstantial evidence for the instability of synthetic intermediate 
(174), which is further reason to suspend the synthetic pathway presented in scheme 54. 
Since, this work was carried out, synthetic work on mitomycins has suggested that aziridine 
target (168) may be obtained by another route. If applied to the nitroimidazole synthesis, the 
fonnation of unstable unsaturated system (174) would be avoided. Since, Wang and Jimenez88 
have synthesised the aziridinomitosene analogue (189) using a diakylvinylsulfonium salt (184 in 
scheme 61). Therefore, the reaction is similar to the Schweizer-Light reaction in that the 
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vinylsulfonium salt (184) undergoes a conjugate addition with the anionic indole to form the 
sulfur ylide (185) in situ (phosphonium ylid in the intramolecular Wittig reaction). The sulfur 
ylid (185) then reacts at the carbonyl centre to form an alkoxide (186), which displaces dimethyl 
sulfide. The resultant oxirane (187) was then readily ring opened with a solution of sodium azide 
to yield azido the alcohol (188), which can readily form the aziridine ring via mesylation and 
reduction. 
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Scheme 61. An alternative roule to aziridinomilosenes 
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2.3 Attempted Synthesis of Nitroimidazole (170) 
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Scheme 62. Putative synthesis of nitroimidazole target 170 
The synthetic route is based on the synthesis of cyclopropamitosene analogues carried out by 
Moody et al." ,84 However, once more the initial alkylation step proved troublesome. 
l-Allyl-5-nitro-lH -imidazole (190) was prepared according to a literature procedure 
(scheme 63),89 which involved heating 4(5)-nitro-lH -imidazole (171) and a1lyl-4-methyl-l-
benzenesulfonate (193, allyl tosylate), under slightly acidic conditions at 130°C. Yields of 
l-allyl-5-nitro-l H-imidazole (190) were invariably low with a significant amount of the 4-nitro 
isomer (194) always given. Column chromatography and I or recrystaIIisation failed to separate 
pure l-allyl-5-nitro-lH -imidazole (190) from the crude product mixture. 
~OTs J~ +~t} ~~} 193 • I!.... TsOH, 130°C ~ N N 1 1 I H 171 
190 (18%) 194 (2%) 
Scheme 63. 4(5)-Nitro-1 H-imidazole reaction with allyltosylate 
It has been reported in the Iiterature90 that alkylations of 4(5)-nitro-lH-imidazole (171) in polar 
aprotic solvents (e.g. DMSO, DMF) improve the regioselective formation of the l-alkyl-5-nitro-
IH-imidazole isomer_ Thus, the allylation of 4(5)-nitro-lH-imidazole (171) with allyl bromide in 
DMF was carried out, but both yields and regioselectivity were very poor (scheme 64). 
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~N-!C"~ ~Br 
i!..../ • N DMF, 50-70°C, 96 h 
I 
H 
171 
190 (3%) 194 (3%) 
Scheme 64. 4(5)-Nitro-1 H-imidazole reaction with allylbromide 
Esters of polyphosphoric acid have also been used to carry out regiose1ective alkylations of 4(5)-
nitro-l H-imidazoles to exclusively obtain the l-alkyl-5-nitro isomer (scheme 65) .91 However, 
this method has been applied only to methylation and ethylation reactions, and was not 
attempted with our starting material (171). 
R = CH3 (63%) 
R = CH2CH3 (74%) 
Scheme 65. Polyphosphoric acid alkyl esters as N-alkylating agents 
~ 02N-(~ a-t3 __ ~ ___ Br_. ):)-N'1I a-t 3 )Cl ~,'l----a-t3 
...... / DMF, AcOH v H~ ~ l. O2 N >70°C 11 ~ 
195 ll~ ~oc 11 
2\)-CH3 
~ 
197 
Scheme 66. A study of temperature effects on alkylation reactions 
Recent mechanistic studies by Singh et al92 have shown that alkylation reactions are greatly 
affected by temperature. For instance, allylation of 2-methyl-4(5)-nitro-1H -imidazole (195) 
using allyl bromide in DMF I AcOH media yielded mainly the 2-methyl-l-allyl-5-nitro-1H-
imidazole (196) at 80°C, while at 140°C the 4-nitro isomer (197) predominated. Below 70°C, 
there was no allylation observed. The mechanism for such a transformation was shown to 
involve quaternization of the initially formed l-allyl-5-nitro-1H -imidazole (196) followed by 
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preferential deallylation to yield the thennodynamically more stable 4cnitro-1 H-imidazole (197) 
at higher temperatures (scheme 66). Despite the increase in the overall yields of allylated 
products at higher temperatures, 2-methyl-1-allyl-5-nitro-1 H-imidazole (196) was never 
separated from the isomeric product mixture, and its overall yield remained low. 
The first published hydroxymethylation procedure of 4(5)-nitro-1 H-imidazoles at the C-2 
position was reported by Ruferetal.93 Many such reactions have also been reported by Sehgal 
and Agrawal,94 and involve heating the 4(5)-nitro-1H-imidazole (190) and parafonnaldehyde in 
DMSO in a sealed tube at temperatures in an excess of 110 cC. As the mixture of 1-allyl-5-nitro-
1H-imidazole (190) and the 4-isomer (194) could not be separated, the mixture was treated 
under similar conditions to fonn (1-allyl-5-nitro-1H -2-imidazolyl)methanol (198) in moderate 
yield (scheme 67). Column chromatography of this reaction mixture allowed the clean 
separation of 1-allyl-4-nitro-1H -imidazole (194), which did not undergo hydroxymethylation 
because the 4-nitro group is less able to stabilize a negative charge at C-2. 
190 
CH20, DMSO ° 1: 
sealed tube, 1200C):~ 2 ~ 
54h • I }-CH 20H I '> 
O2 N + N ~ ~ 
194 198 (40%) 194 
Scheme 67. C-2 Hydroxymethylation of 4(5)-nitro-1 H-imidazole 
Dichloromethane 
reflux, 18 h 
• 
Scheme 68. Oxidation using manganese dioxide 
Oxidation of alcohol (198) to the aldehyde (191), shown in scheme 68 was carried out using 
manganese dioxide (Mn02) in dichloromethane (the product mixture contained 64% of the 
aldehyde 191 and 1 % of the alcohol 198). However, at this stage the synthesis was suspended, 
because of the low yields using this route. The prime problem was the poor yielding first step. 
Despite, regioselective preparations of 1-alkyl-5-nitro-1H -imidazole being present in the 
literature, most of these syntheses are low yielding and capricious. However, the remaining steps 
should be synthetically feasible. There has been literature reports95 of 1-methyl-5-nitro-1 H-
imidazolecarbaldehyde (199) reactions with mono and N,N-dialkylhydrazines to give the the 
respective hydrazones (200 in Scheme 69). 
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CH 3 
--_. J}-c=NX 
N H 
O2 I 
a x= N(CH3)2 
,-(CH3 
b x=~o CH 3 
199 200 
o 
c X =NHC(=S)NH2 
Scheme 69. Hydrazone formation 
The required diazo moiety could be generated by a variation of the Bamford-Stevens reaction,96 
namely the thermolysis of the sodium salt of tosylhydrazones. Padwa et al97reported that on 
heating tricyclic cyclopropane (203) was formed via pyrazoline (202) derived from a concerted 
1,3-dipolar addition of a diazoalkane (201) to a double bond (scheme 70). 
H 
\ + -
~NNHTS Base oc: 
Heat 
1 
201 
N==N 
od cd • 
203 202 
Scheme 70. Bamford-Stevens reaction for the synthesis of cyclopropanes 
Moody et a1 11•84 have taken advantage of this protocol to synthesise numerous analogues of 
cyclopropamitosenes from tosylhydrazones (scheme 71). 
~ ~N~NNHTS 
V 
NaH. Heat 
Scheme 71. Bamford-Stevens reaction in cyclopropamitosene synthesis 
2.4 Conclusions 
The synthesis of nitroimidazoles (168) and (170) proved difficult using the synthetic schemes 
described in sections 2.2 and 2.3. The main problem being the initial regioselective alkylation of 
4(5)-nitro-IH-imidazole (171), which was invariably low yielding. Thus, the next two chapters 
report the development of two new routes to polycyclic diazole systems, which are based on free 
radical chemistry. 
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3.0 Intramolecular Radical CycIisations by "ipso" Substitution at the C-2 
Position of Imidazoles and Benzimidazoles. 
3.1 Introduction 
The last chapter described the difficulties encountered when attempting to synthesise new 
tricyclic nitroimidazole antimicrobial (and anticancer) agents by using conventional synthetic 
routes, which began with the alkylation of 4(5)-nitro-lH-imidazole (171). The overwhelming 
synthetic problem was that it was difficult to prepare pure samples of l-alkyl-5-nitroimidazole in 
high yield, which could be converted to compounds for cyclisation after several synthetic steps. 
Therefore, a more accessible route to such [l,2-a]fused 5-nitroimidazole systems was required, 
which led us to consider radical cyclisations onto imidazole systems. A preliminary 
communication has already been published on this work.98 Moreover, in order to avoid the 
initial alkylation problems, it was decided to begin new syntheses on imidazoles without a nitro 
group, and perform the nitration reaction after the synthesis of the heterocyclic nucleus was 
complete. A putative retrosynthesis of nitroimidazole target (168) is shown in scheme 72. The 
key step is the cyclisation of the aziridinyl radical onto the electrophilic C-2 position of the· 
imidazole ring. 
(168) 
/ 
N (}-z 
N 
I 
H 
Scheme 72. A possible synthesis of nitroimidazole target (168) by radical cyclisation 
A free radical pathway was choosen, since radical cyclisations have become a major route for 
the synthesis of heterocyclic systems.99 Section 1.3.1 reviewed the wide range of reactions 
reported to date, involving aromatic homolytic" ipso" substitution. Moreover, Caddick et a130,31 
have developed a novel approach to [I,2-a ]fused indoles based on an intramolecular aromatic 
"ipso" substitution pathway (see scheme 21, section 1.3.1). The initial aim of our work was to 
adapt this protocol to provide a facile route to a number of [l,2-a ]fused imidazole and 
benzimidazole systems. The chapter also details the understanding developed of the mechanism 
involved in this synthetic protocol. 
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3.2 Free Radical Route to Bicyclic [1,2·alfused Imidazoles and Benzimidazoles 
() 
N 
I 
H 
204 
N-protection 
• () 
N 
I 
CPh 3 
substitution at C-2 
• 
( 
\.- radical cyclisation 
I U'n · ()-Z ~'I--N-_al_ky_la_tio_n_ ~x 
Scheme 73. The synthesis 01 [1.2-a]lused imidazoles by radical cyclisalion 
The free radical route chosen to [1,2-alfused imidazoles is shown in scheme 73. The planned 
route was as follows; Trityl protection of imidazole (204) allows regiose1ective substitution at 
the C-2 position of the diazole ring with an electron withdrawing substituent (Z), which was to 
be accomplished by reacting the l-(trityl)imidazole with n-butyllithium (n-BuLi), and 
quenching the imidazole C-2 anion with a suitable electrophile. Removal of the trityl group, and 
subsequent alkylation provides the radical precursors, which can then be cyclised under standard 
radical conditions O-e. slow syringe pump addition ofBu3SnH and AmN to the refluxing 
reaction solution) to form a series of [1,2-aJfused imidazoles. This methodology was also 
adapted to form a series [1,2-alfused benzimidazoles, which possess important biological 
activity_ 
3.3 The Synthesis of Bicyclic [l,2-a lfused Imidazoles 
3.3.1 Examples of 5,6,7,8-tetrahydro[I,2·alfused imidazoles 
There have been two literature 100,101 accounts of isolated natural products with 5,6,7,8-
tetrahydro[l,2-al fused imidazole structure (Figure 7, n = 2). The five and seven membered 
analogues are not known from natural sources. 
n=1,2,3 
Figure 7. The bicyclic [1.2-a] imidazole skeleton 01 interest 
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The first such compound was isolated from the fermentation broth of Streptomyces 
amakusaensis by Japanese workers 100 in 1992, and was named "nagstatin" (205 in Figure 8). 
Nagstatin was discovered to be a specific inhibitor of the exoglucosidase enzyme NAG-ase 
(N-acetyl-~-D-glucosaminidase).IOO Serum levels of such enzymes have been found to increase 
in diabetes mellitus, 102 leukaemia lO3 and nephritis cancer. 104 Thus, nagstatin may be an 
important inhibitor in gaining an understanding of the mechanisms of cancers and immune 
disorders. 
~HAC 
HOn-l-012C02H 
HO~_J_-HO 205 
Figure 8. "nagstatin" 
In 1996, KeIler and Hammann et al lOl isolated the secondary metabolite sibyllimycine 
(208 in Scheme 74) from the fermentation broth of Thermoactinomyces sp. These organisms 
were found in the 60°C hot springs of Lake Tanganyika in Cape Banza, Africa. Sibyllimycine 
has no known structural analogues from natural sources, and its biological activity is currently 
under screening. The structure of sibyllimycine (208) was verified by its synthesis from 
4-methyl-IH-imidazole (206).101 The imidazole (206) was alkylated with 4-bromobutyronitrile, 
and deprotonated at the C-2 position with n-BuLi, which consequently lead to ring closure. The 
imine (207) was readily hydrolysed to the ketone, sibyllimycine (208). 
n-BuLi ~"t:UN< 
207 I H~H20 
~"t:uo 
208 
Scheme 74. The synthesis of sibyllimycine 
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During the course of our research, a synthesis of bicyclic [I ,2-a ]imidazoles has also been 
reported by Hua eta/,I05 which is shown in scheme 75. The synthesis involves the condensation 
of various lactams (209) with 2-aminoacetylaldehyde diethyl acetal (210) in the presence of 
strong Lewis acids (SnCI4 or TiCI4). The mechanism of the reaction was suggested to involve 
nucleophilic attack by the lactam NH at C-I of the oxonium ion derived from (210) and the 
Lewis acid, followed by ring closure of the amino group with the lactam carbonyl group. 
Dehydration, and elimination of ethanol led to the formation the various bicyclic imidazole 
products (183, and 211-214). The advantages of the synthetic protocol is that various functional 
groups such as hydroxyl and olefinic groups (compounds 215 and 216) have been found to 
tolerate these reaction conditions. Furthermore, the favourability of such cyclisations is 
exemplified by the formation of the seven, eight and nine membered ring compounds (products 
212-214) in high yield. However, not all the lactams used are commercially available, and so 
must be synthesised prior to cyclisation. 
+ 
209 
OH CC EtCh + EtO NH2 
0° + EtCh EtC NH2 
• 140 -155 QC 
SnCI4 or TiCI4 
• 140 -155 QC 
SnCI4 or TiCI4 
• 140 -155 QC 
183, n= 1, 61-80% 
211, n = 2,62-68% 
212, n = 3,80% 
213, n = 4, 83% 
214, n = 5,89-91% 
OH 
0-6 
215 
0-6 
216 
Scheme 75. Lewis acid promoted condensation reaction to synthesise various fused imidazoles 
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3.3.2 The synthesis of 2-(tosyl)- and 2-(phenylsulfanyl)-1H-imidazole (221) and (222). 
Reactions between organolithium reagents, and N-protected imidazoles have provided a valuable 
route to 1,2-disubstituted imidazoles.106 In 1978, Kirk l07,l08,l09 was the first to establish the 
trityl group as an efficient N-protection of imidazole, but not until recently has it been widely 
used for imidazole protection. 110 Thus, the trityl group was chosen as the N-protection for 
imidazole because of the following reasons; 
1. I-(Triphenylmethyl)imidazole [I-(trityl)imidazole, 217] can be readily prepared in high yield 
at room temperature using well documented literature procedures (scheme 76).108 
2. The reagents used in this reaction are very cheap commercially available materials. 
3. The trityl group is resistant to the forcing conditions of ring metallation. 
4. The trityl group is hydrolytically readily cleaved to form the unprotected 2-substituted-IH-
imidazoles in high yield. 
CICPh3, EI3N () 
N 
I 
H 
204 
• () 
N 
I 
CPh3 
217 (90%) 
Scheme 76. Synthesis of 1-(trityl)imidazole 
It has long been recognised that the C-2 position on N-protected imidazole is the most acidic. 1 1 1 
The relatively high kinetic acidity ofH-2, and subsequently it's strikingly greater reactivity than 
that of H-4 or H-S is due mainly to the inductive influence of the two nitrogen atoms on C-2, 
which will be far greater than that on C-4 or CoS. Furthermore, the C-H bond at C-2 also has 
slightly greater s-character than C-4 or CoS. Therefore, the Iithiated C-2 anion of 1-
(trityl)imidazole (217) was formed using n-BuLi in dry THF at - 78°C, and this was quenched 
using sulfur electrophiles at 0 °c, as shown in scheme 77. The use of tosyl fluoride gave the 
required 2-(tosyl)-I-(trityl)-1 H-imidazole (218) in 33% yield, and diphenyl disulfide gave 
2-(phenylsulfanyl)-I-(trityl)-IH-imidazole (219) in 46% yield. We tried to improve the yield of 
the imidazole (218) by using tosyl chloride in place of tosyl fluoride, however 2-chloro-l-
(trityl)-IH -imidazole (220) was the only product obtained from this reaction. Thus, the Iithiated 
imidazole anion is quenched by chlorine rather than the tosyl group, since the tosyl group is a 
better leaving group. 
The trityl group was hydrolytically cleaved, as shown in scheme 78 by refluxing 2-(tosyl)-I-
(trityl)-IH -imidazole (218) and 2-(phenylsulfanyl)-I-(trityl)-1 H-imidazole (219) in acidic 
aqueous methanol over 2 hours. The novel imidazoles (221) and (222) formed, were found to be 
highly polar crystalline white solids, which were precipitated as the free bases from the aqueous 
layer on work up. This should have been expected since N-unsubstituted imidazoles are 
S4 
stabilised by extensive hydrogen bonding, which provides them with the observed crystalline 
properties, as weB as their ready solubility in aqueous solutions. Furthermore, this hydrogen 
bonding is lost in alkylated imidazoles, which are accordingly often liquids. 
N 
( 
\. n-BuLi,( TMEDA), TH~ 
/ -78°C-0°C 
~(}-S02TOI 
(~L~ bPh 3 ~ 218 (33%) I 
CPh 3 
217 CPh
3 ~ PhSSPh 
ToIS02CI 
N (}-a 
N 
I 
CPh3 
220 (14%) 
()-SPh 
N 
I 
CPh3 
219 (46%) 
Scheme 77. 1-(Trityl)imidazole carbanion formation and quenching with electrophiles 
(~S02TOI H'", methanol ()-S02T01 • 
N reflux, 2 h. N 
I I 
CPh3 H 
218 221 (44%) 
(}-SPh 
H'", methanol 
()-SPh • 
N reflux, 2 h. N 
I I 
CPh3 H 
219 222 (85%) 
Scheme 78. Hydrolytic removal of the trityl group 
3.3.3 Problems with l-(ro-haloalkyl)imidazole radical precursors. 
The general procedure for the alkylation of 2-substituted imidazoles is exemplified by the 
synthesis of 1-(3-bromo-2-propenyl)-2-[(4-methylphenyl)sulfonyIJ-lH-imidazole (223), which is 
depicted in scheme 79. The imidazole N-l anion is formed using sodium hydride in dry THF, 
which in this case is quenched using a three fold excess of l,3-dibromopropene. However, the 
radical cyclisation of bromide (223) failed. The synthesis of bicyclic imidazole (182) was also 
attempted using the Schweizer-Light reaction, 83,85 as described section 2.2. Both these methods 
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failed to yield 5H-pyrroI0[I,2-alimidazole (182), because the latter is thought to be too unstable 
to isolate. 
(}-S02T01 
N 
I 
H 
221 
1. NaH, CHaCN, reflux 
• 2. BrCH=CHCH2Br 
(77%) Buasn~ AIBN, • (~ 5 h addition, toluene \) 
reflux 
182 
Scheme 79. Attempted synthesis of 5H·pyrrolo[1 ,2-a)imidazole (182) by radical cyclisation 
Consequently, our attention was turned to the synthesis of the more stable bicyclic [1,2-alfused 
imidazole (183), which it was envisaged could be synthesised by the radical cyclisation of an 
alkyl iodide precursor, since Caddick et a[30,31 had successfully used 1-[ ro-bromo( or 
iodo)a1kyllindoles as radical precursors. Firstly, chloride (224) was made by alkylation of 
2-tosylimidazole (221), which was achieved using two different alkylating agents, as outlined in 
scheme 80. The greatest yield for chloride (224) was obtained when using I-bromo-3-
chloropropane, rather than l-chloro-3-iodopropane. The latter alkylation procedure resulted in 
the formation of a considerable amount of the bisalkylated imidazole (225). 
(}-S02T01 
N 
I 
H 
221 
1. NaH, CHaCN, reflux 
2. a) CI(CH2hl 
b) CI(CH2hBr 
• 
224 
a) (53%) 
b) (68%) 
()-S02TOI 
N 
+ I (Cr 21 a 
(>-S02T01 
N 
225 
(40%) 
(15%) 
Scheme 80. The synthesis of 1-[3·(chloropropyl))-2·tosyl-1 H-imidazole (224) 
The formation of bisalkylated imidazole (225) was attributed to the nucleophilic character of the 
displaced iodide anion during the alkylation process, which can lead to the speculative formation 
of alkyliodide (226), which then undergoes an SN2 reaction with another imidazole anion, as 
outlined in scheme 81. 
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(>-S02T01 
N 
I (Cr V3 
(~S02TOI 
N 
225 
Scheme 81. The mechanism for the formation of the bisalkylated imidazole (225) 
The chloride (224) was converted to the iodide (226) by S N2 displacement (Finkelstein reaction) 
using an excess of sodium iodide in acetone, as shown in scheme 82. However, iodide (226) was 
isolated in only poor yield, and rapidly darkened to yield an intractable mixture, despite being 
kept in the dark and under an atmosphere of nitrogen. Therefore, the synthesis of 6,7-dihydro-
5H-pyrrolo[I,2-aJimidazole (183) using iodide (226) as a radical precursor is not a synthetically 
viable process. The I H NMR spectrum indicated that iodide (226) was polymerising, due to the 
basic imine nitrogen undergoing SN2 substitution displacing the iodide, which is a good leaving 
group. Unlike indoles, the extra basic nitrogen in imidazoles precludes the use of 
ro-iodoalkyl side chains. 
Nal, acetone, reflux 
• 30% (>-S02T01 N 
~I 
226 
Scheme 82. Synthesis of 1-[3-(iodopropyl)-2-tosyl]-1 H-imidazole (226) 
3.3.4 The synthesis of 1.[( co-phenylselanyl)alkylJimidazole radical precursors (227·229). 
The instability of iodide (226) led to the synthesis of 1-[( co-phenylselanyl)alkyIJimidazoles, 
which proved to be valuable radical precursors. The phenylselanyl (PhSe) group is an excellent 
leaving group in radical reactions but a poor leaving group in S N2 reactions. The 
1-[( co-phenylselanyl)alkyIJ-2-tosyl-1 H-imidazole radical precursors (227·229) were synthesised 
in moderate to good yields using sodium hydride and 1-(iodoalkyl)-ro-phenylselenides (233· 
235), as shown in scheme 83. 
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1. Na, CH 3CN, reflux 
• 2.ICH2(CHvnCH2SePh 
(}-S02TOI 
N 
~sePh 
W. n = 1 (48%) 
228. n = 2 (41%) 
229. n = 3 (50%) 
Scheme 83. The synthesis of 1·[ro-(phenylselenyl)alkylj-2-tosyl-1H-imidazole (227-229) 
The l-(iodoalkyl)-ro-phenylselenides (233-235) were synthesised using methodology previously 
developed in the Bowman group, 112 which is detailed in scheme 84. The iodine in l-chloro-ro-
iodoalkanes was displaced by the phenylselenide anion, which had been generated on reduction 
with sodium borohydride (eg. 1). The chlorides (230-232) were then converted to the iodides 
(233-235) by an SN2 displacement using an excess of sodium iodide in acetone (eg. 2). 
I~CI NaBH", Ph2Se2, EtOH • 
/"'-..../""-- Nal, acetone, reflux 
PhSe On Cl • 
PhSe~CI 
230. n = 1 (88%) 
231. n = 2 (63%) 
232. n = 3 (89%) 
Phse~1 
233.n=1 (77%) 
234. n = 2 (78%) 
235. n = 3 (64%) 
Scheme 84. Synthesis of 1·iodoalkyl-ro·phenylselenides (233-235) 
equation 1 
equation 2 
3.3.5 Radical cyclisations of 1-[(ro-phenylselanyl)alkyl]-2-tosyl-1H-imidazole 
radical precursors (227-229). 
The phenylselanyl imidazole precursors (227-229) were treated with BU3SnH under standard 
radical cyciisation conditions which provided the bicyclic imidazoles (183), (211) and (212) in 
good yields (scheme 85). The bicyclic [I,2-a]fused imidazoles formed were isolated cleanly 
after work up with no chromatography required. The work up procedure involved extraction of 
the imidazole products into acid in order to remove tributyltin residues, and subsequent 
basification gave the free imidazole base. 
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BU3SnH, AIBN, 10 h addition (b 
---------. I ~ 
toluene, reflux 
)n 
183. n = 1 (52%) 
211. n = 2 (48%) 
212. n = 3 (63%) 
Scheme 85. Synthesis of bicyclic [1,2- alfused imidazoles by radical cyclisation 
The mechanism for these intramolecular radical cyclisations by "ipso" substitution can be 
depicted using the mechanistic cycle illustrated in scheme 86. The initial SH2 attack by the 
nucleophilic BU3Sn • radical results in the formation of BU3SnSePh, and creates a nucleophilic 
alkyl radical, which will readily cyclise onto the electron deficient C-2 position of the imidazole 
ring in the rate determining step. The C-2 position is deemed electrophilic by virtue of the 
inductive and mesomeric electron withdrawal of the tosyl group. The iminyl radical (236) will 
now rapidly rearomatise the imidazole ring with the elimination of a tosyl (p-TolSOz .) radical. 
The tosyl radical is strongly electrophilic and will attack the weak Sn-H bond so reforming the 
BU3Sn • radical to continue the mechanistic cycle. 
(}-S02T01 
N 
2ZT~sePh 
BU3Sn· 
ABSTRACTION 01 SePh 
H-ABSTRACTIO N 
ToIS02 • 
N:) 
( );:::S02TOI N'j 
ELIMINATION )LJ 
CYC7 
(~T. 
236 183 
Scheme 86. The mechanism for Intramolecular aromatic "ipso" substitition 
These results can now be compared with the analogous radical cyclisations onto the indole 
2-position (i.e. with indoles substituted with SOzTol at the 2-position) performed by Caddick et 
aZ,30,31 The yields reported by this group were much higher for the formation of the five and six 
membered bicyclic [1,2- a ]indoles, but the yield for the seven membered indole cyclisation was 
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only 33% (scheme 21, section 1.3.1). In contrast, the analogous imidazole radical cyclisation 
occurred in better yield, and the reaction was free of any tin hydride reduction products. The 
imidazole radical cyclisation may be more favoured because of the greater resonance 
stabilisation, which exists in the iminyl radical intermediate (236), as compared with the less 
resonance stabilised indole intermediate (237) shown in scheme 87. Although, the addition time 
of the BU3SnH and AffiN to the refluxing reaction solution had to be increased from five to ten 
hours for the six and seven membered cyclisation so to avoid the formation of tin hydride 
reduction products. 
Scheme 87. Radical aromatic "ipso" substitution onto the C-2 position of in doles 
3.3.6 Radical cyclisations of 1-[3-(phenylselanyl)propyl]-2-(phenylsulfanyl) and -2-
(phenylsulfonyl)imidazoles 
The synthesis of 2-(phenylsulfanyl)-1 H-imidazole (222) was discussed in section 3.3.2, and it 
was found that it could be synthesised in higher yields than 2-[( 4-methylphenyl)sulfonyl]-IH-
imidazole (2-tosylimidazole, 221). Consequently, it was important to assess its viability as an 
intermediate for the synthesis of bicyclic [1,2-a]fused imidazoles. 
The oxidation of 2-(phenylsulfanyl)-IH -imidazole (222) was accomplished by the addition of 
an excess of oxone 1M at 0 DC, and stirring of the reaction solution for 48 h at ambient 
temperature. Shorter reaction times gave mixtures of the arylsulfoxide (238) and arylsulfone 
(239), and difficulties were encountered in only getting the arylsulfoxide (238). At the longer 
reaction time, the arylsulfone (239) was formed in good yield, as shown in scheme 88. In 
contrast in the analogous indole reaction30,31 the arylsulfoxide (240) was the only isolated 
product in 50-64% yield, as shown in scheme 89. The chemoselectivity of the commercially 
obtained oxone 1M (potassium peroxymonosulfate, 2KHS05.KHS04.K2S04) has been 
reported 113 to be highly dependent on the concentration of this oxidising agent, the reaction time 
and temperature used. Therefore, the more extreme conditions used in the imidazole reaction 
(scheme 88) allowed the oxidation of the initially formed arylsulfoxide (238) to the arylsulfone 
(239). These novel imidazole compounds may be readily separated by column chromatography, 
since the arylsulfoxide (238) is considerably more polar than the arylsulfone (239). 
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Scheme 88. The oxidation of arylsulfide (222) 
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Scheme 89. The Oxone ™ oxidation of 2-(phenylsulfanyl)indole 
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Scheme 90. Radical cyclisation of the aryl sulfide (241) and the aryl sulfone precursors (239) 
The alkylation of the arylsulfide (222), and the cyclisation of the phenyl selenide (241) is shown 
in scheme 90. The initial alkylation could be perfonned in good yield, however the radical 
cyclisation of phenyl selenide (241) was low yielding, and provided equal amounts of cyclised 
(183) and uncyclised imidazole (242). The result was in agreement with the findings of Caddick 
etal,30,31 since the analogous 2-indolyl aryl sulfide radical cyclisations were also generally 
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lower yielding than those using higher valence sui fur substituents [i.e. S02TOI, and S(O)Ph] at 
the 2-position of the indole ring. It was hypothesised 30,31 that the reason for this phenomena was 
that the arylsulfide moiety was not as strongly electron withdrawing in character, and possesses 
a considerable electron donating (M+) character. Hence, the rate of cyclisation of the 
nucleophilic alkyl radical onto the electrophilic 2-position, i.e. the rate determining step, is 
enhanced by the more electron withdrawing tosyl group, as compared to the aryl sulfide group. 
Thus as expected, the arylsulfone (239) was alkylated and the phenyl selenide (243) was 
radically cyclised in good yield, with no uncyclised imidazole (242) being formed. 
3.4 The Synthesis of Bicyclic [1,2-a ]fused Benzimidazoles 
3.4.1 Examples of pyrrolo[I,2-a ]benzimidazoles 
Pyrrolo[ 1,2-a ]benzimidazoles are an important class of antitumour agents consisting of three 
main analogues (figure 9).1 14,115 The 6-aziridinyl analogues (244, PBIs) possess the most 
potent antitumour activity, requiring a two electron reductive activation. 114 Like other 
bioreductive compounds, this cytoxicity is selective to strictly anaerobic cells. 1,2 The 
6-acetamido (245, APBD and the imino-6-acetamido (246, imino-APBI) derivatives are much 
less potent antitumour agents, but are still of interest due to their specific activity against certain 
cancer cells.1 15 However, APBI (245) and imino-APBI (246) are not bioreductively activated 
anticancer agents, since reductive activation is not required for them to manifest, their 
cytotoxicity. The mechanisms of biological activity remain under investigation. 
t{'H Hs~_~ CYR t>;~~f 
o 
PBI244 APBI245 iminicrAPBI 246 
Figure 9. Pyrrolo[1,2·albenzimidazole anticancer agents 
The first synthesis of the benzimidazole nucleus was carried out as early as 1928 by Phillips,116 
and involved the acid catalysed condensation of o-phenylenediamine (247) with a carboxylic 
acid, as shown in scheme 91. "Internal Phillips reactions" have provided a facile route to various 
pyrrolo[ 1,2-a ]benzimidazoles. 117 For example, enantiomers of pyrrolo[ 1,2-a ]benzimidazoles 
(248) can be formed with the (R) or (S) centre, and have proved important in the "structure-
activity relationship" work carried out by Skibo et al.114,115 
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Scheme 91. The "Phillips Reaction' 
Much of the synthetic methodology used to access pyrrolo[1,2-a]benzimidazoles is based on the 
principle of placing substituents ortho to an aromatic amine to provide a means of cyclisation, 
and formation of nitrogen heterocycIes. 118 Such a synthetic protocol is the so called 
"t-amino effect", which is defined as "a nucleophilic reaction involving the tertiary nitrogen or 
the oxidation of a tertiary nitrogen to the iminium ion, which is then subjected to nucleophilic 
attack." 114 The cyclisation reaction can be used to form the benzimidazole nucleus in the 
presence of a Lewis acid, 119 and elaboration of the N,N-dialkylaniIine substituent can provide a 
route to the pyrrolo[1,2-a]benzimidazole system,120 as shown in scheme 92. 
• (XI Nh ~ N OAc 
I 
Et 
Scheme 92. The 'f-amino effect" 
lackson etal121 have reported the synthesis ofbenzimidazoles with a five, six and seven 
membered fused alicyclic ring formed by rhodium catalysed hydroformylation of N-alkenyl-l ,2-
diaminobenzenes (249), as shown in scheme 93. The intramolecular cyclisation reaction which 
occurs involves initial imine formation, and the subsequent oxidative work up formed the 
benzimidazoles. However, the yields of target benzimidazoles (252) and (254) were particularly 
Iow by this method, which can be explained by the Iow regioselectivity of the initial 
hydroformylation, particularly with N-alkenyl-l,2-diaminobenzene (249c), which provided a 
significant quantity of benzimidazole (255). The hydroformylation of N-alkenyl-l,2-
diaminobenzene (249a) also allowed the isolation of imine (250) and cyclic diamine (256), 
presumably resulting from hydrogenation of the intermediate imine (251). Nevertheless, 
benzimidazole (253) was isolated after chromatographic separation in good yield. 
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Scheme 93. Rhodium catalysed hydroiormylation 
Most recently. Haque and Rasmussen 122 have synthesised tricyclic [1 ,2-a ]fused benzimida20les 
by the intramolecular alkylation reaction of various 2,4-disubstituted benzimidazoles, as outlined 
in scheme 94. The ambident anion formed by the N-l deprotonation of the benzimidazole, and 
the subsequent regioselectivity of the intramolecular alkyation reaction was studied in detail. It 
was concluded that the constrained approach geometries involved in cyclisations to both N-l and 
N-3 sites reduce the steric effect of the 4-substituent, particularly for the five-membered ring 
formation, allowing the electrostatic field and the electronic effect of the substituent to dominate 
regioselectivity. Thus, 4-nitrobenzimida20les gave predominant alkylation at the more 
"crowded" N-3 site, whereas the 4-amino system showed a definite preference for cyclisation at 
the less hindered N-l site. It follows that the more "electronically impartial" 4-methyl system 
showed less regioselectivity than the 4-nitro or amino substituted compounds. However, steric 
factors become dominant in the formation of six membered alicyclic rings, and so large N-l 
selectivity is exhibited by all three C-4 substituted benzimidazoles. 
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Scheme 94. Substituent effects on intramolecular alkylaion 
3.4.2 The synthesis of 2-(phenylsulfanyl)-lH -benzimidazole (261) 
The synthetic route followed is described in section 3.2, which began with the initial trityl 
protection of imidazole (204) or benzimidazole (257). The methodology for imidazole trityl 
protection is outlined in section 3.3.2, and was carried out on benzimidazole (257) to readily 
form l-(trityl)benzimidazole (258) on a multi-gram scale, as shown in scheme 95. However, the 
C-2 anion formed with n-BuLi could only be quenched with tosyl fluoride in poor yield, 
although 2-(phenylsulfanyl)-I-(trityl)benzimidazole (260) was formed in good yield. Acid 
hydrolysis of the protective trityl group allowed the isolation of 2-(phenylsulfanyl)-IH-
benzimidazole (261) in excellent yield. 
3.4.3. Problems with l-(ro-haloalkyl)benzimidazole radical precursors 
The problems encountered using 1-( ro-haloalkyl)imidazole radical precursors are described in 
section 3.3.3. Some of these problems also occurred when using benzimidazoles. For example, 
simple alkylation of benzimidazole (257) did not form the expected 1-(3-bromopropyl)-IH-
benzimidazole (262), and resulted in the formation of either the bisalkylated benzimidazole 
(263) or the dialkylated saIt (264), depending on the relative amount of 1,3-dibromopropane 
used, as outlined in scheme 96. The dialkylation problem is due to the second more basic 
imidazole nitrogen being susceptible to further alkylation and polymerisation reactions. 123 
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Scheme 95. Trityl protection and 2-substitution of benzimidazole 
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Scheme 96. Alkylation of benzimidazole (56) with 1.3-dibromopropane 
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The bromide radical precursor (266) was made via the chloride (265) as shown in scheme 97. 
The bromination followed a literature 124 procedure, which had to be used in place of the typical 
SN2 displacement reaction using an excess of sodium bromide in acetone, i.e. the so called 
Finkelstein reaction conditions. The Finkelstein reaction usually utilises the solubility difference 
in acetone between NaI and NaCI, however the limiting factor in this approach is that an 
equilibrium is established between chloride (265) and bromide (266), and thus most of the 
chloride is recovered. Therefore, an additive is required in these reactions in order to shift the 
equilibrium towards the bromide (266), consequently ethylbromide was added to the reaction 
mixture in N-methylpyrrolidinone. Ethyl bromide reacts with displaced chloride ions (CI-) to 
yield ethyl chloride, and both these low boiling point alkanes were removed by evaporation, and 
only a catalytic amount of sodium bromide is required to initiate this reaction. However, the 
extra cumbersome bromination step led us to use the more accessible benzeneselenides as 
radical precursors. Therefore, the conclusion from both our imidazole and benzimidazole studies 
was that the extra basic nitrogen in diazole precursors precludes the successful use of haloalky I 
radical precursors. 
(XI N~ 1. NaH, acetonitrile j--SPh • 
::::".. N 2. Br(CH2bCI 
I 
H 
261 
NaBr, acetone (XI N,>- SPh 
~::::""N (XI N,>-SPh ~Br ::::".. N 266 
~CI 
265 (39%) 
CH3CH2Br'Na~ (XN 
N-methylpyrrolidinone ,:? I '>- SPh 
::::".. N 
~Br 
266 (22%) 
Scheme 97. Difficulties with bromide formation 
3.4.4 Radical cyclisations of 1.[(co.phenylselanyl)alkyl].2.(phenylsulfanyl).lH~ 
benzimidazole radical precursors (267·269). 
Generally, the alkylation of 2-(phenylsulfanyl)-lH -benzimidazole (261), and the subsequent 
radical cyclisation of 1-[ co-(phenylselanyl)alkyl]-2-(phenylsulfanyl)-1 H-benzimidazoles (267· 
269) occurred in reasonable to good yield, as shown in scheme 98. Although the yield of the 
seven membered [1,2-a]fused benzimidazole (254) was poor, it is similar to the analogous result 
obtained with indoles.30,31 Therefore, it can be generally concluded that radical cyclisations onto 
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the benzimidazole 2-position do not require a strongly electron withdrawing high valence sulfur 
substituent, as was required with radical cycJisations onto imidazoles. 
oc'" N,>-SPh ::::". N 
I 
H 
261 
1. NaH, acetonitrile ocN I '>-SPh ::::". N 
¥sePh 
n = 1 , 267 (44%) 
n = 2, 268 (44%) 
n = 3, 269 (75%) 
j BU3SnH, AIBN, 5 h addition, toluene reflux 
OCN~ 
\.)n 
n = 1 , 252 (49%) 
n = 2, 253 (54%) 
n = 3,254 (17%) 
Scheme 98. The synthesisof tricyclic [1,2-a]benzimidazoles 
3.4.5 A mechanistic study of homolytic aromatic" ipso "substitution reactions onto 
benzimidazoles 
The following section examines the necessity for an electron withdrawing substituent and for 
leaving group at the C-2 position of benzimidazoles. The synthesis, and attempted radical 
cyclisation 1-[3-(phenylselanyl)propyIJ-lH-benzimidazole (271) is shown in scheme 99. 
The attempted radical cyclisation of phenylselenide (271) gave largely l-propyl-IH-
benzimidazole (273), and only a trace of the cyclised benzimidazole (252), which inferred that 
without the presence of an electron withdrawing group at the C-2 position of the benzimidazole 
ring, the rate of cyclisation was much slower than the rate of tin hydride reduction of 
intermediate radical (272). The yields of products (252) and (273) shown in scheme 99 were 
determined by 1 H NMR spectroscopy. 
However, in the intermediate radical (272) a [I,5]-hydrogen abstraction from the 2-position of 
the unsubstituted benzimidazole is possible, as outlined in scheme lOO, which would lead to the 
formation of l-propyl-l H-benzimidazole (273) in increased yield. We tested this hypothesis by 
placing a deuterium atom in the 2-position of benzimidazole, as detailed in scheme 101. The use 
of GC-MS analysis allowed us to deduce the level of deuterium incorporation, and its position in 
the benzimidazole (275). 
68 
(XI) PhSeSePh, NaBH4 (X} ~ N ethanol 
~CI 
270 
• 
~SePh 
271 (61%) 
! BU3SnH, AIBN, 5 h addition, toluene reflux 
(XI) ~ N 
~. 
272 
BU3SnH 
\ ~I;,,~" 
(X) + (Xb ~ N 
~ 
273 (89%) 252 (5%) 
Scheme 99. The attempted radical cyclisation of 1-(3-phenylselanyl)-1 H-benzimidazole (271) 
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Scheme 100. [1,5]-Hydrogen abstraction 
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Scheme 101. Incorperatation of deuterium into the 2-position of benzimidazole 
Reaction between the deuterated and non-deuterated benzimidazole mixture (275) and BU3SnH 
gave predominantly 2-deuterio-l-propylbenzimidazole (276), but surprisingly with a higher 
amount of2,3-dihydro-lH-benzo[d]pyrrolo[1,2-a]imidazole (252) being formed, as shown in 
scheme 102. Analysis by GC-MS showed a 4 : I ratio of uncyclised benzimidazole (276) and 
cyclised benzimidazole (252) had been obtained. The formation of deuterated benzimidazole 
(276) provided evidence that [I,5]-hydrogen abstraction was not occurring to any great extent, 
while the increased level of 2,3-dihydro-IH -benzol d]pyrrolo[ 1,2-a ]imidazole (252), as 
compared to the cyclisation shown in scheme 99, can be attributed experimental error. Although 
the addition time of the tin hydride and AIDN was kept constant in all these experiments, other 
factors remained variable, such as the quality of the commercially obtained tin hydride, and its 
concentration in the reaction mixture. 
Further, unequivocal proof for the absence of [I,5]-hydrogen abstraction was obtained by 
treating 1-[3-(phenylselanyl)propyl]-1 H-benzimidazoles (271) with tin deuteride (Bu3SnD) 
under standard radical cyclisation conditions, as shown in scheme 103. The uncyclised 
benzimidazole (277) was the major product, but with an increase in the formation of 2,3-
dihydro-IH-benzo[d]pyrrolo[l,2-a]imidazole (252). The increased amount of observed cyclised 
product (252) is possibly explained by an isotope effect, since the Sn-D bond is stronger than the 
Sn-H bond, with a resultant decrease in the rate of reduction, i.e. reduction in the rate of 
D-abstraction from BU3SnD by intermediate radical (272) would allow increased time for 
cyclisation. The small amount of radical cyclisation observed in the reactions shown in schemes 
99, 102 and 103 was due to the nucleophilic alkyl radical cycIising onto the electron deficient 
C-2 position of the benzimidazole ring, and the subsequent stability of intermediate cyclised 
radicals formed. According to the "pseudo S RN I " mechanism 45 discussed in section 1.3.3 and 
chapter 4, the acidity of the C-2 position in benzimidazoles will facilitate the rearomatisation of 
any intermediate radical anion formed. 70 
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Scheme 102. Treatment of 2-deutero-1-[(3-(phenylselanylpropyl)]-1 H-benzimidazole (275) with BU3SnH 
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Scheme 103. Experimental evidence for the absence of [1,5]-hydrogen abstraction 
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3.5 Conclusions and Future Work 
We have thus successfully extended the pioneering work of Caddick et a130,31 to provide a new 
route to [l,2-a]fused imidazoles and benzimidazoles. The yields have not been optimised, and so 
the route described holds considerable synthetic promise. The use of bromo and iodo compounds 
was found to be problematic, and so new phenylselenides were synthesised, and have proved to 
be valuable radical precursors. Radical cyclisations onto benzimidazoles were carried out cleanly 
with a phenylsulfanyl substituent at the 2-position, while radical cyclisations onto imidazoles 
could only be carried out cleanly in the presence of higher valence sulfur substituents at the 
imidazole C-2 position. We can conclude that this was due to the fact that the imidazole ring in 
benzimidazoles is much less aromatic than in imidazole, and so the formation of the aromatic 
radical intermediate is easier. Therefore, radical cyclisation onto benzimidazoles takes place 
with 2-phenylsuJfanyl substituent, and does not require the more electron withdrawing tosyl 
group. 
The synthesised imidazoles may be converted into antimicrobial agents by using a literature105 
bromination reaction followed by a lithium-halogen exchange reaction to introduce the nitro 
group into the C-3 position of the bicyclic imidazole (183), as outlined in scheme 104. 
1 
:Q): 
5 
(183) 
NBS,CCI 4 n-BuLi, (CH3l2CHONO~J b 
Scheme 104. The nitration of bicyclic [1,2-alimidazoles 
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4.0 Oxidative Radical Cyciisations onto Imidazoles and Pyrroles using 
BU3SnH 
4.1 Introduction 
One of the long term interests of our group is the synthesis of polycyclic nitroimidazole 
analogues of the mitomycins, as described in section 2.1. The difficulties involved in the 
synthesis of such compounds by conventional means has led us to consider possible free radical 
routes. We have recently reviewed the increasing number of radical cyclisations used for the 
synthesis of heteroaromatic systems. 99 A putative retrosynthesis of target nitroimidazole (280) is 
outlined in scheme 105, and involves the cyclisation of cyclopropanyl radical (279) onto the 
electrophilic 5-position of the imidazole ring. The radical cyclisations were carried out using the 
reductive conditions of BU3SnH, but only "oxidised aromatic heteroarene compounds" were 
isolated. The increasing number of reported oxidative radical cyclisations using BU3SnH were 
reviewed in section 1.3.3. These included oxidative radical cyclisations onto heteroarenes, e.g. 
pyridinium salts,49 pyrroles69 and indoles. 32,63 The rate of radical cyclisation onto pyrroles and 
indoles has been shown to be greatly enhanced by the presence of an aldehyde or ketone 
substituent on the heteroaromatic ring. Therefore, our initial radical cyclisations contain an 
aldehyde group on the 4-position of the imidazole ring, which can be further elaborated to the 
urethane (OCONH2) substituent in the nitroimidazole target (280). The synthesis of a series of 
novel bicyclic [1,2-c)fused imidazoles using radical cyclisations onto imidazole-4-carbaldehyde 
was carried out, and we have recently reported this work in a preliminary communication.125 
For comparison purposes, radical cyclisations onto imidazole-5-carbaldehyde and imidazole-2-
carbaldehyde were also carried out. Furthermore, radical cyclisations onto 
4-phenylimidazole and onto pyrroles allowed us to gain an understanding of the versatility and 
limitations of this synthetic protocol. 
~'OOl1"" ====» ~1f-"" ====>:~ 
280 ij 
') 
X 
OHCy~ ~OHCYI , 
+ l) <-- I!....» ~ i0 
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Scheme 105. A possible synthesis of nitroimidazole target (280) using radical cyclisation 
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The last chapter described the first reported radical cyclisations onto diazoles to form 
[1,2-a]fused imidazoles and benzimidazoles using ipso substitution at the C-2 position. 98 
However, there have been other recent reported syntheses of these [I ,2-a]fused imidazoles 105 
and benzimidazoles 114,121,122 by non-radical routes. The synthesis of imidazoles containing a 
[1,2-c]fused alicyclic ring has not been reported to our knowledge, apart from a free radical 
cyclisation carried out by Bowman and Taylor in 1990. 126 The N-alkenyl-imidazol-5-yl radical 
(281) was readily generated using either BU3SnH or Nal NH3, which via 5-exo cyclisation, 
quantitatively gave pyrrolo[I,2-c]irnidazole (283), as exemplified in scheme 106. The 
regioselectivity obtained indicated that the rate of 5-exo cyclisation of a-radical (281) was far 
greater than the rate of reduction by Bu 3SnH, because no non-cyclised compound (284) was 
obtained. The unfavourability of the 6- endo cyclisation was confirmed by the absence of 
cyclised imidazole resulting from radical (282). The attempted cyclisation of l-allyl-5-bromo-2-
. methyl-lH-imidazole (285) is shown in scheme 107 and resulted in only the BU3SnH reduction 
product (287) because the 5-endo and 4-exo are both unfavoured. The 4-exo cyclisation would 
have resulted in the highly strained 4-membered fused alicyclic system (286). Therefore, there is 
clearly the requirement for a more facile routes to [1,2-c]fused imidazole systems, which has led 
us to carry out the work described in the following sections. 
f)-Me B~N 
~ 
6-endo a)-Me 
BU3SnH (~ ~ N 
• .1 ,Me . 
~ 282 
283 
Scheme 106. Cyclisation of N-(butyl-3-en-l-yl)-1-imidazol-5-yl radicals 
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287 
Scheme 107. Reduction of 1-allyl-5-bromo-2-methylimidazole (285) 
4.2 Radical Cyclisations using Imidazole-4(S)-carbaldehyde 
4.2.1 Alkylation of imidazole-4(S)-carbaldehyde (278) 
OHC<N) 
IN 
I 
H 
1. NaH, THF, reflux 
• 
OHC N N l) + f) 
N OHC N ~CI ~CI 
2. Br(CH2l3CI 
278 288 (58%) 289 (4%) 
Scheme 108. Synthesis of 1-(3-chloropropyl)-1 H-4·imidazolecarbaldehyde (288) 
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Scheme 109. Synthesis of l-(ro-bromoalkyl)-l H-4-imidazolecarbaldehydes 
It has been known for many years that 4(5)-substituted imidazoles usually give mixtures of 
isomeric products when treated with alkylating agents.127 Product ratios are known to vary from 
substrate to substrate, and with reaction conditions and solvents used (see section 2.2) 
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The required 1-(ro-haloalkyl)-IH-4-imidazolecarbaldehyde radical precursors were formed using 
sodium hydride in THF to generate the N-l anion of imidazole-4(5)-carbaldehyde (278), which 
was quenched using a large excess of dihaIoalkane, as outlined in schemes 108 and 109. Thus, 
the alkylation of the imidazole-4(5)-carbaldehyde anion gave the 4-isomer, but in a couple of 
cases small amounts of the 5-isomer were also obtained. Column chromatography using neutral 
alumina gave the clean separation of the two isomers, with the 5-isomers always eluting first. 
The use of longer chain dibromoalkanes resulted in increased preference for the more 
nucleophilic imidazole nitrogen, which allowed for the regioselective synthesis of longer chain 
alkyl bromide radical precursors (294), (296) and (298) in excellent yields, as shown in scheme 
109. The alkylations were not optimised but the reasonable yields and high regioselectivity 
provided a good route to the required radical precursors. 
However, the isolation of useful quantities of ro-(haIoalkyl)-1 H-5-imidazolecarbaldehyde radical 
precursors proved more difficult. The imidazole alkylations had to be carried out under neutral 
conditions in order to force the alkylation onto the more basic "imine" nitrogen. The reaction 
between imidazole-4(5)-carbaldehyde (278) and l-chloro-4-iodobutane in acetonitrile is shown 
in scheme 110, but only gave the desired 5-isomer in 15% yield. Imidazole-4(5)-carbaldehyde 
(278) was also refluxed over two days with 1-(phenylselanyl)-ro-iodoaIkanes in THF, as shown 
in scheme 111. The use of 1-(phenylselanyl)-ro-iodoaIkanes (233) and (234) as aIkylating agents 
instead of I-bromo-ro-iodoalkanes prevented the formation of dialkylation products. However, 
the yields of the desired 5-isomer remained very Iow even with these forcing conditions. 
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Scheme 110. Synthesis of 1-(4-chlorobutyl)-lH-5-imidazolecarbaldehyde (301) 
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Scheme 111. Synthesis of l-[Ol-(phenylselanyl)alkyl]-l H-5-imidazolecarbaldehydes 
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4.2.2 Radical cycIisations onto imidazole-4-carbaldehydes 
The ro-iodoalkyl radical precursors again proved difficult to handle. For example, 
1-(3-iodopropyl)-1 H-4-imidazolecarbaldehyde (306) was synthesised from the chloride (288) by 
SN2 displacement with sodium iodide in acetone (Finkelstein conditions), as shown in scheme 
112. The iodide (306) was formed in excellent yield, and was stored in the dark and under an 
atmosphere of nitrogen. However, the yellow oil of the iodide (306) rapidly darkened to form an 
intractable mixture, which could not be manipulated further. This led us to convert the chloride 
(288) into the iodide (306) in situ prior to treatment with BU3SnH under standard radical 
conditions (scheme 113). Thus, iodide formation, and radical reaction were both carried out in 
the same solvent, i.e. acetonitrile, but only yielded a mixture of the cyC\ised imidazole (307) and 
the Bu 3SnH reduction product (308) in very poor yield. Acetonitrile had to be used as a reaction 
solvent because of the increased polarity of these 4(5)-imidazolecarbaldehyde radical precursors, 
as compared to the l-[(co-(phenylselanyl)alkyl]imidazole radical precursors discussed in 
chapter 3. 
288 
Nal, acetone, rellux 
• (89%) 
Scheme 112. The synthesis of 1-(3-iodopropyl)-1 H-4-imidazolecarbaldehyde (306) 
OHCy ) Nal, acetonitrile. 
IN reflux 
~C1 
OHC OHC N 
BU3SnH, AIBN. 6) le ) 
5 h, addition N + N 
acetonitrile, reflux ~ 
288 307 (3%) 308 (7%) 
Scheme 113. Formation of 1-(3-iodopropyl)-1 H-4-imidazolecarbaldehyde (306) in situ, and treatment 
with BU3SnH 
The successful use of phenylselenides as radical precursors in the radical cyclisations onto 
imidazoles and benzimidazoles as described in chapter 3, led us to synthesise 
1-[3-(phenylselanylpropyl)]-1 H-4-imidazolecarbaldehyde (302). The phenylselenide radical 
precursor (302) was obtained from the bromide (290) via the oxidation of alcohol (309) with 
manganese dioxide, as shown in scheme 114. Treatment of phenylselenide (302) with BU3SnH 
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under standard radical conditions led to the isolation of 6,7-dihydro-5H-pyrrolo[I,2-climidazole-
I-carbaldehyde (307) in 27% yield and I-propyl-I H-4-imidazolecarbaIdehyde (308) in 11 % 
yield. Therefore, despite the phenylselenide radical precursor (302) giving an improved isolated 
yield of the cyclised imidazole (307), the synthesis still required improvement. 
OHCyN l~ (PhSe)2,NaBH4, HO~) Mn02 ~HCy) ethanol l N (72%) II N N 
~Br 
290 
(41%) ~ ~ 
Se Ph SePh 
309 302 
j BU3SnH, AIBN 5 h addition, acetonitrile reflux 
OHCyN 
+ l~ 
~ 
307 (27%) 308 (11%) 
Scheme 114. The synthesis of 1-[3-(phenylselanyl)propyll-1 H-4-imidazolecarbaldehyde(302), and 
radical cyclisation 
1-( co-Bromoalkyl)-I H-4-imidazolecarbaldehydes were obtained in good to excellent yields by 
the alkylation of imidazole-4(5)-carbaldehyde (278), as shown in scheme 109. We found that 
treatment of bromide (290) with BU3SnH gave improved yield of 6,7-dihydro-5H-pyrrolo-
[l,2-climidazole-I-carbaldehyde (307), as shown in scheme 115. The six membered radical 
cyclisation occurred in slightly higher yield and no BU3SnH reduction products were formed. 
The six membered radical cyclisation is more favoured because of the inherent strain in the five 
membered ring product (307). Jones et al33 have offered a similar explanation for the preference 
of 6-endo radical cyclisations over 5-exo radical cyclisations onto indoles. The seven membered 
cyclised imidazole (312) was isolated cleanly after chromatography, but in poor yield, even 
when the rate of addition of BU3SnH and AffiN to the reaction mixture was increased from 5 to 
10 hours to limit the rate of tin hydride reduction. Generally, seven membered ring cyclisations 
are less favourable than five and six because of a less favoured entropy factor. 
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OHC y) BU3SnH, AIBN • 
Il N 5 h addition l _ acetonitrile, reflux 
¥n'-Sr 
290. n= 1 
292.n=2 
294.n=3 
296.n=4 
298. n= 10 
I ~ OHC<SN 
OHCy ) 
+ Il~ N 
n 
307. n = 1 (42%) 
310. n = 2 (49%) 
312. n = 3 (14%) 
314. n = 4 (0%) 
316. n = 10 (0%) 
308. n = 1 (10%) 
311. n = 2 (0%) 
313. n = 3 (8%) 
315. n = 4 (56%) 
317. n = 10 (70%) 
Scheme 115. The radical cyclisation of l-(ro-bromoalkyl)-l H-4-imidazolecarbaldehydes 
Intramolecular SH2' macrocyclisations have been shown to be feasible when the radical 
cyclising ring closure is onto sterically unhindered and electronically activated double 
bonds. 128,129 Such a system is outlined in scheme 116 in which the attempted formation of six 
to nine membered lactones was unsuccessful. 129 However, the formation of ten to fifteen 
membered lactones was reported in 46-80% yield, since only for the longer alky I chains was the 
desired disposition of reactive centres in the required s-Z conformation for radical cyclisation 
achieved. Therefore, in agreement with the lactone macrocyclisations, the unfavoured entropy 
for cyclisation led to the isolation of only the tin hydride reduction product (315) in our 
attempted eight membered radical cyclisation, shown in scheme 115. However, following the 
results for the macrocyclisations presented in scheme 116, the formation ofthe fourteen 
membered [I,2-c]fused imidazole (316) was expected to be more favourable, but disappointingly 
only the reduction product (317) was isolated. The effect ofthe cx,~-unsaturated ester as shown 
in scheme 116 is obviously much stronger than the effect of the cx,~-unsaturated aldehyde 
moiety in 298. 
o 
SU3S~O ))n 
PhSe 
n = 6 (54%) 
n = 7 (46%) 
n = 8 (61%) 
n = 9 (50%) 
n = 10 (80%) 
n= 11 (72%) 
Scheme 116. Intramolecular SH2' Macrocyclisations 
The regioselectivity of the radical cyclisation onto the 5-position, [I,2-c]fused rather than [I,2-a] 
fused, could not be verified using 1 H NMR and BC NMR chemical shifts. The structure of 
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cyclised imidazole (307) was confirmed using X-ray crystallography, as shown in figure 10. A 
90' rotation of the molecule is also shown, which illustrated the profound planarity of the 
molecule. 
The regioselectivity for radical cycIisation onto the 5-position rather than the 2-position for these 
imidazole-4-carbaldehyde radical precursors was further ascertained by blocking the 5-position 
with a methyl substituent. Attempted cycIisation of the 5-methyIimidazole (318) led to only the 
formation of the tin hydride reduction product (319), and no cycIisation onto C-2 (scheme 117). 
Conversely, when the 2-position contained a methyl substituent, the radical cyclisation was 
observed to form the cycIised imidazole (322) in excellent yield. The reactive aldehyde (321) 
was not isolated, since the more stable (l,p-unsaturated methyl ketone adduct (322) was formed 
via an aldol type condensation reaction with acetone. 
OHC ) 
-y BU3SnH, AIBN ~ ~ 5 h addition • 
Hs 7 acetonitrile. reflux 
~Br 
OHCy ) 
Hs~N ~ 
318 319 (46%) 
Hscoc 
• 5 h addition 
acetonitrile. reflux 
OHC6~ 1 }--CHa 
N 
+ H. acetone 
• 
320 321 322 (75%) 
Scheme 117. Regioselective radical cyclisation onto the 5-position of imidazole-4-carbaldehydes 
The synthesis of 1-(2-bromobenzyl)-1 H-imidazolecarbaldehyde (323), and it's attempted radical 
cycIisation is shown in scheme 118. The reasons for the failure of the radical cycIisation is 
unknown, since an analogous cyclisation has been reported on pyrrole-2-carbaldehyde (scheme 
49, 1.3.3).69 Furthermore, molecular modelling studies have been carried out, which supported 
the favourabiIity of the cycIisation.130 
OHC'iC~ 
lC./ N 
I 
H 
278 
OHCy ) 
1. NaH. THF. reflux I!....N Br 
,~ · U 
323 (45%) 
OHCt ) 
_Bu_3_S.,..n ..... H,.... A_I_B_N~.~ Nu 
5 h. addition. reflux I: 
324 (51%) 
Scheme 118. Synthesis and attempted radical cyclisation of 1-(2-bromobenzyl)-IH-4-imidazolecarbaldehyde 
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09 N2 
Figure 10. X-ray crystal structures of 6,7-dihydro-5H-pyrrolo[I,2-c]imidazole-l-carbaldehyde 
(307) 
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4.2.3 The mechanism for radical cyclisations onto imidazole-4-carbaldehyde 
There is no definitive mechanism for oxidative radical cyclisations using BU3SnH. The many 
examples described in section 1.3.3 proceed to aromatic products which provides a strong 
driving force. The "pseudo SRNl" mechanism45 proposed for these reactions can be applied to 
radical cyclisations onto imidazole-4-carbaldehydes, as shown in scheme 119. The nucleophilic 
alkyl radical (325) is formed via SH2 abstraction of bromide by the nucleophilic BU3Sn· radical. 
The nucleophilic alkyl radical (325) cyclises regioselectively onto the ~-position ofthe 
a,~-unsaturated aldehyde moiety in a Michael type manner. Consequently, the 1t-radical 
intermediate (326) is formed, and undergoes a rapid loss of a proton to BU3SnH, which gives the 
highly stabilised radical anion (327). The radical anion intermediate (327) is a highly stabilised 
entity by virtue of the delocalisation of the extra electron throughout the aromatic imidazole 
system and the conjugated aldehyde group. Consequently, radical anion (327) is a highly 
stabilised ketyl radical anion, and such radical intermediates are well known and have been 
observed by EPR spectroscopy. 64 The normal steps of a typical SRN 1 reaction 73 are then 
followed i.e. radical anion (327) undergoes a single electron transfer process (SET) with a 
molecule of substrate (290) to form the cycIised imidazole (307), and the substrate radical anion 
(328). The radical anion (328) dissociates to reform the initial nucleophilic radical, so sustaining 
the chain mechanism (see section 1.3.4) 
OHCt 
.. ~i:J 
290 
- Br· 
~?'t)_ 
DISSOCIATION Of·~ CYCLISATION 
RADICAL ANION 
325 
OH
t9C • N H ~ 
326 
328 DEPROTONATION 
OHCj~ 
Qt" OHC)-~ 
307 tz) 
B~ 
SET OHCj~ C} 
327 
Highly Stabilized Radical Anion 
290 
Scheme 119. The ''pseudo SRN 1" with 1·(3·bromopropyl)-1H-4·imidazolecarbaldehyde (290) 
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The most debatable step in the "pseudo SRN 1" mechanism is the loss of a proton from radical 
intermediate (326), which suggests that Bu 3SnH is both a radical initiator and a base. While, the 
acidity of radicals have not been extensively studied, a number of examples show that they are 
considerably more acidic than the corresponding non radical compounds, often by an order of 
106.1 31 The stability of the 1t-radical (326) is possibly similiar to the 1t*-radical anion (327), 
which suggests that the proton loss may be rapid. AIBN has also been proposed as a possible 
oxidant for radical intermediates such as (326), since certain reported oxidative radical 
cyclisation reactions using BU3SnH only reached completion with an excess of AlBN and 
prolonged heating (scheme 39, section 1.3.3).52.53.56 Furthermore, Engel and Wu54 have shown 
that AIBN abstracts hydrogens in radical reactions, as outlined in scheme 120. The authors 
reported the formation of benzhydryl radicals upon the photolysis of benzopinacol, followed by 
rapid hydrogen transfer from the benzhydryl radical to the least hindered nitrogen atom of the 
azo linkage in various azoalkanes. A second hydrogen abstraction gave the air sensitive 
hydrazine product. 
P~ /Ph A 
p~Y-Y-Ph • 
OH OH 
2 Ph>-OH 
Ph ! RN=NR 
Ph2CO + RNHNR 
• ! RNH~R 
RNHNHR + RN=NR 
Scheme 120. Reduction of azoalkanes by benzhydryl radicals 
Lobo, Prabhakar et ai, 57 in their recent studies of the syntheses of phenanthridines, which appear 
to proceed by the same oxidative cyclisation, have shown that the "hydrogen" which is lost in 
the oxidation is not abstracted by 2-cyanoprop-2-yl radicals (scheme 42, section 1.3.3). 
Alternatively, the radical intermediate (326) may be reduced by BU3SnH to form 
4,5-dihydroimidazole (imidazoline, 329), as in normal BU3SnH reductive cyclisations (scheme 
121). The radical cyclisations were carried out under an atmosphere of nitrogen using anhydrous 
solvents, thus the oxidative rearomatisation of intermediate (329) can only occur upon work up. 
Such 4,5-dihydroimidazoles (329) are unlikely reaction intermediates, since 
4,5-dihydroimidazoles are known to be stable.132 Furthermore, the 4,5-dihydroimidazole system 
occurs in a number of pharmacologically active molecules. 133 The 4,5-dihydroimidazole 
intermediate (329) may also form upon the disproportionation of radical intermediate (326), as 
shown in scheme 122. 
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BU3SnH 
\ 
\ • 
__ [0....:.1 __ • I" OHC6~
N 
BU3Sri 
326 329 307 
Scheme 121 . BU3SnH reduction of radical intermediate (326) 
2X ""v 
326 
[01 
U 
307 
Scheme 122. Disproportionation of radical intermediate (326) 
4.2.4 Radical cyclisations of imidazole-S-carbaldehydes 
11 \ BU3SnH, AIBN J- '} 5haddition' lib 
OHC N~ acetonitrile, reflux )!... 
OHC )n 
n SePh 
303. n= 1 
305. n = 2 
330. n = 1 (0%) 
332. n = 2 (53%) 
+ J} 
OHC Yn 
331 . n = 1 (73%) 
333. n = 2 (0%) 
Scheme 123. Reaction between 1-[ro-(phenylselanyl)alkyll-1H-5-imidazolecarbaldehydes and BU3SnH 
The radical cyclisation of 1-[3-(phenylselanyl)propyl]-IH-5-imidazolecarbaldehyde (303) gave 
only the reduced imidazole (331), while the cycIisation of 1-[4-(phenylselanyl)butyIJ-IH-5-
imidazolecarbaldehyde (305) gave only the six membered cyclised [1 ,2-a Jfused imidazole (332), 
as shown in scheme 123. Therefore, the five membered transition state leading to cyclised 
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imidazole (330) is less favoured due to strain and distortion, which does not occur in the six 
membered transition state leading to cyclised imidazole (332). The aldehyde group has a strong 
directing influence on the cyclisation of the nucleophilic alkyl radical onto the electrophilic 2-
position of the imidazole ring, since the aldehyde group is fully conjugated with the imidazole 2-
position. The"pseudo SRNI" mechanism45 for phenylselenide radical cyclisations is shown in 
scheme 124, and there are two main differences to the mechanism described in scheme 119 for 
bromide radical precursors. The first difference is the phenylselenide anion (PhSe-) can undergo 
a single electron transfer (SET) process, which follows well established SRN 1 reactivity patterns 
for phenylsufide (PhS-) and phenylselenide (PhSe-) anions. 134 The second difference is the 
(PhSe-) anion is a strong base and is capable of proton abstraction, and the formation of the 
highly stabilised radical anion intermediate (334). The normal steps of SRN 1 reactions 73 are then 
followed. The mechanism for phenylselenide radical cyclisations infers that BU3SnH merely 
initiates the radical cyclisation, and thus future studies into proving the "pseudo SRN I" 
mechanism should examine the possibility of performing radical cyclisations with 
phenylselenide substrates using only catalytic amounts ofBu3SnH or (Bu3Snh 
r N OHC~) 
~S~ 
BU3Sn ~ r~) OHC ~ )\"""\ 
PhSe-
OHC-f") --k-
PhS I \ ~ PhSe' 
305 
- (PhSe ) DISSOCIATION 01 
RADICAL ANION 
r N OHC~) 
PhS~ 
N ' 
lJ 
CYCLlSATION 
305 DEPROTONATION 
r N OHc~A (J r N 332 OHC~) 
PhS~ 
305 
PhSeH 
334 
Highly Stabilized Radical Anion 
Scheme 124. The "pseudo SRN 1" mechanism with 1-[4-(phenylselanyl)butyl)-1 H-S-imidazolecarbaldehyde 
(305) 
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4.3 Attempted Radical Cyclisations of Imidazole.2-carbaldehyde 
The last section described the synthesis of imidazole-4-carbaldehyde and imidazole-S-
carbaldehyde radical precursors, and the results obtained on treatment with BU3SnH under 
standard radical conditions. This section examines the possibility of radical cyclisations with the 
aldehyde group in the 2-position of the imidazole ring. 
4.3.1 Preparation of imidazole-lH -2-carbaldehyde (181) 
( 
'\ 1. n-BuLi, THF, 78 :C 
rI 2. DMF 
CPh
3 
(74%) 
217 
N 
( }-CHO _fi+--,-, m_et_ha_n_o_1 ~.~ 
N reflux 
tPh 3 (26%) 
335 
(N}-CHO 
N 
I 
H 
181 
Scheme 125. Preparation of Imidazole-1 H-2-carbaldehyde (181) 
Imidazole-lH-2-carbaldehyde (181) can be commercially obtained, but is rather expensive 
(£25.50 I g), and of dubious purity, so it was prepared according to a modified literature 107 
procedure shown in scheme 125. The overall yield was Iow, and other more recently 
reported 135,136 syntheses of imidazole-lH -2-carbaldehyde (181) were attempted, but with no 
improvement on the yield. This included the synthesis of aldehyde (181) via a Comforth-
Huang 135 reaction to form 2-(dichloromethyl)imidazole (336), and in situ hydrolysis of 
imidazole (336), as shown in scheme 126. 
NaOMe yl flH 
--M-e"-O-H-~'~ CI- y- c- OMe 
H ! H2NCH2CH(OMe)2 
11 rr 
Cl-c-c-NHCH 2CH(OMe)2 
I 
H 
N 
--_0 (}-CHO 
N 
I 
H 
336 181 
Scheme 126. The synthesis of Imidazole-1 H-2-carbaldehyde (181) via a Cornforth-Huang type reactior 
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f{'C'OCH3 CH2NMe2 
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I 
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Scheme 127. Synthesis of Imidazole-1 H-2-carbaldehyde via aminal (337) 
Aldehyde (181) can also be obtained via aminal protection of imidazole, followed by a well 
documented C-2 lithiation and substitution, as shown in scheme 127.136 Hydrolysis of the 
aminal protecting group gave imidazole-lH -2-carbaldehyde (181). The reason for the low yields 
of aldehyde (181) in all these preparations was due to the considerable polarity and instability of 
this compound, which had to be precipitated as the free base from acidic solutions. Imidazole-
lH-2-carbaldehyde (181) has also been reported to be highly unstable to various organic and 
aqueous bases)36 
4.3.2 Preparation of 1-[3-(phenylselanyl)propyl].IH-2.imidazolecarbaldehyde (338) 
The most obvious preparation of the required l-[3-(phenylselanyl)propyl]-lH -2-
imidazolecarbaldehyde (338) is by the alkylation of imidazole-l H-2-carbaldehyde (181). The 
attempted alkylation of imidazole-l H-2-carbaldehyde (181) by treatment with sodium hydride, 
and quenching of the imidazole N-l anion with 3-iodo-l-(phenylselanyl)propane (233) failed to 
yield the desired imidazole (338), as shown in scheme 128. Bauer et al 136 have recently reported 
a similar observation shown in scheme 129. This involved the attempted sulfonylation of 
aldehyde (181) in the presence of either organic or aqueous bases, which resulted in intractable 
mixtures, which the authors suggested were due to the instability of the aldehyde (181) under 
alkaline conditions. 
(}-CHO 
N 
I 
H 
181 
1. NaH, THF 
2.I(CH2l3SePh 
X · (}-CHO N 
~sePh 
338 
Scheme 128. Attempted alkylation of imidazole-1 H-2-carbaldehyde (181) 
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Scheme 129. Attempted sulfonylation of imidazole-1 H-2-carbaldehyde (181) 
The alternative route to 1-[3-(phenylselanyl)propyIJ-lH -2-imidazolecarbaldehyde (338) shown 
in scheme 130 was also attempted. The initial alkylation of imidazole (204) occurred in 
reasonable yield using one equivalent of3-iodo-l-(phenylselanyl)propane (233), but when two 
equivalents were used the dialkylated imidazole (340) was obtained, which was due to the extra 
basic nitrogen in imidazoles (see section 3.4.3). For unknown reasons, the attempted lithiation of 
the C-2 position of imidazole (339) with n-BuLi, and subsequent quenching of the lithiated 
anion with DMF failed to yield the desired aldehyde (338). This reaction was repeated several 
times, but only the starting imidazole (339) was recovered. 
() 1. NaH, THF 
N 2. I(CH2l3SePh 
I (41%) 
H 
204 
1. NaH. THF 
2. Excess I(CHv3SePh 
(20%) 
• (~ 
1. n-BuLi, THF 
2.DMF 
N 
X 
~sePh 
339 
~sePh 
fi.0 
() I" 
N 
~sePh 
340 
• (}.-CHO 
N 
~sePh 
338 
Scheme 130. An attempted synthesis of 1-[(3-phenylselanyl)propyl]-1 H-2-imidazolecarbaldehyde (338) 
The successful preparation of 1-[3-(phenylselanyl)propyIJ-lH-2-imidazolecarbaldehyde (338) 
was achieved via the initial literature 137 preparation of acetal (341), as shown in scheme 131. 
The acetal was alkylated using sodium hydride and 3-iodo-l-(phenylselanyl)propane (233) to 
form 1-[(3-(phenylselanyl)propyIJ-2-(diethoxymethyl)imidazole (342) in good yield. The acetal 
was then hydrolysed to form 1-[3-(phenylselanyl)propyIJ-lH-2-imidazolecarbaldehyde (338), 
also in good yield. 
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H 
181 
(86%) 
• 
(
N OEI 
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Scheme 131. The synlhesis of 1-[(3-phenylselanyJ)propyJ]-1 H-2-imidazoJecarbaldehyde (338) 
4.3.3 Attempted radical cyclisation of 1-[3-(phenylselanyl)propyl]-1 H-2-
imidazolecarbaldehyde (338) 
(}-.CHO 
N 
~sePh 
338 
5 h addition 
acetonitrile, reflux 
() 
N 
~sePh 
339 
Scheme 132. Treatment of 1-[(3-phenyJseJanyJ)propyl]-1 H-2-imidazolecarbaJdehyde (338) with BU3SnH 
The attempted radical cyclisation of aldehyde (338) is shown in scheme 132. The aldehyde 
substituent in the 2-position of the imidazole ring proved unstable under these standard radical 
conditions, and was reduced to form imidazole (339). It can be inferred that the selective loss of 
the C-2 aldehyde is faster than SH2 abstraction of the phenylselenide group. The mechanism of 
the reaction is unknown, and not obvious. Because of the difficulty of the synthesis the reaction 
was not repeated once the synthesised material had been used up. Likewise, the more promising 
cyclisation of the 1-[4-(phenylselanyl)butyl]-1 H-2-imidazolecarbaldehyde (338a) shown in 
scheme 132a was not contemplated for the same reasons. Although, the results described in the 
last section suggest that this may be a more favoured process. Unfortunately, the attempted 
cyclisation of 1-[3-(phenylselanyl)propyl]-lH-2-imidazolecarbaldehyde (338) was carried out 
before our successful6-exo radical cyclisation of 1-[4-(phenylselanyl)butyIJ-lH-S-
imidazolecarbaldehyde (305 in scheme 123). 
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Scheme 132a. Radical cyclisalion of 1·[(4-phenylselanylbutyl)]-1 H-2-imidazolecarbaldehyde (338a) 
4.4 Radical Cyclisations onto 4-Phenylimidazole and 4-Nitroimidazole 
The regioselective cyclisation of 1-(ro-bromoalkyl)-IH-4-imidazolecarbaldehydes onto the C-S 
position of the imidazole ring is described in section 4.2.2. It was concluded that this was an 
addition of nucleophilic alkyl radicals onto the ~-position of a,~-unsaturated aldehydes in a 
Michael type manner. The work described in this section aimed to test the regioselectivity of 
these radical cyclisations with two different substituents at the 4-position of the imidazole ring 
(i.e. phenyl and nitro groups). 
The required 1-( ro-bromoalkyl)-4-phenyl-l H-imidazoles were obtained readily using sodium 
hydride in THF to generate the N-l anion of 4-phenylimidazole (343), which was quenched 
using a large excess of ro-dibromoalkane, as shown in scheme 133. The regioselective formation 
of the 4-isomer was facilitated by the steric hindrance imposed by the phenyl group on the N-3 
position, which prevented any formation of the S-isomer. 
Ph 
1. NaH, THF, reflux. ·l) 
2. BrCH 2(CH VnCH2 Br N 
~Br 
344. n = 1 (49%) 
345. n = 2 (40%) 
Scheme 133. The alkylation of 4-phenylimidazole (343) 
The regioselective formation of l-alkyl-S-nitroimidazoles proved difficult, as described in 
chapter 2. However, the regioselective formation of l-alkyl-4-nitroimidazoles is a much easier 
process, and is well documented. 79 Sodium hydride in THF was used to form the N-l anion, 
which was quenched with an excess of 1,4-dibromobutane to form 1-(4-bromobutyl)-4-nitro-1H-
imidazole (346 in scheme 134) in reasonable yield. The regioselectivity of the alkylation at the 
N-l position rather than the N-3 position is due to the much greater basic and nucleophilic 
character of the N-l anion (i.e. more distant from the electron withdrawing N02 group). 
Furthermore, the N-3 anion is deactivated by the large inductive electron withdrawal of the 
adjacent nitro group. 
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Scheme 134. Synthesis of 1-(4-bromobutyl)·4·1H·nitroimidazole (70) 
The treatment of 1-(3-bromopropyl)-4-phenyl-1H-imidazole (344) with BU3SnH gave almost 
equal quantities of the cycIised [1,2- a ]fused imidazole (347) and the uncycIised imidazole (348), 
as shown in scheme 135. In contrast, the treatment of 1-(4-bromobutyl)-4-phenyl-1H-imidazole 
with BU3SnH gave no uncycIised imidazole, and only the products of radical cycIisation onto the 
imidazole ring were obtained. Once more, the 5-membered ring cycIisation is less favoured than 
the six membered ring cycIisation because of strain. The 4-phenyl group has a much smaller 
directing influence on radical cycIisation onto the imidazole ring than the 4-aldehyde group, 
which resulted in some unexpected cycIisation onto the C-2 position in the six membered radical 
cycIisation. CycIisation onto the C-2 position of the imidazole ring is facilitated by virtue of it's 
electrophilic nature, which is due to the inductive influence of the adjacent nitrogen atoms. 
The two cycIised imidazoles (349) and (350) could not be separated by chromatography, and so 
the relative yields were estimated by GC-MS analysis. 
• 
Ph5 I ~ N Phy) + IlN ~ BU3SnH, AIBN, 5 h addition toluene, reflux 
344 347 348 
1.0: 1.1 
• 
PhYN l~ N 
BU3SnH, AIBN, 5 h addition 
toluene, reflux 
~Br 
345 349 350 
2.5: 1 
Scheme 135. The radical cyclisation of 1·(ro-bromoalkyl)-4-phenyl-1 H·imidazoles 
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The influence of the 4-phenyl substituent on the putative "pseudo-SRN 1 mechanism" is 
interesting. The phenyl group is +M, and therefore will not make the C-5 position more 
electrophilic to facilitate cyclisation, hence the competitive C-2 cyclisation occurred. The 
intermediate cyclised radical would be strongly stabilised by conjugation with the phenyl 
substituent, but much more so for cyclisations onto C-5 than C-2 (scheme 135a). This suggests 
that the stability of the intermediate cyclised radical is not crucial. The phenyl group also helps 
stabilise a radical anion by delocalisation. 
• • :e. • • V· 
• • • • 
Scheme 135a. Resonance stabilised It-radical intermediates 
The attempted radical cyclisation of 1-(4-bromobutyl)-4-nitro-lH-imidazole (346) using 
BU3SnH gave an intractable mixture, since the BU3Sn • radical can add onto the nitro group to 
yield unidentifiable products. 138 Furthermore, the N02 group will form radical anions according 
to the "pseudo-SRN 1 mechanism," which may be too stable to undergo the required single 
electron transfer process.8,45 
4.5 Radical Cyclisation Reactions onto Pyrroles 
The analogous oxidative radical cyclisations using BU3SnH were carried out on 3-acetylpyrroles 
and pyrrole-2-carbaldehydes for comparison purposes. The only previous examples of oxidative 
radical cyclisations onto pyrroles using the reductive conditions of BU3SnH addition have been 
reported by Muchowski et al69 (see scheme 49, section 1.3.3). The development of new 
synthetic methodology towards new pyrrolizidines is important, since many natural products 
possess this structural unit. 139 Some initial studies were carried out by Emma Mann, a final year 
project student. 
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4.5.1 The synthesis of 3-acetylpyrrole (353) 
Pyrrole is an electron rich or Tt-excessive heterocycle and unlike imidazole, can easily undergo 
aromatic electrophilic substitution reactions. The preferred position for aromatic electrophilic 
substitution is at the C-2 position, consequently it is difficult to obtain preparatively useful 
amounts of 3-substituted pyrroles by direct substitution reactions. Hence, it was necessary to 
protect pyrrole with the electron withdrawing phenylsulfonyl group,140 whjch deactivates the cr-
positions to acylation, and suppresses diacylation in the Friedel-Crafts reaction shown in scheme 
136.141 The phenyl sulfonyl group was hydrolysed using sodium hydroxide solution to give 3-
acetylpyrrole (353) in excellent yield. 141 
• Q (66%) 
COCH3 
1.AICI3,Ac20 Q~ 
-~-2. NaOH,dioxane 
(82%) ~ I 
H 
351 353 
Scheme 136. The synthesis of 3-acetylpyrrole (353) 
The 3-acety lpyrrole radical precursors were used instead of the analogous aldehydes, because of 
the shorter synthesis of 3-acetylpyrrole (353). Pyrrole-3-carbaldehyde (355) can only be 
prepared via the synthesis of l-[l-(sulfonylphenyl)-IH-pyrrololyl]-l-ethanone (354). since it 
was reported in the literature 142 that the synthesis of aldehyde (355) directly from a Friedel-
Crafts reaction on l-(sulfonylphenyl)pyrrole (352) had failed. A literature143 synthesis of 
pyrrole-3-carbaldehyde is outlined in scheme 137. Other syntheses of this compound have been 
reported. 142 
OH OH 
OCOCH3 1.5e02 0 ¥ ~ __ 2_. _Na_B_H_4_-.. ¥ ~ 1. Nal04 • 2. NaOH, dioxane 
I I 
S02Ph S02 Ph 
354 
CHO 
o 
I 
H 
355 
Scheme 137. The synthesis of pyrrole-3-carbaldehyde (355) 
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4.5.2 Alkylations of 3-acetylpyrrole (353) and pyrrole-2-carbaldehyde (177) 
COCH3 Q 
I 
H 
353 
In 
"ri"'CHO 
I 
H 
177 
COCH3 n 
2. BrCH2(CH2lnCH2Br i(~ 
1. NaH, THF, reflux 
• 
Br~ 
356.n=1 (51%) 
357. n = 2 (56%) 
358. n = 3 (63%) 
1. NaH, THF, reflux 
• 
359. n = 1 (71%) 
360. n = 2 (62%) 
361. n = 3 (45%) 
Scheme 138. The alkylation of pyrroles 
The alkylation of pyrroles is straightforward, unlike imidazoles which contain an extra basic 
nitrogen. Therefore, 1-[(ro-bromoalkyl)-1 H-pyrrolyl]-I-ethanones (356-358) and 
1-( ro-bromoalkyl)-1 H-2-pyrrolecarbaldehydes (359-361) were obtained regioselectively in good 
to excellent yields, as shown in scheme 138. 
4.5.3 Radical cyclisation of 1-[ (ro-bromoalkyl)-1H -pyrrolyl]-1-ethanones (356-358) and 
1-( ro-bromoalkyl)-1H-2-pyrrolecarbaldehydes (359-361). 
The radical cyclisations onto 3-acetylpyrroles are shown in scheme 139 and are used as a 
comparison for the analogous imidazole-4-carbaldehyde reactions. The regioselectivity exhibited 
by the 3-acetyl pyrroles was found to be similar to that observed in the imidazole series, that is 
addition of the nucleophilic radical onto the ~-position of the a,~-unsaturated ketone in a 
Michael type manner. The cyclisation at the C-2 position was completely selective for the 
6-membered cyclisation, and some uncyclised pyrroles were isolated in the 5- and 7-membered 
ring cyclisations. This again is due to strain in the five membered cyclisation, and a less 
favourable entropy factor in the seven membered cyclisation. 
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COCHa Q1 ,",'oH. A"N. , " "'''!'' (6,," 1 ~ n + reflux, toluene 
Br~ 
COCHa Q 
Yn 
362. n = 1 (46%) 
364. n = 2 (45%) 
366. n = 3 (54%) 
363. n = 1 (10%) 
365. n = 2 (0%) 
367. n = 3 (18%) 
Scheme 139. Radical cyclisations onto 3-acetylpyrroles using BU3SnH 
The radical cyclisation reactions onto pyrrole-2-carbaldehydes shown in scheme 140 are used as 
a comparison to the analogous imidazole-5-carbaldehyde reactions. The radical cyclisations 
were all regioselective with the highest yield obtained for the six membered ring cyclisation. The 
lowesh yields were due to problems of separating tin residues from the products. Unlike 
imidazoles, pyrroles cannot undergo an acidic extraction to remove tin residues, and so column 
chromatography had to be used in order to obtain pure samples of cyclised products. The 
oxidative Fentons conditions have also been used by Muchowski et aZ40 to synthesise 
2,3-dihydro-IH -pyrrolizinecarbaldehyde (368), and 5,6,7,8-tetrahydro-3-indolizinecarbaldehyde 
(369) in 50, and 58% yield respectively, as shown in scheme 141. 
n. OHc~if 
BN 
BU3SnH, AIBN, 5 h addition 
• 
reflux, toluene J:Q~ OHC 
)n 
368. n = 1 (28%) 
369. n = 2 (55%) 
370. n = 3 (40%) 
Scheme 140. Radical cyclisations onto pyrrole-2-carbaldehydes using BU3SnH 
J:Q~ OHC 
)n 
n. OHc~if 
Br~ 
• DMSO 
368. n = 1 (50%) 
369. n = 2 (58%) 
Scheme 141 . Radical cyclisations onto pyrrole-2-carbaldehydes using Fenton's conditions 
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4.6 Conclusions and Future Work 
We have thus reported the synthesis of novel bicyclic [l,2-a] and [1,2-c]fused imidazoles, and 
pyrrolizidines using radical cyclisation reactions. These can now be added to the growing list of 
reported oxidative radical cyclisation reactions using BU3SnH, which were reviewed in section 
1.3.3. The regioselectivity of radical cyclisations onto imidazole-4-carbaldehydes, and 
3-acetylpyrroles were determined by the addition of the nucleophilic alkyl radicals onto the ~­
position of a,~-unsaturated aldehydes or ketones in a Michael type manner. Aromatic 
conjugation present in the imidazole and pyrrole heterocycles, allows the aldehyde group to 
direct the addition of the nucleophilic alkyl radical onto the C-2 position in cyclisations onto 
imidazole-5-carbaldehyde, and onto the C-5 position in cyclisations of pyrrole-2-carbaldehydes. 
The regioselectivity of radical cyclisations was reduced in 4-phenyl substituted imidazoles, and 
in the formation of five and seven membered fused imidazoles and pyrroles. Work must now be 
carried out to determine the mechanism of these radical cyclisation reactions. 
The putative synthesis of the tricyclic imidazole (372) is shown in scheme 142, and may now be 
possible using the synthetic methodology described in this chapter. The biggest problem in this 
synthesis will probably be the preparation of the cyclopropane (371). Two literature144,145 
routes to cyclopropane (371) are outlined in schemes 143 and 144. Both these routes involve the 
initial generation of the dibromocarbene from bromoform, and it's 1,2-dipolar addition onto a 
double bond to form the cyclopropane ring. However, both these initial reactions have only been 
reported in poor yields, e.g. cyclopropane (373) was reported in 4% yield. 144 The longer 
synthesis shown in scheme 144 is necessary because the addition of dihalocarbenes to a,~­
unsaturated aldehydes is known not to be a feasible process, thus the acid (374) had to be 
made. 146 
OHC
tN BU3SnH, AIBN 
°1 OHC..!() 1. NaH I " . I " • • I!.... 0> Bb) N N I H 2. 278 372 Br 371 
Scheme 142. A possible synthesis of tricyclic imidazole (372) 
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~Br CHBr3, NaOH 
TEBA, water 
BrZBr 
• ~Br • Br 
373 371 
Scheme 143. A two step synthesis of 1,1-dibromo-2-bromomethylcyclopropane (371) 
CHBr3, NaOH 
TEBA, water 
• 
Br~ ___ K_M_nO--'.4_...;.~ Bry. U B,r 
~COOH 
374 
1. MeLi 
2. LiAIH4 
3. SOBr2 
~Br 
371 
Scheme 144. A longer synthesis of 1, 1-dibromo-2-bromomethylcyclopropane (370) 
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5.0 Experimential 
5.1 General 
5.2 Experimental for Chapter 2 
1) Preparation of 2-(5-nitro-l H-l-imidazolyl)-I-ethanol (175) 
2) Preparation of 1-(2-chloroethyl)-5-nitro-lH-imidazole (172) 
3) Preparation of 2(4)-chloro-l-(2-chloroethyl)-5-nitro-lH -imidazole (176) 
4) Attempted synthesis of 5H-pyrrolo[I,2-a]imidazole (182) by an intramolecular 
Schewizer-Light reaction 
5) Preparation of allyI4-methyl-l-benzenesulfonate [allyl tosylate, 193] 
6) Preparation of l-allyl-5-nitro-lH-imidazole (190) (using allyl tosylate) 
7) Preparation of l-allyl-5-nitro-lH-imidazole (190) (using allyl bromide) 
8) Preparation of (l-allyl-5-nitro-lH-imidazolyl)methanol (198) 
9) Preparation of l-allyl-5-nitro-lH -imidazolecarbaldehyde (191) 
5.3 Experimental for Chapter 3 
10) Preparation of 1-(triphenylmethyl)imidazole [1-(trityl)imidazole, 217] 
11) Preparation of 2-[(4-methylphenyl)sulfonyl]-I-(triphenylmethyl)-IH -imidazole (218) 
12) Preparation of 2-(phenylsulfanyl)-I-(triphenylmethyl)-IH -imidazole (219) 
13) Preparation of 2-chloro-I-(triphenylmethyl)-1 H-imidazole (220) 
14) Preparation of 2-[(4-methylphenyl)sulfonyl]-IH-imidazole [2-tosylimidazole, 221] 
15) Preparation of2-(phenylsulfanyl)-lH-imidazole (222) 
16) Preparation of 1-(3-bromo-2-propenyl)-2-[(4-methylphenyl)sulfonyl]-IH -imidazole (223) 
17) Attempted radical cyclisation of 1-(3-bromo-2-propenyl)-2-[(4-methylphenyl)sulfonyl]-IH-
imidazole (223) 
18) Preparation of 1-(3-chloropropyl)-2-[(4-methylphenyl)sulfonyl]-IH-imidazole (224) (using 
l-chloro-3-iodopropane) 
19) Preparation of 1-(3-chloropropyl)-2-[(4-methylphenyl)sulfonyl]-IH-imidazole (224) (using 
I-bromo-3-chloropropane) 
20) Preparation of 1-(3-iodopropyl)-2-[(4-methylphenyl)sulfonyl]-IH -imidazole (226) 
21) Preparation of 2-[( 4-methylphenyl)sulfonyl]-I-[(3-phenylselanyl)propyl]-IH -imidazole 
(227) 
22) Preparation of 2-[(4-methylphenyl)sulfonyl]-I-[(4-phenylselanyl)butyl]-1 H-imidazole (228) 
23) Preparation of 2-[(4-methylphenyl)sulfonyl]-I-[(5-phenylselanyl)pentyl]-IH -midazole (229) 
24) Preparation of 3-chloro-I-(phenylselanyl)propane (230) 
25) Preparation of 4-chloro-I-(phenylselanyl)butane (231) 
26) Preparation of 5-chloro-l-(phenylselanyl)pentane (232) 
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27) Preparation of 3-iodo-l-(phenylselanyl)propane (233) 
28) Preparation of 4-iodo-l-(phenylselanyl)butane (234) 
29) Preparation of 5-iodo-l-(phenylselanyl)pentane (235) 
30) Preparation of 6,7-dihydro-5H-pyrrolo[I,2-a]imidazole (183) (from the tosylate 227) 
31) Preparation of 5,6,7,8-tetrahydroimidazo[I,2-a]pyridine (211) 
32) Preparation of 6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepine (212) 
33) Preparation of 2-(phenylsulfonyl)-IH -imidazole (239) 
34) Preparation of 1-[(3-phenylselanyl)propyl]-2-(phenylsulfanyl)-1 H-imidazole (241) 
35) Radical cyclisation of 1-[(3-phenylselanyl)propyl]-2-(phenylsulfanyl)-1 H-imidazole (241) 
36) Preparation of 1-[(3-phenylselanyl)propyl]-2-(phenylsulfonyl)-IH -imidazole (243) 
37) Preparation of 6,7-dihydro-5H-pyrrolo[I,2-a]imidazole (183) (from the phenylsulfonate 243) 
38) Preparation of 1-(triphenylmethyl)benzimidazole [1-(trityl)benzimidazole, 258] 
39) Preparation of 2-[(4-methylphenyl)sulfonyl]-I-(triphenylmethyl)benzimidazole (259) 
40) Preparation of 2-(phenylsulfanyl)-I-(triphenylmethyl)benzimidazole (260) 
41) Preparation of 2-(phenylsulfanyl)-1 H-benzimidazole (261) 
42) Preparation of 1-[3-(lH -benzoimidazol-l-yl)propyl]-IH -benzoimidazole (263) 
43) Preparation of 1,3-di(3-bromopropyl)-3H-benzoimidazol-l-ium bromide (264) 
44) Preparation of 1-(3-chloropropyl)-2-(phenylsulfanyl)-1 H-benzimidazole (265) 
45) Attempted preparation of 1-(3-bromopropyl)-2-(phenylsulfanyl)-IH -benzimidazole (266) 
using sodium bromide in acetone (Finkelstein conditions) 
46) Preparation of 1-(3-bromopropyl)-2-(phenylsulfanyl)-IH -benzimidazole (266) 
47) Preparation of 1-[3-(phenylselanyl)propyl]-2-(phenylsulfanyl)-1 H-benzimidazole (267) 
48) Preparation of 1-[4-(phenylselanyl)butyl]-2-(phenylsulfanyl)-1 H-benzimidazole (268) 
49) Preparation of 1-[5-(phenylselanyl)pentyl]-2-(phenylsulfanyl)-IH -benzimidazole (269) 
50) Preparation of 2,3-dihydro-l H-benzo[ d]pyrrolo[1 ,2-a ]imidazole (252) 
51) Preparation of 1 ,2,3,4-tetrahydrobenzo[ 4,5]imidazo[ 1 ,2-a ]pyridine (253) 
52) Preparation of 7,8,9,1 0-tetrahydro-6H-benzo[ 4,5]imidazo[ 1 ,2- a ]azepine (254) 
53) Preparation of 1-(3-chloropropyl)-IH -benzimidazole (270) 
54) Preparation of 1-[3-(phenylselanyl)propyl]-IH-benzimidazole (271) 
55) Attempted radical cyclisation of 1-[3-(phenylselanyl)propyl]-IH-benzimidazole (271) 
56) Preparation of 2-deuterio-l-[3-(phenylselanyl)propyl]-1 H-benzimidazole (275) 
57) Radical cyclisation of 2-deuterio-l-[3-(phenylselanyl)propyl]-1 H-benzimidazole (275) 
58) Radical cyclisation of 1-[3-(phenylselanyl)propyl]-1 H-benzimidazole (271) using BU3SnD 
5.4 Experimental for Chapter 4 
59) Preparation of 1-(3-chloropropyl)-IH -4-imidazolecarbaldehyde (288) 
60) Preparation of 1-(3-bromopropyl)-IH-4-imidazolecarbaldehyde (290) 
61) Preparation of 1-(4-bromobutyl)-IH-4-imidazolecarbaldehyde (292) 
62) Preparation of 1-(5-bromopentyl)-1 H-4-imidazolecarbaldehyde (294) 
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63) Preparation of 1-(6-bromohexyl)-lH -4-imidazolecarbaldehyde (296) 
64) Preparation of 1-(12-bromododecyl)-lH-4-imidazolecarbaldehyde (298) 
65) Preparation of 1-(4-chlorobutyl)-lH-5-imidazolecarbaldehyde (301) 
66) Preparation of 1-[(3-phenylselanyl)propyIJ-lH -5-imidazolecarbaldehyde (303) 
67) Preparation of 1-[(4-phenylselanyl)butyl)J-l H-S-imidazolecarbaldehyde (305) 
68) Preparation of 1-(3-iodopropyl)-IH-4-imidazolecarbaldehyde (306) 
69) Preparation of 6,7-dihydro-SH-pyrrolo[1,2-cJimidazole-l-carbaldehyde (307) (from the in 
situ formation of the iodide 306) 
70) Preparation of (l-[3-(phenylselanyl)propyIJ-lH-4-imidazolyl}methanol (309) 
71) Preparation of (l-[3-(phenylselanyl)propyl]-IH-4-imidazolecarbaldehyde (302) 
72) Preparation of 6,7-dihydro-SH-pyrrolo[1,2-c]imidazole-l-carbaldehyde (307) (from the 
selenide 302) 
73) Preparation of 6,7-dihydro-SH-pyrrolo[I,2-c]imidazole-l-carbaldehyde (307) (from the 
bromide 290) 
74) Preparation of S,6,7,8-tetrahydroimidazo[1 ,S-aJpyridine-l-cabaldehyde (310) 
7S) Preparation of S,6,7,8-tetrahydro-SH-imidazo[1,S-a]azepine-l-cabaldehyde (312) 
76) Attempted radical cyclisation of 1-(6-bromohexyl)-IH-4-imidazolecarbaldehyde (296) 
77) Attempted radical cyclisation of of 1-(12-bromododecyl)-IH-4-imidazolecarbaldehyde (298) 
78) Preparation of 1-(3-bromopropyl)-S-methyl-lH -4-imidazolecarbaldehyde (318) 
79) Attempted radical cyclisation of 1-(3-bromopropyl)-S-methyl-lH -4-imidazolecarbaldehyde 
(318) 
80) Preparation of 1-(3-bromopropyl)-2-methyl-lH -4-imidazolecarbaldehyde (320) 
81) Preparation of (E)-4-(3-methyl-6,7 -dihydro-SH -pyrrolo[ 1 ,2-c Jimidazol-l-yl)-3-buten-2-one 
(322) 
82) Preparation of 1-(2-bromobenzyl)-1 H-4-imidazocarbaldehyde (323) 
83) Attempted radical cyclisation of 1-(2-bromobenzyl)-IH-4-imidazocarbaldehyde (323) 
84) Attempted radical cyclisation of 1-[(3-(phenylselanyl)propyl]-IH -S-imidazolecarbaldehyde 
(303) 
8S) Preparation of S,6,7 ,8-tetrahydroimidazo[1 ,2-aJpyridine-3-carbaldehyde (332) 
86) Preparation of l-(triphenylmethyl)-1 H-2-imidazolecarbaldehyde (335) 
87) Preparation of imidazole-l H-2-carbaldehyde (181) 
88) Attempted alkylation of imidazole-lH-2-carbaldehyde (181) 
89) Preparation of 1-[3-(phenylselanyl)propyl]imidazole (339) 
90) Preparation of 1 ,3-di[3-(phenylselanyl)propyll-l H-imidazol-3-ium iodide (340) 
91) Attempted preparation of 1-[3-(phenylselanyl)propyll-lH-2-imidazolecarbaldehyde (338) 
(from 1-[3-(phenylselanyl)propyllimidazole 339) 
92) Preparation of 2-(diethoxymethyl)imidazole (181) 
93) Preparation of 2-(diethoxymethyl)-I-[3-(phenylselanyl)propyll-l H-imidazole (342) 
94) Preparation of 1-[3-(phenylselanyl)propyI1-2-imidazolecarbaldehyde (338) 
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9S) Attempted radical cycIisation of 1-[3-(phenylselanyl)propyl]-2-imidazolecarbaIdehyde (338) 
96) Preparation of 1-(3-bromopropyl)-4-phenyl-lH-imidazole (344) 
97) Preparation of 1-(4-bromobutyl)-4-phenyl-IH-imidazole (345) 
98) Preparation of 1-(4-bromobutyl)-4-nitro-IH-imidazole (346) 
99) Preparation of l-phenyl-6,7-dihydro-5H-pyrrolo[I,2-c]imidazole (347) 
lOO) Radical cycIisation of 1-(4-bromobutyl)-4-phenyl-IH-imidazole (345) 
101) Attempted radical cycIisation of 1-(4-bromobutyl)-4-nitro-IH-imidazole (346) 
102) Preparation of 1-(phenylsulfonyl)-lH-pyrrole (352) 
103) Preparation of 1-(lH -3-pyrrolyl) I-ethanone [3-acetylpyrrole, 353] 
104) Preparation of 1-[1-(3-bromopropyl)-1 H -3-pyrrolyl]-I-ethanone (356) 
105) Preparation of 1-[ 1-( 4-bromobutyl)-IH -3-pyrrolyl]-I-ethanone (357) 
106) Preparation of 1-[I-(5-bromopentyl)-IH-3-pyrrolyl]-I-ethanone (358) 
107) Preparartion of 1-(3-bromopropyl)-1 H-pyrrolecarbaIdehyde (359) 
108) Preparartion of 1-(4-bromobutyl)-IH-pyrrolecarbaldehyde (360) 
109) Preparartion of 1-(S-bromopentyl)-IH-pyrrolecarbaIdehyde (361) 
110) Preparation of 1-(2,3-dihydro-1 H-7-pyrroIizinyl)-I-ethanone (362) 
Ill) Preparation of 1-(S,6,7,8-tetrahydro-l-indoIizinyl)-I-ethanone (364) 
112) Preparation of 6,7,8,9-tetrahydro-SH-pyrrolo[I,2-a]azepine-3-carbaldehyde (366) 
113) Preparation of 2,3-dihydro-IH-5-pyrroIizinecarbaldehyde (368) 
114) Preparation of S,6,7,8-tetrahydro-3-indolizinecarbaldehyde (369) 
liS) Preparation of 6,7,8,9-tetrahydro-SH-pyrrolo[I,2-a]azepine-3-carbaldehyde (370) 
101 
5.0 Experimental 
5.1 General 
IR spectra were detennined using a Nicolet 205 Ff-IR spectrometer and Perkin Elmer Ff-IR 
Paragon 1000 spectrometer as KBr discs for solids and as thin films for liquids. 1 H NMR spectra 
were measured using the Bruker AC 250 spectrometer at 250.0 MHz unless otherwise stated. J 
values are given in Hz. l3C NMR spectra were measured using the Bruker DPX 400 MHz 
spectrometer at 100.6 MHz unless otherwise stated. NMR spectra were recorded with CDCI 3 as 
solvent and tetramethylsilane (TMS) as internal reference unless otherwise stated. Mass spectra 
were recorded using a Kratos MS 80 instrument, and EPSRC Mass Spectrometry Service, 
Swansea University. Elemental analysis was carried out on a Perkin Elmer 2400 CHN 
Elemental Analyser. The GC-MS used was the Fisons GC 8000 series (AS 800). Melting points 
were carried out using Leica Galen Melting Point Apparatus, and are uncorrected. 
TLC using silica gel as absorbent was carried out with aluminium backed plates coated with 
silica gel (Merck Kieselgel 60 F254), and TLC using a1umina as absorbent was carried out with 
aluminium backed plates coated with neutral aluminium oxide (Merck 150 F254,TypeT). 
Column chromatography using silica gel was carried out with Merck Kieselgel 60 H silica and 
column chromatography using alumina was carried out with Aldrich aluminium oxide, activated 
neutral, Brockmann I, STD Grade, 150 mesh size. Prep-TLC was carried out using aluminium 
oxide (Merck 60 PF254,Type E). 
All of the following alkylations and radical cyclisation reactions of imidazoles, benzimidazoles 
and pyrroles were carried out using dry glassware and under an atmosphere of nitrogen. 
Anhydrous acetonitrile, THF and toluene were obtained commercially, and were used as 
reaction solvents in all the stated cases. Sodium hydride was obtained as 60% dispersion in oil, 
and was washed with light petroleum and 2.5 M solution of n-butyllithium in hexane was used 
in all stated cases. 
The work up of reactions and column chromatography were carried out using light petroleum 
(refers to the bp 40-60 °C fraction), ethyl acetate, dichloromethane, diethyl ether and 
methanol. Light petroleum and ethyl acetate were distilled from calcium chloride and 
dichloromethane was distilled over phosphorus pentoxide. Analytical grade diethyl ether and 
methanol were obtained commercially. 
102 
5.2 Experimental for Chapter 2 
1) 2-(5-Nitro-lH -1-imidazolyl)-I-ethanol (175)94 
O:!N<"\ l.» N 
I 
H 
171 
• 
175 
4(5)-Nitroimidazole 171 (12.50 g, 0.111 mol) and potassium iodide (5.00 g, 30.1 mmol) were 
added to 2-chloroethanol (250 rnl) and heated under reflux for 18 h. The solution was evaporated 
to dryness to yield a tan residue, which was added to water (200 ml). The solution was gravity 
filtered to remove the unreacted nitroimidazole and the filtrate basified to pH 8 with saturated 
sodium carbonate solution. The solution was extracted into ethyl acetate (2 x 100 ml) and 
evaporated to dryness to yield a brown residue, which was recrystallised from absolute ethanol 
to yield pale brown crystals of2-(5-nitro-IH-I-imidazolyl)-I-ethanoI175 (3.82 g, 22%), mp 99-
100°C (lit. 94 mp 96-97 0C); (Found: C, 38.2; H, 4.1; N, 26.8. C5H7N303 requires C, 38.2; H, 
4.4; N, 26.8%); OH 2.06 (I H, s, OH), 3.99-4.02 (2 H, t, J 4.8, 2'-CH2), 4.52-4.56 (2 H, t, J 4.8, 
NCH2), 7.66 (I H, s, Im-2-H) and 8.00 (I H, s, Im-4-H). 
2) 1-(2-Chloroethyl)-5-nitro-lH-imidazole (172)82 
172 
2-(5-Nitro-IH -I-imidazolyl)-I-ethanol 175 (2.00 g, 12.7 mrnol) was added to thionyl chloride 
(50 ml) and heated under reflux for 3 h. The excess thionyl chloride was evaporated to leave 
a tan residue, which was added to water (100 ml). The aqueous solution was basified to pH 8 
with saturated sodium carbonate solution and extracted into ethyl acetate (2 x 100 ml). The 
solution was evaporated to dryness to yield a brown residue, which was purified by column 
chromatography using neutral alumina as absorbent with dichloromethane as eluent to yield pale 
yellow needles of 1-(2-chloroethyl)-5-nitro-1H-imidazole 172 (0.78 g, 35%), mp 49-50 °C (lit.82 
mp 49-51 0C); OH 3.87-3.90 (2 H, t, J 5.4, 2'-CH2), 4.66-4.70 (2 H, t, J 5.4, NCH2), 7.67 (1 H, s, 
Im-2-H) and 8.04 (I H, s, Im-4-H); Oc (62.5 MHz) 42.50 (2'-CH2), 49.51 (NCH2), 134.04 (lm-
4-CH) and 142.51 (Im-2-CH); mlz 175 (M+, 35%), 158 (9),140 (25),129 (9), 67 (39), 63 (60) 
and 28 (lOO). 
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3) 2( 4)-Chloro-l-(2-chloroethyl)-5-nitro-1H -imidazole (176) 
J f'!o ------. 1-7 ~ N 
> 
175 176 
2-(5-Nitro-1H-l-imidazolyl)-I-ethanoI175 (2.00 g, 12.7 mmol) was added to thionyl chloride 
(50 ml) and heated under reflux for 54 h. The excess thionyl chloride was evaporated to leave a 
tan residue, which was added to water (100 ml). The aqueous solution was basified to pH 8 with 
saturated sodium carbonate solution and extracted into ethyl acetate (2 x lOO ml). The solution 
was evaporated to dryness to yield a brown residue, which was purified by column 
chromatography using neutral alumina as absorbent with dichloromethane as eluent to yield 
cream coloured crystals of 2(4)-chloro-I-(2-chloroethyl)-5-nitro-IH-imidazole 176 (1.2 g, 45%), 
mp 92-93 °C (Found: M+, 208.9759. CSH5N3CI202requires M, 208.9757); Vrnax !cm-! 3107, 
1538 (N02), 1506, 1390, 1360 (N02), 1340 and 827; OH 3.82-3.87 (2 H, t, J 5.7, 2'-CH2), 4.37-
4.41 (2 H, t, J 5.7, NCH2) and 7.87 (1 H, s, Im-2(4)-H); oc 42.02 (2'-CH2), 49.61 (NCH2), 
121.73 (Im-CH), 132.68 (Im-CH) and 146.14 (q-C, Im-5-C); m/z 209 (M+, 28%), 90 (66), 63 
(100) and 27 (53). 
4) Attempted synthesis of 5H-pyrrolo[I,2-a]imidazole (182) by an intramolecular 
Schewizer-Light reaction 
N 
[ }-CHO 
N 
I 
H 
181 
I-I:!C= C-PPh3 8r-H 
vinyl phosphonium bromide 182 
Imidazole-2-carbaldehyde (0.27 g, 2.8 mmol) was added to sodium hydride (0.08 g, 3.4 mmol) 
in THF (100 ml), and the mixture was stirred and heated under reflux for 2 h. 
Vinyltriphenylphosphonium bromide (Schweizer reagent, 1.14 g, 3.1 mmol) was added, and the 
mixture was stirred and heated under reflux for a further 5 h. The salts formed were removed by 
filtration on a celite bed and the solution was evaporated to dryness to give a tan residue, which 
rapidly darkened to yield unidentifiable products. 
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5) AllyI4-methyl-l-benzenesulfonate [allyl tosylate, 193] 
25% Aqueous sodium hydroxide solution (70 ml, 0.4 mol) was added dropwise to a solution of 
allyl alcohol (51.2 g, 0.9 mol) and p-toluenesulfonyl chloride (76.4 g, 0.4 mol) at 0-10 CC. The 
reaction mixture was allowed to stand at ambient temperature for 18 h and was poured onto ice-
water (400 ml). The aqueous solution was extracted with dichloromethane (2 x 200 ml), and the 
combined organic extracts dried (MgS04) and evaporated to dryness to yield allyl 4-methyl-l-
benzenesulfonate 193 (56.0 g, 66%) as a colourless oil; OH 2.42 (3 H, s, CH3), 4.48-4.51 (2 H, m, 
1'-CH2), S.20-S.24 (I H, m, 3'-cis-H), S.24-S.32 (1 H, m, 3'-trans-H), S.73-S.84 (I H, m, 2'-CH), 
7.31-7.34 (2 H, d, 17.S, ArH) and 7.7S-7.78 (2 H, d, J 7.5, ArH). 
6) l-Allyl-5-nitro-lH-imidazole (190) (using allyl tosylate) 
~OTs 
~tN 193 N ~~~ • 02):J + I ~ l( N N ~ I ~ H 171 
190 194 
4(5)-Nitroimidazole 171 (1S.0 g, 0.133 mol), allyI4-methyl-I-benzenesulfonate 193 (32.0 g, 
0.150 mol) and 4-methyl-I-benzenesulfonic acid monohydrate [p-toluenesulfonic acid 
monohydrate] (1.0 g, 5 mmol) were heated at 130°C for 18 h. Sodium carbonate solution (300 
ml, 1.0 M) was added to the cooled melt, and stirred for 10 min. The mixture was gravity 
filtered to remove unreacted nitroimidazole and the filtrate extracted with dichloromethane (2 x 
150 rnI). The combined organic extracts were dried (MgS04) and evaporated to dryness to give 
a brown oil containing I-allyl-S-nitro-IH-imidazole 190; OH 4.97-5.00 (2 H, m, NCH2), 5.15-
5.22 (1 H, dd, J 1.5 andJ 17.1, 3'-trans-H), 5.32-S.36 (I H, d, J9.6, 3'-cis-H), 5.94-6.09 (IH, m, 
2'-H), 7.60 (!H, s, Im-2-H) and 8.02 (!H, s, Im-4-H) and l-allyl-4-nitro-IH-imidazole 194 
(4.0 g, 18% and 2% yield respectively by IH NMR spectroscopic analysis of reaction mixture 
using a known amount of 1,4-dimethoxybenzene as internal standard). 
7) l-Allyl-5-nitro-lH-imidazole (190) (using allyl bromide) 
02):} 
02t N ~~) ~Br + I ~ • N ~ N ~ I H 
171 190 194 
10S 
4(5)-Nitroimidazole 171 (2.00 g, 18 mmol) and allyl bromide (1.5 ml, 18 rnrnol) were added to 
DMF (75 ml). The mixture was stirred and heated under reflux at 50-75°C for 96 h. The 
solution was evaporated to dryness to yield a tan residue, which was added to sodium carbonate 
solution (100 ml) and the mixture gravity filtered to remove unreacted nitroimidazole. The 
filtrate was extracted with dichloromethane (2 x 50 ml), the combined organic extracts washed 
with brine (3 x 50 ml), dried (MgS04 ) and evaporated to dryness to give a tan oil containing 
l-allyl-5-nitro-IH-imidazole 190 and l-allyl-4-nitro-lH-imidazole 194 (0.17 g, 3% and 3% yield 
respectively by IH NMR spectroscopic analysis of reaction mixture using a known amount of 
1,4-dimethoxybenzene as internal standard). 
8) (I-Allyl-S-nitro-lH-2-imidazolyl)methanol (198) 
190 194 198 194 
A crude mixture of l-allyl-5-nitro-l H-imidazole 190 and l-allyl-4-nitro-1 H-imidazole 194 
(2.55 g, 9/1 respectively by IH NMR spectroscopic analysis), paraformaldehyde (3.09 g, 0.102 
mol) and DMSO (150 ml) were introduced into a Carius tube and sealed. The sealed tube was 
heated at 120°C for 54 h, and the contents of the tube were allowed to cool to room temperature. 
The tube was opened and the solution was evaporated to dryness to yield a brown residue, which 
was purified by column chromatography using neutral alumina as absorbent with 
dichloromethane followed by 5% methanol 1 dichloromethane as eluent to yield unreacted 
yellow needles of l-allyl-4-nitro-lH-imidazole 194 (0.14 g), mp 44-46 °C (Found: M+, 
153.0537. C6H7N30Z requires M, 153.0538); vrnax Icm-! 3426,3078, 1545 (NOz), 1525, 1345 
(NOz) and 1294; OH 4.63-4.65 (2 H, m, NCH2), 5.32-5.36 (I H, d, 16.8 Hz, 3'-trans-H), 5042-
5046 (1 H, d, J 10.3, 3'-cis-H), 5.91-6.07 (I H, m, 2'-H), 7045 (I H, s, Im-2-H), and 7.77 (1 H, s, 
Im-5-H); oc 50.54 (NCH2), 119.20 (3'-CH2), 120.94 (CH), 130.57 (CH) and 135.83 (CH); mlz 
153 (M+, 61 %), 137 (32), 107 (60) and 41 (100); Further elution yielded a brown oil of (I-allyl-
5-nitro-lH-2-imidazolyl)methanoI198 (1.11 g, 40%), containing a residual amounts of DMSO; 
(Found: M+, 183.0624. C7H9N303 requires M, 183.0644); Urnax Icm-! 2878, 1537 (N02), 1467, 
1382 and 1359 (N02); OH 3.34-3.39 (I H, t, J 6.2, OH), 4.73-4.77 (2 H, rn, CH20H), 5.01-5.09 
(I H, dd, J 1.9 and J 17.5, 3'-trans-H), 5.10-5.12 (2 H, m, NCH2), 5.25-5.30 (I H, dd, J lA and 
J lOA, 3'-cis-H), 5.92-6.05 (1 H, m, 2'-H) and 7.96 (1 H, s, Im-4-H); oc 47.96 (NCHz), 56041 
(CH20H), 118.16 (3'-CH2), 131.31 (CH), 133.33 (CH) and 151.56 (Irn-2-C); mlz 183 (M+, 7%), 
152 (12),142 (8), 41 (100),31 (27) and 29 (50). 
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9) l-AlIyl-5-nitro-lH-imidazolecarbaldehyde (191) 
198 191 
(I-AIIyl-5-nitro-IH-2-imidazolyl)methanol 198 (0.300 g, 1.64 mmol) and activated manganese 
dioxide (0.712 g, 8.2 mmol) were heated under reflux in dry dichloromethane (150 ml) for 18 h. 
The mixture was cooled, filtered on a celite bed and the residue washed with dichloromethane (3 
x 50 ml). The combined filtrate washings were evaporated to give a brown oil of l-aIlyl-5-nitro-
IH-imidazolecarbaldehyde 191; OH 5.13-5.20 (I H, dd, J 1.9 and J 17.1, 3'-trans-H), 5.25-5.30 
(I H, d, J 12.4, 3'-cis-H), 5.51-5.54 (2 H, m, NCH2), 5.90-6.04 (I H, m, 2'-H), 8.14 (I H, s, Im-
4-H) and 9.94 (1 H, s, CHO) and recovered (1-aIlyl-5-nitro-IH-2-imidazolyl)methanoI198 
(0.183 g, 64% and I % yield respectively by IH NMR spectroscopic analysis of reaction mixture 
using a known amount of 1,4-dimethoxybenzene as internal standard). 
5.3 Experimental for Chapter 3 
10) 1-(Triphenylmethyl)imidazole [1-(Trityl)imidazole, 217] 
N [~ 
N 
I 
H 
204 
• 
N [~ 
N 
I 
CPh 3 
217 
Imidazole 204 (10.2 g, 0.150 mol) was dissolved in dichloromethane (200 ml). Triphenylmethyl 
chloride (46.0 g, 0.165 mol) was added over 20 min and the mixture stirred until the solution 
was complete. Triethylamine (42 ml, 0.300 mol) was added slowly to the stirred solution and 
the stirring was continued overnight at ambient temperature. The solution was evaporated to 
dryness and the residue was recrystallised from absolute ethanol and dried to give 
I-(triphenylmethyl)imidazole 217 as pale white needles (42.0 g, 90%), mp 229-230 °C (lit. 108 
mp 229-230 0C). 
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11) 2-[(4-MethylphenyI)sulfonyIJ-1-(triphenylmethyI)-lH-imidazole (218) 
N (> 
N 
I 
CPh 3 
217 
• 
N 
( '>-S02T01 
N 
I 
CPh3 
218 
l-(Trityl)imidazole 217 (9.0 g, 27 mmol) was dissolved in THF (300 ml) and TMEDA (12 ml, 
81mmol) was added to the stirred solution at ambient temperature. The temperature of the stirred 
solution was lowered to -78°C, and a solution ofn-butyllithium (13 ml, 32 mmol) added 
dropwise. The solution turned red and was stirred at 0 °C for a further 20 min. A solution of p-
toluenesulfonyl fluoride (14.1 g, 81 mmol) in THF (50 ml) was added dropwise and the stirring 
was continued at ambient temperature for a further 2 h. The solution was evaporated to dryness 
and saturated ammonium chloride (50 ml) and water (100 ml) was added to the residue. The 
aqueous mixture was extracted with dichloromethane (3 x 50 rnI), the organic extracts dried 
(MgS04), and the solution evaporated to dryness. The crude solid was purified by column 
chromatography using silica gel as absorbent with light petroleum and dichloromethane as 
eluent. Evaporation of the eluates containing the second component gave white crystals of 
2-[(4-methylphenyl)sulfonyII-I-(triphenylmethyl)-IH-imidazole 218 (4.1 g, 33%), mp 175 
-176°C (Found: C, 75.3; H, 5.4; N, 5.4. C29H2~202S requires C, 75.0; H, 5.2; N, 5.6%); 
vrnax !cm-! 1594, 1493, 1447, 1337 (S02), 1233, 1174 and 1148 (S02); m/z 464 (M+, 85%),387 
(lOO), 188 (40), 105 (lOO), 91 (27),77 (53) and 28 (27). 
12) 2-(Phenylsulfanyl)-1-(triphenylmethyl)-lH-imidazole (219) 
() 
N 
I 
CPh 3 
217 
• (}-SPh 
N 
I 
CPh 3 
219 
l-(Trityl)imidazole 217 (8.0 g, 25.8 mmol) was dissolved in THF (300 ml), the temperature of 
this stirred solution was lowered to -78°C, and a solution of n-butyllithium (13 rnI, 31.0 mmol) 
added dropwise. The solution turned red and was stirred at 0 °C for a further 20 min. A solution 
of diphenyl disulfide (16.9 g, 77.4 mmol) in THF (100 rnI) was added dropwise and the stirring 
was continued at ambient temperature for a further 2 h. The solution was evaporated to dryness 
and saturated ammonium chloride (50 ml) and water (lOO ml) was added to the residue. The 
aqueous mixture was extracted with dichloromethane (3 x 50 ml), the organic extracts dried 
(MgS04) and evaporated to dryness. The crude solid was purified by column chromatography 
using silica gel as absorbent with light petroleum / dichloromethane and then diethyl ether as 
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eluent. Evaporation of the eluates containing the second component gave white crystals of 
2-(phenylsulJanyl)-1-(triphenylmethyl)-lH-imidazole 219 (5.0 g, 46%), mp 172-174 cC, 
(Found: C, 80.2; H, 5.2; N, 6.3. C2SH22N2S requires C, 80.4; H, 5.3; N, 6.7%); vrnax !cm- l 1580, 
1492, 1479, 1446, 1415, 1233, 1112,753,705,689 and 640. 
13) 2-Chloro-l-(triphenylmethy\)-IH-irnidazole (220) 
N (~ 
N 
I 
• 
N ( }-CI 
N 
I 
CPh3 CPh 3 
217 220 
1-(Trityl)imidazole 217 (2.00 g, 6 mmol) was dissolved in THF (lOO ml) and the temperature of 
the stirred solution was lowered to -78 cC, and a solution of n-butyllithium (3 ml, 7 mmol) 
added dropwise.The solution turned red and was stirred at 0 cC for a further 20 min. A solution 
of p-toluenesulfonyl chloride (3.7 g, 18 mmol) in THF (50 ml) was added dropwise and the 
stirring was continued at ambient temperature for a further 2 h. The solution was evaporated to 
dryness and saturated ammonium chloride (50 m\) and water (lOO ml) was added to the residue. 
The aqueous mixture was extracted with dichloromethane (3 x 50 ml), the organic extracts dried 
(MgS04), and the solution evaporated to dryness. The crude solid was purified by column 
chromatography using silica gel with light petroleum and dichloromethane as eluent. 
Evaporation of the eluatescontaining the second component gave yellow crystals of 2-chloro-l-
(triphenylmethyl)-IH-imidazole 220, (0.29 g, 14%), mp 225-227 cC. 
General procedure for the removal of the trityl protective group 
14) 2-[(4-Methylphenyl)sulfonyl]-IH-imidazole [2-tosylimidazole, 221] 
(}-S02T01 
N 
I 
CPh 3 
218 
• 
2-[(4-Methylphenyl)sulfonyl]-I-(triphenylmethyl)-IH-imidazole 218 (3.00 g, 6.5 mmol) was 
dissolved in methanol (lOO ml) and concentrated hydrochloric acid (l0 ml, 31-34% w/w 
solution) added. The solution was heated under reflux for 2 h. After cooling the solution to 
ambient temperature, most of the solvent was evaporated and the residue added to water 
(100 ml). The acidic aqueous mixture was extracted with dichloromethane (2 x 50 ml), which 
removed the hydrolysis product, triphenylmethylalcohol. The acidic aqueous layer was 
evaporated to leave approximately 30-40 ml of a solution containing the salt of the imidazole 
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compound, which was precipitated as the free base from the saturated aqueous acidic solution 
using solid sodium carbonate until foaming ceased. The precipitate was filtered, dried (MgS04) 
and recrystaIlised with absolute ethanol to yield white needles of 2-[(4-methylphenyl)sulfonyIJ-
lH-imidazole 221 (0.63 g, 44%), mp 200-202 °C (Found: C, 53.7; H, 4.1; N, 12.4. 
ClOHlON202S requires C, 54.0; H, 4.5; N, 12.6%); vrnax fcm- l 1333 (S02), 1152 (S02), 1107 
and 1082; OH ([2H6J Me2S0) 2.36 (3 H, s, CH3), 7.22 (2 H, bs, Im-4, 5-H), 7.40-7.43 (2 H, d, J 
7.5, Ar-H) and 7.77-7.80 (2 H, d, J 7.5, Ar-H); Oc ([2H6J Me2S0) 22.96 (CH3), 129.27, 
132.02,139.06 (q-C), 145.34 (q-C) and 46.69 (q-C); m/z 158 (M+, 100%),131(31),91(48), 
77(5),65(24) and 39 (12). 
15) 2-(phenylsulfanyl)-IH -imidazole (222) 
(}-SPh 
I CPh 3 
219 
• 
N ( }-SPh 
N 
I 
H 
222 
The general procedure for the removal of the trityl protective group was followed. 
2-(Phenylsulfanyl)-I-(triphenylmethyl)-IH-imidazole 219 (4.67 g, 11.2 mmol) gave white 
needles of 2-(phenylsulfanyl)-IH -imidazole 222 (1.61 g, 85%), mp 175-176 ·C, (Found: MH+, 
177.0486. C9HSN2S + H requires M, 177.0486); Vrnax fcm'! 2625, 1582, 1479, 1441, 1416, 
1326,1100,964,751 and 739; OH ([2H6J Me2S0) 7.10-7.35 (7 H, m, Im-4(5)-H and Ar-H) and 
12.81 (1 H, bs, NH); Oc([2H6J Me2S0) 124.54, 125.40, 126.38, 128.30, 133.65 (q-C) and 
134.96 (q-C); m/z 176 (M+, 43%), 175 (92),77 (88), 72 (73), 69 (35), 65 (48) and 51 (100). 
General procedure for the alkylation of imidazoles 
16) 1-(3-Bromo-2-propenyl)-2-[(4-methylphenyl)sulfonyIJ-lH-imidazole (223) 
• 
2-[(4-Methylphenyl)sulfonyIJ-lH-imidazole 221 (0.600 g, 2.7 mmol) was added to sodium 
hydride (70 mg, 3 mmol) in acetonitrile (100 ml). The mixture was stirred and heated under 
reflux for 1 h, and l,2-dibromopropene (mixture of cis and trans isomers, 1.620 g, 8.1 mmol) 
was added. The mixture was stirred and heated under reflux for a further 2 h. The salts formed 
were removed by filtration on a celite bed and the solution was evaporated to dryness to yield a 
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tan solid. The crude product was purified by column chromatography using silica gel with 60% 
diethyl ether flight petroleum as eluent to yield yellow crystals of 1-(3-bromo-2-propenyl)-2-
[(4-methylphenyl)sulJonylI-lH-imidazole 223 (0.920 g, 77%), as a mixture of cis and trans 
isomers in a ratio approximately to that of the the starting dibromopropene, mp 99-100 °C 
(Found: M+, 340.9825. C13H13N2Br02S requires M, 340.9825); vrnax /cm-! 1624, 1594, 1329 
(S02), 1152, 1147 (S02) and 782; OH 2.40 (3 H, s, CH3), 4.92-4.94 (2 H, d, l5.0, 1'-cis CH2), 
5.09-5.12 (2 H, dd, J 1.5 Hz and 1 6.5, 1 '-trans-CH2), 6.24-6.33 (I H, m, 2'-cis and trans-H), 
6.43-6.47 (I H, m, 3'-cis and trans-H), 7.04 (I H, d, lO.8, Im-4(5)-H), 7.10 (I H, d, lO.8, Im-
4(5)H), 7.31-7.35 (2H, d, J 7.5, Ar-H) and 7.87-7.90 (2 H, d, 17.5, Ar-H); oc 22.08 (CH3), 
47.30 (I'-cis -CH2), 49.56 (1 '-trans-CH2), 111.57, 112.96, 124.18-124.37 (Im-CH), 128.71, 
129.48 (2'-cis and trans-H), 130.37 and 130.47; m/z 341 (M+, 5%), 277 (77), 197 (100),155 
(5),119 (12),106 (46), 65 (20) and 39 (33). 
General procedure for the radical cycIisation of imidazoles and benzimidazoles 
17) Attempted radical cyclisation of 1-(3-bromo-2-propenyl)-2-[(4-methylphenyl)sulfonyl]-
1H-imidazole (223) 
()....S02T01 
N 
x • 
~Br 
182 
223 
A solution oftri-n-butyltin hydride (0.5 ml, 1.89 mmol) and AIDN (0.160 g, 0.95 mmol) in 
toluene (50 ml) was added to 1-(3-bromo-2-propenyl)-2-[(4-methylphenyl)sulfonyl]-1 H-
imidazole 233 (0.427 g, 1.26 mmol) in toluene (200 ml) at reflux over 5 h. The solution was 
stirred and heated under reflux for a further 1 h. After cooling to room temperature, the solution 
was evaporated to dryness, and 2 M hydrochloric acid solution (50 ml) was immediately added, 
and the acidic solution was washed with light petroleum (12 x 50 ml). The solution was basified 
to pH 8 with saturated sodium carbonate solution followed by the addition of 2 M sodium 
hydroxide solution until the aqueous solution was at pH 14. The hydroxide solution was 
extracted into dichloromethane (2 x 100 ml), and the combined organic extracts dried (MgS04) 
and evaporated to dryness to yield a brown oil residue, which was placed under an atmosphere 
of nitrogen. TLC and! H NMR spectroscopic analysis showed a complete conversion of the 
starting bromide to unidentifiable products. 
III 
18) 1-[3-Chloropropyl]-2-[(4-methylphenyl)sulfonyl]-IH-imidazole (224) (using l-chloro-3-
iodopropane) 
• + 
The general procedure for the alkylation of imidazoles in acetonitrile was followed. 
2-[(4-Methylphenyl)sulfonyl]-IH-imidazole 221 (0.160 g, 0.72 mmol), sodium hydride (26 mg, 
1.08 mmol) and l-chloro-3-iodopropane (0.23 ml, 2.16 mmol) in acetonitrile (100 ml) gave a 
tan residue, which was purified by column chromatography using silica gel as absorbent with 
light petroleum and ethyl acetate as the eluent to yield 1-[3-chloropropyIJ-2-
[(4-methylphenyl)sulJonyIJ-IH-imidazole as yellow needles 224 (0.114 g, 53%), mp 68-69 °C 
(Found: M+, 298.0543. C13H!sN2CI02S requires M, 298.0543); vrnax fcm-! 3137,2922, 1328 
(S02), 1145 (S02), 658 and 600; IiH 2.32-2.39 (2 H, rn, 2'-CH2), 2.44 (3 H, s, CH3), 3.51-3.58 (2 
H, t, J 6.3, CH2CI), 4.51-4.56 (2 H, t, J 6.3, NCH2), 7.07 (I H, s, Im-4(5)-H), 7.12 (I H, s, Im-
4(5)-H), 7.34-7.37 (2 H, d, J7.5, AT-H) and 7.90-7.93 (2 H, d,J 7.5 , AT-H); lie 20.15 (CH3), 
32.07 (2'-CH2), 39.75 (CH2CI), 43.72 (NCH2), 123.08 (Im-CH), 126.81(lm-CH), 128.18, 
128.23, 135.25 (q-C), 141.79 (q-C) and 143.81 (q-C); m/z 299 (MH+, 3%), 249 (3), 199 (34), 
172 (lOO), 152 (15), 91 (94),77 (13), 65 (48) and 41 (39). Evaporation of the eluates containing 
the second component gave 2-[(4-methylphenyl)sulfonyl]-I-(3-{2-[(4-methylphenyl)sulfonyl]-
IH-imidazolyl}propyl)-IH-imidazole [1,3-bis(2-tosylimidazolyl)propane, 225], as white needles 
(0.143 g, 40%); IiH 2.44 (6 H, s, CH3), 2.47-2.50 (2 H, rn, 2'-CH2), 4.41-4.47 (4 H, t, J7.5, 
NCH2), 7.04 (2 H, s, Im-4(5)-H), 7.14 (2 H, s, Im-4(5)-H), 7.35-7.38 (4 H, d, J 7.5, ArH) and 
7.88-7.91 (4 H, d, J7.5, ATH). 
19) 1-[3-Chloropropyl]-2-[(4-methylphenyl)sulfonyl]-IH-imidazole (224) (using I-bromo-3-
chloropropane) 
2-[(4-Methylphenyl)sulfonyl]-IH-imidazole 221 (0.260 g, 1.17 mmol), sodium hydride (42 mg, 
1.75 mmol) and l-bromo-3-chloropropane (0.35 ml, 3.51 mmol) in acetonitrile (100 ml) gave a 
tan residue, which was purified by column chromatography using silica gel as absorbent with 
light petroleum and ethyl acetate as the eluent to yield 1-[3-chloropropyl]-2-
[(4-methylphenyl)sulfonyl]-IH-imidazole 224, as a yellow needles (0.348 g, 68%) and 2-[(4-
methylphenyl)sulfony 1]-1-(3-{2-[( 4-methylphenyl)sulfonyl]-IH -imidazolyl }propyl)-IH-
imidazole 225, as white needles (87 mg, 15%). 
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20) 1-(3-Iodopropyl)-2-[(4-methylphenyl)sulfonyl]-IH-imidazole (226) 
N 
( ')-S02TOI 
N 
~a 
224 
N 
-----. ( ')-S02 Tol 
N 
~I 
226 
1-[3-Chloropropyl]-2-[(4-methylphenyl)sulfonyl]-IH-imidazole 224 (0.110 g, 0.36 mrnol), and 
sodium iodide (0.270 g, 1.80 mrnol) were added to dry acetonitrile (50 rnI), and heated under 
reflux for 6 h. The precipitated sodium chloride was removed by filtration on a celite bed, and 
the solution was evaporated to dryness. The residue was added to saturated sodium sulfite 
solution (100 rnI) and extracted with dichloromethane (2 x 50 rnI). The combined organic 
extracts dried (MgSO 4) and evaporated to dryness to yield a tan residue, which was purified by 
column chromatography using silica gel as absorbent with 25% ethyl acetate flight petroleum as 
eluent to yield colourless needles of 1-(3-iodopropyl)-2-[(4-methylphenyl)suljonylj-IH-
imidazole 226 (42 mg, 30%), (Found: MH+ 390.9977. C13H!sN2I02S + H requires M, 
389.9979); Vrnax !cm-! 3111, 2925, 1596, 1330 (S02), 1293, 1186, 1147 and 1082; OH 2.34-2.42 
(2 H, m, 2'-CH2), 2.45 (3 H, s, CH3), 3.12-3.17 (2 H, t, J 6.3, CH21), 4.45-4.51 (2 H, t, 17.5, 
NCH2), 7.09 (1 H, s, Im-4(5)-H), 7.12 (1 H, s, Im-4(5)-H), 7.36-7.39 (2 H, d, J 7.5, Ar-H) and 
7.91-7.94 (2 H, d, 17.5, Ar-H); OC 0.00 (CH21), 20.03 (CH3), 32.62 (2'-CH2), 46.67 (NCH2), 
122.66 (Im-CH), 126.69 (Im-CH), 128.06 (Ar-CH), 128.27 (Ar-CH), 141.63 (q-C) and 143.69 
(q-C); m/z 391 (MH2+, 38%), 265 (8),223 (9), 111 (16),109 (100) and 69 (8), which rapidly 
darken to unidentifiable products on standing at ambient temperature. 
21) 2-[(4-Methylphenyl)sulfonyl]-I-[3-(phenylselanyl)propyl]-IH-imidazole (227) 
(}-S02TOI 
N 
I 
H 
221 
• (}-S02TOI 
N 
~sePh 
227 
The general procedure for the alkylation of imidazoles in acetonitrile was followed. 
2-[(4-Methylphenyl)sulfonyl]-IH-imidazole 221 (0.121 g, 0.55 mmol), sodium hydride (16 mg, 
0.66 mrnol) and 3-iodo-l-(phenylselanyl)propane 233 (0.180 g, 0.55 mrnol) in acetonitrile (150 
ml) gave a- tan residue, which was purified by column chromatography using silica gel as 
absorbent with light petroleum and diethyl ether as eluent to yield 
2-[(4-methylphenyl)suljonylj-I-{3-(phenylselanyl)propyl]-IH-imidazole 227, as a yellow oil 
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(0.1 10 g, 48%); (Found: M+, 420.0413. Cl9H2oN202SSe requires M, 420.0410); vrnax Icm-1 
1596, 1579, 1478, 1438, 1332, 1293, 1266, 1148 (S02), 736 and 658; OH 2.13-2.24 (2 H, m, 2'-
CH2), 2.40 (3 H, s, CH3), 2.82-2.88 (2 H, t, J7.1, CH2SePh), 4.41-4.47 (2 H, t, J7.1, NCH2), 
6.94 (1 H, s, Im-4(5)-H), 7.08 (1 H, s, Im-4(5)-H), 7.25-7.28 (3 H, m, SePh-H), 7.30-7.33 (2 H, 
d, J7.5, Ar-H), 7.46-7.50 (2 H, m, SePh-H) and 7.87-7.90 (2 H, d, J7.5, Ar-H); Oc (62.5 MHz) 
21.63 (CH3), 23.84 (2'-CH2), 31.35 (PhSeCH2), 47.49 (PhSeCH2), 124.15, 127.25, 128.19, 
129.21,129.66,129.87, 132.87,136.67 (q-C), 143.33 (q-C) and 146.00 (q-C); mJz 265 (100%), 
155 (13), 108 (17), 91 (72),41 (21) and 65 (66). 
22) 2-[(4-Methylphenyl)sulfonyl]-t-[ 4-(phenylselanyl) butyl]-t H -imidazole (228) 
-----.... (}-S02T01 
~sePh 
228 
The general procedure for the alkylation of imidazoles in acetonitrile was followed. 
2-[(4-Methylphenyl)sulfonyl]-IH-imidazole 221 (0.195 g, 0.88 mmol), sodium hydride (25 mg, 
1.06 mmol) and 4-iodo-l-(phenylselanyl)butane 234 (0.289 g, 0.88 mmol) in acetonitrile (150 
ml) gave a tan residue, which was purified by column chromatography using silica gel as 
absorbent with light petroleum and diethyl ether as eluent to yield 2-[(4-methylphenyl)sulfonyll-
1-[4-(phenylselanyl)butylf-lH-imidazole as 228 cream coloured crystals (0.156 g, 41 %), mp 
105-107 °C (Found: M+, 434.0567. C20H22N202SSe requires M, 434.0567); vrnax /cm-1 2915, 
1598, 1478, 1463, 1430, 1330 (S02), 1296, 1148 and 788; OH 1.67-1.74 (2 H, m, 3'-CHV, 1.91-
1.98 (2 H, m, 2'-CH2), 2.43 (3 H, s, CH3), 2.86-2.92 (2 H, t, J7.1, CH2SePh), 4.30-4.36 (2 H, t, 
J7.3, NCH2), 6.95 (1 H, s, Im-4(5)-H), 7.11 (1 H, s, Im-4(5)-H), 7.25-7.28 (3 H, m, SePh-H), 
7.33-7.36 (2 H, d, J7.5, Ar-H), 7.46-7.50 (2 H, m, SePh-H) and 7.89-7.92 (2 H, d, J7.5 ,Ar-H); 
Oc (62.5 MHz) 21.63 (CH3), 26.81 (3'-CH2), 26.95 (2'-CH2), 31.09 (PhSeCH2), 47.44 (N-CH2), 
123.93, 126.98, 127.97, 128.13, 129.62, 129.87, 132.76, 132.79, 136.80 (q-C), 143.60 (q-C) and 
145.14 (q-C); mJz 434 (M+, 4%), 279 (30),223 (12), 157 (20),122 (21) and 91 (100). 
23) 2-(4-Methylphenyl)sulfonyl]-t-[S-(phenylselanyl)pentyl]-tH-imidazole (229) 
• 
114 
(}-.S02T01 
N 
~sePh 
229 
The general procedure for the alkylation of imidazoles in acetonitrile was followed. 
2-[(4-Methylphenyl)sulfonyIJ-IH-imidazole 221 (0.130 g, 0.59 mmol), sodium hydride (21 mg, 
88 mmol) and 5-iodo-I-(phenylselanyl)pentane 235 (0.208 g, 0.59 mmol) in acetonitrile 
(100 ml) gave a tan residue, which was purified by column chromatography using silica gel as 
absorbent with light petroleum and dichloromethane as eluent to yield 
2-[(4-rnethylphenyl)suljonyll-I-[5-(phenylselanyl)pentyl]-1H-irnidazole, as 229 white crystals 
(0.132 g, 50%), mp 83-85 °C (Found: M+, 448.0724. C2lH2<!N202SSe requires M, 448.0723); 
vrnax /cm-l 2937, 1578, 1477, 1460, 1432, 1326 (S02), 1174 (S02), 1074,813 and 796; 8H 
1.32-1.45 (2 H, m, 3'-CHz), 1.68-1.81 (4 H, m, 2' and 4'-CHz), 2.38 (3 H, s, CH3), 2.85-2.88 
(2 H, t, 17.3, CH2SePh), 4.27-4.31 (2 H, t, 17.4, NCH2), 6.95 (I H, s, Im-4(5)-H), 7.10 (I H, s, 
Im-4(5)-H), 7.22-7.27 (3 H, m, SePh-H), 7.30-7.32 (2 H, d, 17.5 ,Ar-H), 7.46-7.48 (2 H, m, 
SePh-H) and 7.88-7.90 (2 H, d, J 7.5, Ar-H); 8c 21.93 (CH3), 26.93 (3'-CH2), 27.67 (4'-CHz), 
30.21,31.15,48.37 (N-CH2), 124.50, 127.23, 128.44, 129.24, 130.30, 130.64, 132.81, 137.44 
(q-C), 143.49 (q-C), 145.52 (q-C) and 153.18 (q-C); rn/z448 (M+, 16%),293 (29), 223 (49),157 
(30), 136 (28) and 91 (lOO). 
General procedure for the introduction of the phenylselanyl group 
24) 3-Chloro-l-(phenylselanyl)propane (230) 112 
I~CI • PhSe~CI 
230 
Diphenyl diselenide (3.70 g, 11.9 mmol) was dissolved in absolute ethanol (600 ml) at ambient 
temperature. Sodium borohydride (1.00 g, 26.4 mmol) was added slowly to the stirred solution 
at 0 ·C. After 30 mins, I -chloro-3-iodopropane (4.85 g, 23.7 mmol) added dropwise and the 
mixture was stirred at ambient temperature for 16 h. The solution was evaporated to dryness and 
2 M hydrochloric acid (50 ml) was added and the solution extracted with diethyl ether (6 x 
50 ml). The combined organic extracts were washed with sodium carbonate (2 x 50 ml) and 
brine (50 ml) and dried (MgS04). The crude product was purified by column chromatography 
using silica gel as absorbent with 80% light petroleum / dichloromethane as eluent to yield 3-
chloro-l-(phenylselanyl)propane 230, as a yellow oil (4.77 g, 88%); 8H 2.07-2.18 (2 H, m, 2'-
CH2), 3.02-3.07 (2 H, t, 17.1, CH2SePh), 3.63-3.68 (2 H, t, J 6.3, CH2CI), 7.26-7.30 (3 H, m, 
Ph-H) and 7.49-7.53 (2 H, m, Ph-H); 8c 24.16 (2'-CH2), 32.24 (PhSeCH2), 43.88 (CICH2), 
126.72 (Ph-CH), 128.76 (Ph-CH) 129.13 (q-C) and 132.48 (Ph-CH). 
25) 4-Chloro-l-(phenylselanyl)butane (231)112 
I~CI 
115 
• PhS~CI 
231 
The general procedure for the introduction of the phenylselanyl group was followed. 
Diphenyl diselenide (2.00 g, 6.4 mmol), sodium borohydride (0.61 g, 16.0 mmol) and l-chloro-
4-iodobutane (2.79 g, 12.8 mmol) gave a crude yellow oil, which was purified by column 
chromatography using silica gel as absorbent with 80% light petroleum I dichloromethane as 
eluent. 4-Chloro-l-(phenylselanyl)butane 231 was given as a yellow oil (1.97 g, 63%); 8rI 1.82-
1.94 (4 H, m, 2' and 3'-CH2), 2.91-2.96 (2H, t, J 6.8, CH2SePh), 3.51-3.56 (2 H, t, J 6.2, CH2Cl), 
7.24-7.30 (3 H, m, Ph-H) and 7.46-7.52 (2 H, m, Ph-H); oc (62.5 MHz) 26.91, 27.19, 32.34 
(PhSeCH2), 44.27 (ClCH2), 126.86 (Ph-CH), 127.66 (q-C), 129.02 (Ph-CH) 129.13 (Ph-CH), 
131.46 (Ph-CH) and 132.65 (Ph-CH). 
26) 5-Chloro-l-(phenylselanyl)pentane (232) 
I~a ------. Phse~a 
232 
The general procedure for the introduction of the phenylselanyl group was followed. 
Diphenyl diselenide (2.00 g, 6.4 mmol), sodium borohydride (0.61 g, 16.0 mmol) and l-chloro-
5-iodopentane (2.98 g, 12.6 mmol) gave 5-chloro-l-(phenylselanyl)pentane 232, as a yellow oil 
(2.94 g, 89%), which required no further purification; vrnax I cm-! 1579, 1477, 1436, BOO, 1073, 
1022,735 and 691; OH 1.61-1.64 (2 H, m, 3'-CH2), 1.75-1.83 (4 H, m, 2' and 4'-CH2), 2.94-2.97 
(2 H, t, J 7.3, CH2SePh), 3.53-3.56 (2 H, t, J 6.5, CH2Cl), 7.27-7.32 (3 H, m, Ph-H) and 7.52-
7.55 (2 H, m, Ph-H); Oc 27.26 (3'-CH2), 27.68, 28.29,32.54 (PhSeCH2), 45.17 (ClCH2), 127.11 
(Ph-CH), 129.17 (Ph-CH), 129.43 (Ph-CH), 130.74 (q-C) and 133.01 (Ph-CH). 
General procedure for iodide formation 
27) 3-Iodo-l-(phenylselanyl)propane (233)112 
PhSe~CI 
230 
• 
3-Chloro-l-(phenylselanyl)propane 230 (2.50 g, 10.7 mmol) and sodium iodide (16.00 g, 0.107 
mol) were added to dry acetone (250 ml) and heated under reflux for 18 h. The precipitated 
sodium chloride was removed by filtration on a celite bed and the solution was evaporated to 
dryness. The solid residue was triturated with diethyl ether and the solution filtered a second 
. time. The ether solution was evaporated to dryness to yield 3-iodo-l-(phenylselanyl)propane 
233, as a yellow-orange oil (2.69 g, 77%), which required no further purification; 8rI 2.09-2.20 
(2 H, m, 2'-CH2), 2.95-3.01 (2 H, t, 17.1, CH2SePh), 3.26-3.31 (2 H, t, J 6.8, CH2I), 7.26-7.28 
(3 H, m, Ph-H) and 7.49-7.51 (2H, m, Ph-H); oc 4.83 (CH2I), 27.07 (2'-CH2), 32.22 (PhSeCH2), 
126.08 (Ph-CH), 127.99 (Ph-CH) 128.39 (q-C) and 131.96 (Ph-CH). 
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28) 4-Iodo-1-(phenylselanyl)butane (234)112 
Phse~CI 
231 
• PhSe~1 
234 
4-Chloro-l-(phenylselanyl)butane 231 (1.80 g, 7.3 mmol) and sodium iodide (10.87 g, 72.6 
mmol) were added to dry acetone (250 ml) and heated under reflux for 18 h. The standard work 
up procedure for the formation of iodides was followed to give 4-iodo-l-(phenylselanyl)butane 
234, as a yellow-orange oil (1.92 g, 78%); OH 1.78-1.84 (2 H, m, 2' (3')-CH2), 1.93-1.99 (2 H, m, 
2' (3')-CH2), 2.89-2.95 (2 H, t, 17.2, CH2SePh), 3.15-3.21 (2 H, t, J 6.8, CH2I), 7.26-7.30 (3 H, 
m, Ph-H) and 7.49-7.52 (2 H, m, Ph-CH); oc (62.5 MHz) 6.44 (CH21), 27.41, 31.67, 34.09 
(PhSeCH2), 127.76 (Ph-CH), 129.84 (Ph-CH) 129.90 (Ph-CH), 130.89 (q-C) and 133.66 (Ph-
CH). The oil rapidly darkens and solidifies on standing at ambient temperature. 
29) 5-Iodo-1-(phenylselanyl)pentane (235) 
Phse~CI 
232 
• Phse~1 
235 
5-Chloro-l-(phenylselanyl)pentane 232 (1.80 g, 6.9 mmol) and sodium iodide (10.30 g, 68.7 
mmol) were added to dry acetone (250 ml) and were. heated under reflux for 18 h. The standard 
work up procedure for the formation of iodides was followed to give 5-iodo-l-
(phenylselanyl)pentane 235 as a yellow-orange oil (1.56 g, 64%); (Found: M+, 353.9384. 
Cl1H1SISe requires M, 353.9385); Vrnax I cm-1 2253, 1478, 1438, 1199, 1023,909,733,692 and 
650; OH 1.49-1.58 (2 H, m, 3'-CH2), 1.67-1.86 (4 H, m, 2' and 4'-CH2), 2.88-2.94 (2 H, t, 17.3, 
CH2SePh), 3.14-3.19 (2 H, t, 17.0, CH2I), 7.25-7.31 (3 H, m, Ph-H) and 7.48-7.52 (2 H, m, Ph-
H); Oc 7.42 (CH2I), 28.55, 30.09, 31.65, 33.95 (PhSeCH2), 127.76 (Ph-CH), 130.05 (Ph-CH) 
132.52 (q-C), 133.55 (Ph-CH) and 133.59 (Ph-CH); mlz 354 (M+, 6%),227 (37),171 (18), 157 
(87),91 (48),77 (76), 69 (97) and 41 (100). 
30) 6, 7-Dihydro-5H-pyrrolo[1, 2-a]imidazole (183)105 (from the tosylate 227) 
l}-S02T01 
N 
~sePh 
227 
• 
1 
:Q): 
5 
183 
A solution of tri-n-butyltin hydride (0.1 ml, 0.35 mmol) and AIDN (30 mg, 0.18 mmol) in 
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toluene (30 ml) was added to 2-[(4-methylphenyl)sulfonyll-l-[3-(phenylselanyl)propanel-lH-
imidazole 227 (95 mg, 0.23 mmol) in toluene (100 m!) at reflux over 5 h. The solution was 
stirred and heated under reflux for a further 1 h. After cooling to room temperature, the standard 
work up procedure for the radical cyclisation of imidazoles and benzimidazoles was followed to 
yield white crystals of6,7-dihydro-5H-pyrrolo[l, 2-alimidazole 183 (13 mg, 52 %), mp 72 °C 
(lit. 105 72.5-75.5 °C), which required no further purification; OH 2.57-2.68 (2 H, m, 6-CH2), 
2.83-2.89 (2 H, t, 17.5, 7-CH2), 3.94-3.99 (2 H, t, 17.0, NCH2), 6.87 (1 H, s, lm-2(3)-H) and 
7.04 (I H, s, lm-2(3)-H); Oc 23.41 (6-CH2), 26.77 (7-CH2), 45.00 (NCH2), 114.88 (lm-CH), 
133.41 (lm-CH) and 155.10 (q-C, lm-7a-C). 
31) 5, 6, 7, 8-Tetrahydroimidazo[I,2-alpyridine (211)105 
• 
N1 :(~ 4N07 
5 6 
211 
A solution of tri-n-butyltin hydride (0.39 ml, 1.48 mmol) and AmN (70 mg, 0.49 mmol) in 
toluene (50 ml) was added to 2-[(4-methylphenyl)sulfonyll-l-[3-(phenylselanyl)butane1-IH-
imidazole 228 (0.427 g, 0.98 mmol) in toluene (200 ml) at reflux over 10 h. The solution was 
stirred and heated under reflux for a further 1 h. After cooling to room temperature, the standard 
work up procedure for the radical cyclisation of imidazoles and benzimidazoles was followed to 
yield 5,6,7,8-tetrahydroimidazo[1,2-alpyridine 211 (57 mg, 48%), as a colourless sticky oil, 
which required no further purification; OH 1.89-1.97 (4 H, m, 6 and 7-CH2), 2.82-2.87 (2 H, t, 
J 6.0, 8-CH2), 3.90-3.95 (2 H, t, J 5.6, NCH2), 6.75 (I H, s, lm-2(3)-H) and 6.94 (I H, s, lm-
2(3)-H); Oc 21.21 (7-CH2), 23.54 (6-CH2), 24.95 (8-CH2), 45.09 (NCH2), 118.27 (lm-CH), 
135.57 (lm-CH) and 145.21 (q-C, lm-8a-C). 
32) 6, 7, 8, 9-Tetrahydro-5H -imidazo[1,2-a lazepine (212) 105 
• :~~B U7 
6 
212 
A solution oftri-n-butyltin hydride (0.11 ml, 0.42 mmol) and AIBN (23 mg, 0.14 mmol) in 
toluene (50 ml) was added to 2-[(4-methylphenyl)sulfonyll-l-[5-(phenylselanyl)pentyIl-IH-
imidazole 229 (0.125 g, 0.28 mmol) in toluene (200 ml) at reflux over 10 h. The solution was 
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stirred and heated under reflux for a further 1 h. After cooling to room temperature, the standard 
work up procedure for the radical cyclisation of imidazoles and benzimidazoles was followed to 
yield the 6, 7,8, 9-tetrahydro-5H-imidazo[I,2-a]azepine 212 (32 mg, 63%), as a colourless 
sticky oil, which required no further purification; SH 1.64-1.80 (6 H, m, 6,7, 8-CH2), 2.87-2.92 
(2 H, m, 9-CH2), 3.90-3.94 (2 H, m, NCH2), 6.74 (lH, s, Im-2(3)-H) and 6.79 (1 H, s, 
Im-2(3)-H); Se 22.56 (7-CH2), 26.11 (8-CH2), 29.40 (6-CH2), 30.11 (9-CH2), 48.77 (NCH2), 
119.22 (lm-CH), 126.21 (lm-CH) and 150.90 (q-C, Im-9a-C). 
33) 2-(Phenylsuifonyl)-IH-imidazole (239) 
()-SPh 
N 
-----> ()-S{O)Ph + 
N 
I 
H 
222 
I 
H 
238 
A solution of 2-(phenylsulfanyl)-1 H-imidazole 222 (0.440 g, 2.5 mmol) in THF-methanol 
(25 ml, 1: 1) was added dropwise to a solution of oxone TM (3.380 g, 5.5 mmol) at 0 'c in THF-
methanol (25 ml, 1: 1) and the solution was stirred at ambient temperature for a further 48 h. 
The solution was filtered on a celite bed, the filtrate added to water (100 ml) and extracted 
with dichloromethane (3 x 50 ml). The combined organic extracts dried (MgS04) and 
evaporated to dryness to yield a white solid. The residue was purified by column 
chromatography using silica gel as absorbent with ethyl acetate as eluent to yield white needles 
of 2-(phenylsulfonyl)-IH-imidazole 239 (0.302 g, 58%); mp 188-190 'C, (Found: C, 51.3; H, 
3.8; N, 12.9. C9HgN202S requires C, 51.9; H, 3.9; N, 13.5%); vrnax /cm-I 2764, 1446, 1330 
(S02), 1155 (S02) and 1107; SH ([2H6]Me2S0) 7.33 (2 H, m, Im-4(5)-H), 7.64-7.68 (2 H, m, 
Ar-H), 7.72-7.75 (I H, m, Ar-H) and 7.94-7.97 (2 H, m, Ar-H); Se ([2H6] Me2S0) 134.14, 
136.56, 140.94, 146.84 (q-C) and 149.92 (q-C); mlz 208 (M+, 8%), 144 (88),117 (76), 90 (21), 
77(100) and 51 (57). Further elution with ethyl acetate / methanol yielded white needles of 
2-(phenylsuljinyl)-IH-imidazole 238 (0.101 g, 21%); mp 160-161'C, (Found: M+, 192.0357. 
C9HgN20S requires M, 192.0357); vrnax Icm-I 2628, 1441, 1330, 1086 and 1054; SH 7.19-7.20 
(2 H, m, Im-4(5)-H), 7.46-7.49 (3 H, m, Ar-H) and 7.71-7.75 (2 H, m, Ar-H); Se 120.20, 125.35, 
129.96,132.24, 142.79 (q-C) and 146.55 (q-C). mlz 192 (M+, 8%), 175 (62),144 (lOO), 125 
(12),117 (39),77 (72) and 51 (61). 
34) 1-[3-(Phenylselanyl)propyl]-2-(phenylsulfanyl)-IH-imidazole (241) 
N ( }-SPh 
N 
I 
H 
222 
119 
> 
N ( }-SPh 
N 
~sePh 
241 
The general procedure for the alkylation of imidazoles in acetonitrile was followed. 
2-(Phenylsulfanyl)-lH-imidazole 222 (0.470 g, 2.67 mmol), sodium hydride (0.160 g, 6.68 
mmol) and 3-iodo-l-(phenylselanyl)propane 233 (0.870 g, 2.67 mmo\) in acetonitrile (150 ml) 
gave a tan residue, which was purified by column chromatography using silica gel as absorbent 
with light petroleum and diethyl ether as eluent to yield 1-[3-(phenylselanyl)propyI1-2-
(phenylsulfanyl)-IH-imidazole 241 as a yellow oil (0.555 g, 56%); Vrnax /cm-1 2940, 1580, 
1478,1458,1438, 1428, 1027, 1023,690; SH 1.95-2.06 (2 H, m, 2'-CH2), 2.71-2.76 (2 H, t, J 
7.0, CH2SePh), 4.09-4.14 (2 H, t, 17.0, NCH2), 7.04 (2 H, m, Im-4(5)-H), 7.14-7.29 (8 H, m, 
Ar-H) and 7.42-7.46 (2 H, m, Ar-H); Se 23.98 (2'-CH2), 30.80 (PhSeCH2), 46.36 (NCH2), 
122.43,126.61,127.22,128.03,129.16,130.52 and 132.97. 
35) Radical cyclisation of 1·[3·(phenylselanyl)propyl].2.(phenylsulfanyl)·1H·imidazole 
(241) 
(}-SPh 
N 
~sePh 
241 
• + 
183 242 
A solution oftri-n-butyltin hydride (0.59 ml, 2.19 mmol) and AIBN (0.120 g, 0.73 mmol) in 
toluene (50 ml) was added to 1-[3-(phenylselanyl)propyI1-2-(phenylsulfanyl)-1 H-imidazole 241 
(0.547 g, 1.46 mmo\) in toluene (200 ml) at reflux over 5 h. The solution was stirred 
and heated under reflux for a further 1 h. After cooling to room temperature, the standard work 
up procedure for the radical cyclisation of imidazoles and benzimidazoles was followed to yield 
a tan oil containing 6,7-dihydro-5H-pyrrolo[l, 2-alimidazole 183 and I-propyl-lH-imidazole 
242; SH 0.80-0.86 (3 H, t, 17.4, CH3), 1.62-1.70 (2 H, m, 2'-CH2), 3.92-3.96 (2 H, t, J 6.8, 
NCH2) and 7.02-7.56 (7 H, m, Im-H, and Ar-H); (82 mg, 16% and 18% yield respectively by IH 
NMR spectroscopic analysis of reaction mixture using a known amount of 
1,4-dimethoxybenzene as internal standard). 
36) 1·[3·(Phenylselanyl)propyll·2·(phenylsulfonyl)·1H·imidazole (243) 
N ( }-S02Ph 
N 
1 
H 
239 
• (}-S02Ph 
N 
~sePh 
243 
The general procedure for the alkylation of imidazoles in acetonitrile was followed. 
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2-(Phenylsulfonyl)-IH-imidazole 239 (0.136 g, 0.65 mmol), sodium hydride (24 mg, 0.98 
mmol) and 3-iodo-l-(phenylselanyl)propane 233 (0.212 g, 0.65 mmol) in acetonitrile (100 ml) 
gave a tan residue, which was purified by column chromatography using silica gel as absorbent 
with light petroleum and diethyl ether as eluent to yield 1-[3-(phenylselanyl)propyll-2-
(phenylsulJonyl)-IH-imidazole 243, as a yellow oil (0.214 g, 81 %), (Found: M+, 406.0254. 
ClSHlSN202SSe requires M, 406.0254); OH 2.10-2.21 (2 H, m, 2'-CH2), 2.80-2.86 (2 H, t, 17.1, 
CH2SePh), 4.40-4.46 (2 H, t, J 7.1, NCH2), 6.95 (1 H, m, Im-4(5)-H), 7.09 (1 H, m, Im-4(5)-H), 
7.25-7.27 (3 H, m, SePh-H), 7.45-7.49 (2 H, rn, SePh-H), 7.50-7.53 (2 H, d, J 7.5, Ar-H), 7.57-
7.63 (1 H, m, Ar-H) and 7.97-8.00 (2 H, d, J 7.5, Ar-H); oe (62.5 MHz) 23.92 (2'-CH2), 31.50 
(PhSeCH2), 47.68 (NCH2), 124.55, 127.38, 128.14, 129.22, 129.35, 130.00, 132.99, 134.10, 
139.93 (q-C) and 142.79 (q-C); m/z 406 (M+, 100%), 376 (30), 329 (14), 305 (41), 284 (45), 
265 (lOO), 157 (23) and 77 (66). 
37) 6, 7-Dihydro-5H-pyrrolo[1,2-a]imidazole (183) (from the phenylsulfonate 243) 
• 
183 
A solution of tri-n-butyltin hydride (0.16 ml, 0.54 mmol) and AIDN (30 mg, 0.18 mmol) in 
toluene (50 ml) was added to 1-[3-(phenylselanyl)propyl]-2-(phenylsulfonyl)imidazole 243 
(0.146 g, 0.36 mmol) in toluene (100 ml) at reflux over 5 h. The solution was stirred and 
heated under reflux for a further 1 h. After cooling to room temperature, the standard work up 
procedure for the radical cyclisation of imidazoles and benzirnidazoles was followed to yield 
6, 7-dihydro-5H-pyrrolo[I,2-a]imidazole 183 (19 mg, 51 %), as a colourless sticky oil, which 
required no further purification. 
38) 1-(Triphenylmethyl)benzimidazole [l-(Trityl)benzimidazole,258] 
(JC} • 
I 
H 
2Sl 
(JCI} ~ N 
I 
CPh 3 
258 
1-(Trityl)benzimidazole 257 was prepared by the same method as used for the tritylation of 
imidazole. Triphenylmethyl chloride (39 g, 0.140 mol), benzimidazole (15 g, 0.128 mol) and 
121 
triethylamine (35 ml, 0.250 mol) gave a residue, which was recrystallised twice with absolute 
ethanol and dried to give cream coloured needles of 1-(triphenylmethyl)benzimidazole 258 
(31 g, 67%), mp 181-182 °C (lit. 147 mp 180-181 0C), (Found: M+, 360.1620. C26H2oN2 
requires M, 360.1626); Vrnax I cm-I 1609, 1478, 1443, 1274, 1224,781,748 and 700; mlz 360 
(M+. 6%).243 (100),165 (53),118 (24) and 91 (12). 
39) 2-[(4.Methylphenyl)sulfonyl].t.(triphenylmethyl)benzimidazole (259) 
ocl N"> ~ N 
I 
CPh 3 
258 
• OCN I ">-S02TO) ~ N 
I 
CPh 3 
259 
1-(Trityl)benzimidazole 258 (1.00 g. 2.75 mmol) was dissolved in THF (100 ml) and TMEDA 
(1.2 ml. 8.25 mmol) added to the stirred solution at ambient temperature. The temperature of the 
stirred solution was lowered to -78 'C and a solution ofn-butyllithium added dropwise (1.6 ml, 
4.12 mmol). The solution turned pink and was stirred at 0 'C for a further 20 min. A solution of 
p-toluenesulfonyl fluoride (1.44 g, 8.45 mmol) in THF (10 ml) was added dropwise and the 
stirring was continued for a further 3 h. The solution was evaporated and saturated ammonium 
chloride (50 ml) and water (100 ml) added to the residue. The aqueous mixture was extracted 
with dichloromethane (3 x 50 ml), the organic extracts dried (MgS04) and the solution 
evaporated to dryness to yield a crude solid, which was purified by column chromatography 
using silica gel with light petroleum and dichloromethane as eluent. Evaporation of the eluates 
containing the second component gave white crystals of 2-[(4-methylphenyl)sulfonyl]-I-
(triphenylmethyl)benzimidazole 259 (0.16 g, 11 %), mp 86-87 'C; mlz 517 (MW .100%), 162 
(90), 138 (95), 90 (98) and 65 (55). 
40) 2-(Phenylsulfanyl)·t·( triphenylmethyl)benzimidazole (260) 
oc) 
I 
CPh 3 
258 
• ocl }-SPh ~ N 
I 
CPh3 
260 
I-(Trityl)benzimidazole 258 (4.0 g, 11 mmol) was dissolved in THF (200 ml) and TMEDA 
(5.0 ml, 34 mmol) added to the stirred solution at ambient temperature. The temperature of the 
stirred solution was lowered to -78 'C and a solution of n-butyllithium added dropwise (5.2 ml, 
13 mmol). The solution turned pink and was stirred at 0 'C for a further 20 min. A solution of 
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diphenyl disulfide (7.3 g, 34 mmol) in THF (30 ml) was added dropwise and the stirring was 
continued for a further 3 h. The solution was evaporated and saturated ammonium chloride 
(50 ml) and water (lOO m!) added to the residue. The aqueous mixture was extracted with 
dichloromethane (3 x 50 ml), the organic extracts dried (MgS04), and the solution evaporated to 
dryness to yield a crude solid, which was purified by column chromatography using silica gel as 
absorbent with light petroleum and dichloromethane as eluent. Evaporation of the eluates 
containing the second component gave white crystals of 2-(phenylsulfanyl)-I-
(triphenylmethyl)benzimidazole 260 (3.5 g, 68%), mp 182-184 'C (Found: M+ 469.1734. 
C32H2SN2S requires M, 469.1738); vrnax 1581,1492,1440,1267 and 745 cm-I; miz 469 (M+, 
31%),243 (lOO), 225 (33),165 (37) and 31 (27). 
41) 2-(Phenylsulfanyl)-IH-benzimidazole (261) 
ocl )-SPh ~ N 
I 
CPh3 
260 
• ocl )-SPh ~ N 
I 
H 
261 
The general procedure for the removal of the trityl protective group was followed. 
2-(Phenylsulfanyl)-I-(triphenylmethyl)benzimidazole 260 (0.95 g, 2 mmol) gave white needles 
of2-(phenylsulfanyl)-IH-benzimidazole 261 (0.32 g, 70%), mp 201-203 'C (lit. 148, mp 201.5-
202.5 0c), (Found: C, 68.7; H, 4.3; N, 12.4. C13HloN2S requires C, 69.0; H, 4.5; N, 12.4%); 
vrnax I cm- l 1618,1477, 1442, 1413, 1349, 1266, 1235,978,740 and 686; miz 226 (60%), 225 
(100), 167 (5),155 (8),90 (5), 77 (8) and 51 (l0). 
42) 1-[3-(IH-Benzoimidazol-l-yl)propyIJ-IH-benzoimidazole (263) 
ocl N) ~ N 
I 
H 
2'!i1 
• 
263 
Benzimidazole 257 (5.00 g, 42.3 mmol) was added slowly to sodium hydride (1.22 g, 50.8 
mmol) in THF (350 ml). The mixture was stirred and heated under reflux for 1 h, and 
1,3-dibromopropane (2.1 ml, 21.1 mmol) was added dropwise. The mixture was heated under 
reflux for a further 2 h. The salts formed were removed by filtration on a celite bed and the 
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solution was evaporated to dryness to yield a tan solid, which was purified by column 
chromatography using neutral alumina as absorbent with ethyl acetate / methanol as eluent to 
yield 1-[3-(lH-benzoimidazol-l-yl)propyl]-IH-benzimidazole 263, as a white solid (5.14 g, 
44%); mp 119-121°C (Iit.123, mp 120-121 0C); OH 2.50-2.59 (2 H, m, 2'-CH2), 4.18-4.24 (4 H, t, 
J 6.9, NCH2), 7.28-7.35 (4 H, m, Ar-H), 7.84-7.88 (4 H, m, Ar-H) and 8.10 (2 H, s, Im-2-H). 
43) t,3-Di(3-bromopropyl)-3H-benzoimidazol-t-ium bromide (264) 
(X) 
I 
H 
257 
• 
C"Br 
(XI ~ Br ~ N 
~Br 
264 
Benzimidazole 257 (1.00 g, 8.5 mmol) was added slowly to sodium hydride (0.25 g, 10.2 mmol) 
in THF (200 ml). The mixture was stirred and heated under reflux for 1 h, and 
1,3-dibromopropane (8.6 ml, 84.6 mmol) was added dropwise. The mixture was heated under 
reflux for a further 2 h. The salts formed were removed by filtration on a celite bed and the 
solution was evaporated to dryness to yield a tan residue, which was purified by column 
chromatography using neutral alumina as absorbent with ethyl acetate / methanol as eluent to 
yield 1,3-di(3-bromopropyl)-3H-benzoimidazol-I-ium bromide 264, as a white solid (0.31 g, 
10%); mp >300 °C (Found: M+, 358.9758. CI3H17N2Br2 requires M, 358.9758); BH 2.53-2.71 
(4 H, m, 2'-CH2), 3.50-3.54 (2 H, t, J 6.0, CH2Br), 3.65-3.70 (2 H, t, J 5.8, CH2Br) 4.67-4.84 (4 
H, t, 17.0, NCH2), 7.57-7.64 (2 H, m, Ar-H), 7.81-7.88 (2 H, m, Ar-H) and 11.15 (l H, s, Im-2-
H); Bc 29.94 (2'-CH2), 30.21(2'-CH2), 32.35 (CH2Br), 32.41 (CH2Br), 42.05 (NCH2), 45.33 
(NCH2), 113.57 (Ar-H), 113.62 (Ar-H), 127.68 (Ar-H), 127.83 (Ar-H), 131.73 (q-C),131.86 
(q-C) and 143.42 (q-C, Im-2-C); mlz 361 (M, 37%), 317 (lOO), 271 (87),235 (23), 208 (9) and 
131 (11). 
44) 1-(3-Chloropropyl)-2-(phenylsulfanyl)-IH -benzimidazole (265) 
(XI )-SPh ~ N 
I 
H 
261 
(XI )-SPh ~ N 
~CI 
265 
2-(Phenylsulfanyl)-IH-benzimidazole 261 (0.657 g, 2.9 mmol) was added slowly to sodium 
hydride (86 mg, 3.6 mmol) in THF (200 ml), and heated under reflux for 1 h, and I-bromo-3-
124 
chloropropane (0.2 ml, 2.2 mmol) was added dropwise. The mixture was heated under reflux for 
a further 2 h. The salts fonned were removed by filtration on a celite bed and the solution was 
evaporated to dryness to yield a tan solid, which was purified by column chromatography using 
neutral alumina as absorbent with light petroleum and dichloromethane followed by diethyl 
ether as eluent to give 1-(3-chloropropyl)-2-(phenylsulJanyl)-lH-benzimidazole 265 as a cream 
coloured needles (0.342 g, 39%); OH (400 MHz) 2.14-2.21 (2 H, m, 2'-CH2), 3.49-3.52 (2 H, t, 
J 6.1, CH2CI), 4.39-4.43 (2 H, t, J 7.0, NCH2), 7.28-7.33 (5 H, m, Ar-H), 7.43-7.45 (3 H, m, 
Ar-H) and 7.77-7.79 (I H, m, Ar-H); Oc 32.80 (2'-CH2), 42.11 (CH2CI), 42.20 (NCH2), 109.92, 
120.46,122.96,123.86,128.34,129.61,131.03,132.25 (q-C), 136.31 (q-C), 143.74 (q-C) and 
147.88 (q-C). 
45) Attempted preparation of 1-(3-bromopropyl)-2-(phenylsulfanyl)-lH -benzimidazole 
(266) using sodium bromide in acetone (Finkelstein conditions) 
oc N I '>-SPh ~ N 
~CI 
NaBr, acetone X . ocN I '>-SPh ~ N 
~Br· 
265 266 
1-(3-Chloropropyl)-2-(phenylsulfanyl)-IH-benzimidazole 265 (0.291 g, 0.96 mmol) and sodium 
bromide (0.99 g, 9.63 mmol) were added to dry acetone (100 ml), and heated under reflux for 18 
h. The solution was evaporated to dryness and the solid residue was triturated with diethyl ether 
and the solution filtered a second time. The ether solution was evaporated to dryness, but only 
the 1-(3-chloropropyl)-2-(phenylsulfanyl)-IH-benzimidazole 265 was isolated. 
46) 1-(3-Bromopropyl)-2-(phenylsulfanyl)-lH-benzimidazole (266) 
(JCI }-SPh ~ N 
~CI 
265 
CH3CH2Br, NaBr (cat.) 
N-methylpyrrolidinone 
• ocl }-SPh ~ N 
~Br. 
266 
1-(3-Chloropropyl)-2-(phenylsulfanyl)-1 H-benzimidazole 265 (0.171 g, 0.56 mmol), 
bromoethane (1.25 m!, 16.8 mmol), and sodium bromide (30 mg, 0.29 mmol) were added to dry 
N-methy!-2-pyrrolidinone (50 ml) and heated at 65 ·C for 36 h. The mixture was added to brine 
(50ml) and extracted with diethyl ether (3 x 50 ml), and the organic extracts dried (MgS04). 
The solution was evaporated to dryness to yield a white solid containing 1-(3-bromopropyl)-2-
(phenylsu!fanyl)-IH-benzimidazole 266; OH 2.23-2.31 (2 H, m, 2'-CH2), 3.33-3.38 (2 H, t, J 6.2, 
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CH2Br), 4.37-4.42 (2 H, t, 17.1, NCH2), 7.28-7.37 (5 H, m, Ar-H), 7.42-7.46 (3 H, m, Ar-H) 
and 7.77-7.80 (1 H, m, Ar-H); Bc 18.06 (CH2Br), 32.89 (2'-CH2), 42.11 (NCH2), 110.02, 
120.45,122.99,123.87, 128.36, 129.88,131.05, 132.21 (q-C), 136.28 (q-C), 143.71 (q-C), and 
147.90 (q-C) and 1-(3-chloropropyl)-2-(phenylsulfanyl)-IH-benzimidazole 265 (47 mg, 22% 
and 2% yield respectively by iH NMR spectroscopic analysis using a known amount of 
1,4-dimethoxybenzene as internal standard). 
General procedure for the alkylation of benzimidazoles 
47) 1-[3-(Phenylselanyl)propyl]-2-(phenylsulfanyl)-IH-benzimidazole (267) 
(XI )-SPh ~ N 
I 
H 
261 
• (XI )-SPh ~ N 
~sePh 
267 
2-(Phenylsulfanyl)-1 H-benzimidazole 261 (0.650 g, 3.0 mmol) was added slowly to sodium 
hydride (86 mg, 3.6 mmol) in THF (200 ml). The mixture was stirred and heated under reflux 
for I h, and 3-iodo-l-(phenylselanyl)propane 233 (0.730 g, 2.3 mmol) in THF (200 ml) was 
added dropwise. The mixture was heated under reflux for a further 2 h. The salts formed were 
removed by filtration on a celite bed and the solution was evaporated to dryness to yield a tan 
solid, which was purified by column chromatography using neutral aIumina as absorbent with 
light petroleum and dichloromethane followed by diethyl ether as eluent to give 
1-[3-(phenylselanyl}propyI1-2-(phenylsulJanyl}-lH-benzimidazole 267 as a yellow oil (0.560 g, 
44%) (Found: M+, 424.0525. C22H2oN2SSe requires M, 424.0525); vrnax I cm-i 1579, 1478, 
1423, 1355, 1248, 1023,909,739 and 690; OH 2.04-2.15 (2 H, m, 2'-CH2), 2.81-2.86 (2 H, t, 
f 6.9, CH2SePh), 4.31-4.37 (2 H, t, 17.1, NCH2), 7.24-7.33 (8 H, m, Ar-H), 7.41-7.49 (4 H, m, 
Ar-H) and 7.77-7.81 (2 H, m, Ar-H); Bc 23.48 (2'-CH2), 28.79 (PhSeCH2), 43.27 (NCH2), 
108.68,119.07,121.49,122.33, 126.31, 129.94, 128.36, 129.66, 131.07 (q-C), 132.04, 134.86 
(q-C), 144.48 (q-C) and 146.61 (q-C); miz 424 (M+, 34%), 315 (43), 267 (88), 239 (50), 157 
(26), 129 (33), 109 (48), 77 (100) and 51 (75). 
48) 1-[ 4-(phenylselanyl)butyl]-2-(phenylsulfenyl)-IH -benzimidazole (268) 
(XI )-SPh ~ N 
I 
H 
261 
126 
• (XI )-SPh ~ N 
~sePh 
268 
The general procedure for the alkylation ofbenzimidazoles in THF was followed. 
2-(Phenylsulfanyl)-IH-benzimidazole 261 (0.265 g, 1.17 mmol), sodium hydride (42 mg, 1.76 
mmol) and 4-iodo-l-(phenylselanyl)butane 234 (0.300 g, 0.88 mmol) in THF (l50ml) gave a 
tan residue. The residue was purified by column chromatography using neutral alumina as 
absorbent with light petroleum and dichloromethane followed by diethyl ether as eluent to give 
1-[4-(phenyIselanyI)butyIl-2-(phenyIsulJenyI)-lH-benzimidazole 268, as a yellow oil (0.228 g, 
44%); (Found: M+, 438.0669. C23H22N2SSe requires M, 438.0668); vmax I cm- i 1581,1479, 
1462, 1438, 1424, 1360, 1279, 1024,907 and 733; (lH 1.24-1.57 (2 H, m, 3'-CH2), 1.60-1.75 (2 
H, m, 2'- CH2), 2.68-2.74 (2 H, t, J7.1, CH2SePh), 4.06-4.11 (2 H, t, J7.2, NCH2), 7.11-7.21 (8 
H, m, Ar-H), 7.27-7.33 (4 H, m, Ar-H) and 7.65-7.69 (2 H, m, Ar-H); (lC (62.5 MHz) 27.08 (3'-
CH2), 27.16 (2'-CH2), 30.35 (PhSeCH2), 44.11 (NCH2), 109.66, 119.94, 122.33, 123.19,127.01, 
129.39, 129.67, 130.43 (q-C), 132.91, 135.67 (q-C) and 143.40 (q-C); mJz 438 (M+, 54%), 281 
(100),239 (46), 225 (70), 171 (50),157 (43), 109 (48), 91 (58),77 (94) and 51 (47). 
49) 1-[5-(Phenylselanyl)pentyI1-2-(phenylsulfanyl)-IH-benzimidazole (269) 
(XI }-SPh 
::::".. N 
I 
H 
261 
• (XI }-SPh 
::::".. N 
~sePh 
269 
The general procedure for the alkylation of benzimidazoles in THF was followed. 
2-(Phenylsulfenyl)-1 H-benzimidazole 261 (0.661 g, 2.92 mmol), sodium hydride (0.105 g, 4.39 
mmol) and 5-iodo-l-(phenylselanyl)pentane 235 (1.034 g, 2.92 mmol) in THF (200 ml) gave a 
tan residue. The residue was purified by column chromatography using neutral alumina as 
absorbent with light petroleum and dichloromethane followed by diethyl ether as eluent to give 
1-[5-(phenylselanyl)pentyI1-2-(phenylsuljanyl)-lH-benzimidazole 269 as a yellow oil (0.992 g, 
75%); (Found: M+, 452.0825. C24H2~2SSe requires M, 452.0825); vmax I cm- i 1579,1478, 
1422, 1355, 1266, 1023,738 and 690; (lH 1.41-1.44 (2 H, m, 3'-CH2), 1.65-1.71 (4 H, m, 2' and 
4'-CH2), 2.80-2.86 (2 H, t, J7.3, CH2SePh), 4.18-4.24 (2 H, t, J7.4, NCH2), 7.25-7.31 (8 H, m, 
Ar-H), 7.39-7.49 (4 H, m, Ar-H) and 7.77-7.79 (2 H, m, Ar-H); Bc (62.5 MHz) 26.84 (3'-CH2), 
27.34 (4'-CH2), 29.00 (2'-CH2), 29.64 (PhSeCH2), 44.53 (NCH2), 109.70, 119.85, 122.29, 
123.19,126.79,129.03,130.52,132.52,135.70 (q-C), 143.25 (q-C) and 147.43 (q-C); mJz452 
(M+,6%), 295 (16), 225 (28), 206 (12), 158 (35),157 (35), 91 (43),78 (100) and 51 (64). 
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50) 2,3-Dibydro-IH-benzo[d]pyrrolo[I,2-a]imidazole (252)121 
(XI }-SPh ~ N • 
~sePh 
267 
252 
A solution oftri-n-butyltin hydride (0.42 ml, 1.59 mmol) and AIDN (90 mg, 0.80 mmol) in 
toluene (50 mI) was added to 1-[3-(phenylselanyl)propyl]-2-(phenylsulfanyl)-1 H-benzimidazole 
267 (0.450 g, 1.06 mmol) in toluene (150 mI) at reflux over 5 h. The solution was stirred and 
heated under reflux for a further 1 h. The standard work up procedure for the radical cycIisation 
of imidazoles and benzimidazoles was followed. The crude white product was purified by 
column chromatography using silica gel as absorbent with light petroleum and ethyl acetate as 
eluent to give 2,3-dihydro-lH-benzo[dJpyrrolo[1,2-a]imidazole 252 as white crystals (83 mg, 
49%), mp 105-107·C (Iit.!2!, mp 114-115 ·C) (Found: M+, 158.0844. CIOHION2fequires M, 
158.0844); OH 2.66-2.78 (2 H, m, 2'-CH2), 3.04-3.10 (2 H, t, 17.5, CCH2), 4.08-4.14 (2 H, t, J 
7.0, NCH2), 7.17-7.33 (3 H, m, Ar-H) and 7.68-7.72 (1 H, m, Ar-H); OC 23.89 (3'-CH2), 26.48 
(2'-CH2), 43.12 (NCH2), 109.86, 119.99, 122.05, 122.14, 132.79 (q-C), 149.30 (q-C) and 161.55 
(q-C); mlz 158 (M+, 96%),157 (100),130 (16), 129 (14),103 (24), 102 (15), 86 (25), 84 (38) 
and 51 (31). 
51) 1,2,3, 4-Tetrabydrobenzo[4,5]imidazo[I,2-a]pyridine (253)121 
(XI }-SPh ~ N • 
~sePh 
253 
268 
A solution oftri-n-butyItin hydride (0.17 mI, 0.63 mmol) and AIDN (34 mg, 0.21 mmol) in 
toluene (50 mI) was added to 1-[4-(phenylseIanyl)butyl]-2-(phenylsulfanyl)-IH-benzimidazole 
268 (0.184 g, 0.42 mmol) in toluene (150 ml) at reflux over 5 h. The solution was stirred and 
heated under reflux for a further 1 h. After cooling to room temperature, the standard work up 
procedure for the radical cycIisation of imidazoles and benzimidazoles was followed to yield 
white crystals of 1,2,3,4-tetrabydrobenzo[4,5]imidazo[I,2-a]pyridine 253 (39 mg, 54%), mp 98-
100 ·C (lit.!2! mp, 99.8-100.1·C), which required no further purification; (Found: M+, 172.1000. 
Cl1H12N2 requires M, 172.1000); Vrnax fcm-! 1615,1509,1483,1458,1416,1320,1286,1274, 
1228,1158, 1006,769 and 756; OH 2.01-2.10 (2 H, m, 3'-CH2), 2.12-2.18 (2 H, m, 2'- CH2), 
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3.08-3.13 (2 H, t, J 6.5, CCH2), 4.07-4.11 (2 H, t, J 6.0, NCH2), 7.22-7.32 (3 H, m, Ar-H) and 
7.68-7.72 (1 H, m, Ar-H); Oc 20.28 (3'-CH2), 22.18 (2'-CH2), 24.95 (CCH2), 41.94 (NCH2), 
108.19,118.37, 121.15, 121.57, 134.10 (q-C), 142.32 (q-C) and 151.18 (q-C); m/z 172 (M+, 
100),144 (54),117 (51),102 (38), 90 (45), 77 (53) and 51 (51). 
52) 7,8,9,10-Tetrahydro-6H -benzol 4,5]imidazo[1,2-a ]azepine (254) 121 
(XN I }-SPh ~ N • 
~sePh 
269 254 
A solution oftri-n-butyltin hydride (0.41 mI, 1.54 mmol) and AIBN (85 mg, 0.52 mmol) in 
toluene (50 ml) was added to 1-[5-(phenylselanyl)pentyl]-2-(phenylsulfanyl)-IH -benzimidazole 
269 (0.465 g, 1.03 mmol) in toluene (250 ml) at reflux over 10 h. The solution was stirred and 
heated under reflux for a further 1 h. After cooling to room temperature, the standard work up 
procedure for the radical cyclisation of imidazoles and benzimidazoles was followed to yield 
white crystals of 7,8,9,IO-tetrahydro-6H-benzo[4,5]imidazo[I,2-a]azepine 254 (31 mg, 17%), 
mp 124·C (lit. 121 mp, 124-125 ·C); OH 1.73-1.95 (6 H, m, 2', 3', 4'-CH2), 3.Q7-3.11 (2 H, m, 
CCH2), 4.14-4.18 (2 H, m, NCH2), 7.18-7.28 (3 H, m, Ar-H) and 7.65-7.69 (l H, m, Ar-H); Oc 
27.53,30.71,31.85,32.87, 46.51(NCH2), 110.66, 121.17, 124.08, 124.47, 137.76 (q-C), 144.21 
(q-C) and 150.29 (q-C) 
53) 1-(3-Chloropropyl)-1H-benzimidazole (270) 
(XI N,> ~ N 
I 
H 
257 
• (X} 
~CJ 
270 
Benzimidazole 257 (2.00 g, 16.9 mmol) was added slowly to sodium hydride (0.48 g, 
20.3 mmol) in THF (200 mI). The mixture was stirred, and heated under reflux for 1 hand 
l-bromo-3-chloropropane (1.3 ml, 13.0 mmol) was added dropwise. The mixture was heated 
under reflux for a further 2 h. The salts formed were removed by filtration on a celite bed and the 
solution was evaporated to dryness to yield a tan solid, which was purified by column 
chromatography using neutral alumina as absorbent with ethyl acetate I methanol as eluent to 
yield 1-(3-chloropropyl)-IH-benzimidazole 270, as a brown oil (1.80 g, 55%), (Found: M+, 
194.0614. CJOH l1N2Cl requires M, 194.0611); vrnax I cm-I 1614, 1496, 1459, 1384, 1366, 1331, 
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1286, 1246, 1203,767 and 745; oH 2.28-2.38 (2 H, m, 2'-CH2), 3.46-3.51 (2 H, t, J 5.9, CH2Cl), 
4.40-4.45 (2 H, t, J 6.5, NCH2), 7.27-7.36 (2 H, m, Ar-H), 7.43-7.47 (1 H, m, Ar-H), 7.82-7.85 
(1 H, m, Ar-H) and 7.95 (1 H, s, Im-2-H); oe 32.50 (2'-CH2), 41.60 (CH2Cl), 41.96 (NCH2), 
109.86, 120.91, 122.75, 123.55, 134.00 (q-C), 143.46 (2-C) and 144.21 (q-C); miz 194 (M+, 
37%), 131 (100), 104 (14), 77 (23), 51 (9) and 39 (11). 
54) 1-[3-(Phenylselanyl)propyl]-lH-benzimidazole (271) 
(JCI N"> ~ N • (JCI N"> ~ N 
~a ~sePh 
270 271 
Diphenyl diselenide (0.500 g, 1.6 mmol) was dissolved in absolute ethanol (300 ml) at ambient 
temperature. Sodium borohydride (0.132 g, 3.5 mmol) was added slowly to the stirred solution 
at 0 DC. The solution was stirred for a further 10 min at ambient temperature, and a solution of 
1-(3-chloropropyl)benzimidazole 270 (0.623 g, 3.2 mmol) in absolute ethanol (50 ml) added. 
After stirring for 3 h at ambient temperature, the solution was evaporated to dryness, and 2 M 
hydrochloric acid solution (100 ml) added, and the acidic solution washed with light petroleum 
(5 x 100 ml). The solution was basified to pH 8 with saturated sodium carbonate solution 
followed by the addition of 2 M sodium hydroxide solution until the aqueous solution was at pH 
14. The hydroxide solution was extracted with dichloromethane (2 x 100 ml), and the combined 
organic extracts dried (MgS04), and evaporated to dryness to yield 1-[3-(phenylselanyl)propyIJ-
IH-benzimidazole 271, as a viscous yellow oil (0.617 g, 61%) which required no purification; 
(Found: M+, 316.0481. C!6H !6N2Se requires M, 316.0478); vrnax / cm-! 1615, 1579, 1495, 
1478, 1459, 1438, 1367, 1287, 1260, 1228 and 741; OH 2.17-2.29 (2 H, m, 2'-CH2), 2.81-2.87 
(2 H, t, J 6.8, PhSeCH2), 4.29-4.35 (2 H, t, J 6.8, NCH2), 7.28-7.39 (5 H, m, Ar-H), 7.47-7.49 (3 
H, m, Ar-H), 7.79-7.81 (1 H, m, Ar-H) and 7.84 (1 H, m, Im-2-H); oe 23.24, 28.62 (SeCH2), 
43.10 (NCH2), 108.58, 119.47, 121.94, 121.16, 121.94, 128.00, 128.28, 131.86, 132.65 (q-C), 
141.95 and 142.92 (q-C); miz 316 (M+, 8%), 160 (38),131 (100), 104 (7), 77 (25) and 51 (20). 
55) Attempted radical cyclisation of 1-(3-phenylselanylpropyl)-lH-benzimidazole (271) 
(JCI) ~ N 
~sePh 
• (JC) + 
~ 252 
271 273 
130 
A solution of tri-n-butyltin hydride (0.77 ml, 2.85 mmol) and AIDN (0.160 g, 0.95 mmol) in 
toluene (50 ml) was added to 1-[3-(phenylselanyl)propyl]-IH-benzimidazole 271 (0.600 g, 1.89 
mmol) in toluene (200 ml) at reflux over 5 h. The solution was stirred and heated under reflux 
for a further 1 h. The standard work up procedure for the radical cyclisation of imidazoles and 
benzimidazoles was followed to yield a brown oil of I-propyl-1H -benzimidazole 273 (0.294 g, 
98%), which was not further purified; (Found: M+, 160.1000. CIOH!2N2 requires M, 160.1000); 
Vrnax I cm-! 1615, 1498, 1459, 1384, 1287, 1259, 1213 and 743; oH 0.86-0.92 (3 H, t, 17.3, 
CH3), 1.77-1.92 (2 H, m, 2'-CH2), 4.02-4.07 (2 H, t, 17.0, NCH2), 7.21-7.29 (2 H, m, Ar-H), 
7.32-7.37 (1 H, m, Ar-H), 7.77-7.81 (1 H, m, Ar-H) and 7.82 (1 H, s, Im-2-H); Cc 11.67 (CH3), 
23.47 (2'-CH2), 47.03 (NCH2), 109.89, 118.89, 120.67,122.33,123.90,134.23 (q-C) and 
143.36, 144.28 (q-C); m/z 160 (M+, 66%),131 (lOO), 118 (l0), 104 (10) and 77 (22). There was 
a trace of 2, 3-dihydro-1H-benzo[dJpyrrolo[I,2-a]imidazole 252 (5%, by IH NMR spectroscopic 
analysis of reaction mixture using a known amount of 1,4-dimethoxybenzene as internal 
standard). 
56) 2-Deuterio-l-[3-(Phenylselanyl)propyl]-lH -benzimidazole (275) 
(XI) ~ N 
! 
CPh 3 
258 
• 
• (XI ~D ~ N 
I 
H 
274 
• (XI }-D ~ N 
~sePh 
275 
1-(Trityl)benzimidazole 258 (6.00 g, 16.5 mmol) was dissolved in THF (350 ml) and TMEDA 
(7.3 ml, 49.5 mmol) was added to the stirred solution at ambient temperature. The temperature 
of the stirred solution was lowered to -78 'c and a solution of n-butyIIithium (7.2 ml, 
18.1 mmol) added dropwise. The solution turned pink and was stirred at 0 'C for a further 
20 min. A solution of deuterium oxide (1.0 ml, 50.0 mmol) in THF (30 ml) added dropwise, and 
the stirring was continued for a further 3 h. The solution was evaporated and saturated 
ammonium chloride (50 ml) and water (100 m) added to the residue. The aqueous mixture was 
extracted with dichloromethane (3 x 50 ml), and evaporated to dryness to yield a crude white 
solid, which was dissolved in methanol (250 ml). Concentrated hydrochloric acid (10 ml, 
31-34% w/w solution) was added, and the solution was heated under reflux for 2 h. After 
cooling the solution to ambient temperature, most of the solvent was evaporated and the residue 
added to water (100 ml). The acidic aqueous mixture was extracted with dichloromethane (2 x 
50 ml), which removed the hydrolysis product, triphenylmethylaIcohoI. The acidic aqueous 
layer was evaporated to leave approximately 30-40 ml of a solution containing the salt of 
benzimidazole. The benzimidazole was precipitated from the saturated aqueous acidic solution 
using solid sodium carbonate until effervescence ceased. The precipitate was filtered and dried 
to yield crude 2-deuterio-IH-benzimidazole 274 (1.19 g, 61 %), as white crystals. The general 
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procedure for the alkylation of benzimidazoles in THF was followed. 2-Deuterio-IH-
benzimidazole 274 (1.19 g, 10.0 mmol), sodium hydride (0.29 g, 12.0 mmol) and 
3-iodo-l-(phenylselanyl)propane 233 (2.43 g, 7.5 mmol) gave a tan residue. The residue was 
purified by column chromatography using neutral alumina as absorbent with light petroleum and 
dichloromethane followed by diethyl ether as eluent to give a mixture 
2-deuterio-l-[ 3-(phenylselanyl)propyl]-1 H-benzimidazole 275, and 
1-[3-(phenylselanyl)propylj-IH-benzimidazole 271, as a yellow oil (1.49 g, 1.6/1.0 
respectively by GC-MS analysis); 275 (Found: M+, 317.0541. CI6HISN2DSe requires M, 
317.0540); OH 2.17-2.29 (2 H, m, 2'-CH2), 2.81-2.87 (2 H, t, J 6.8, PhSeCH2), 4.29-4.35 (2 H, t, 
J 6.8, NCH2), 7.28-7.39 (5 H, m, Ar-H), 7.47-7.49 (3 H, m, Ar-H) and 7.79-7.81 (1 H, m, Ar-H); 
OC 23.24, 28.62 (SeCH2), 43.10 (NCH2), 108.58, 119.47, 121.94, 121.16, 121.94, 128.00, 
128.28,131.86,132.65 (q-C), 141.95 and 142.92 (q-C); mlz 317 (M+, 17%),160 (30),157 (27), 
132 (100),131 (42),78 (31),77 (79) and 51 (31). 
57) Radical cyclisation of 2-deuterio- 1-[3-(phenylselanyl)propylj·lH·benzimidazole (275) 
(x}-o 
~sePh 
275 
• (XI N}-o ~ N + 
~ 252 
276 
A solution of tri-n-butyltin hydride (0.57 ml, 2.16 mmol) and AIBN ( 0.118 g, 0.72 mmol) in 
toluene (50 ml) was added to the mixture of 2-deuterio-I-[3-(phenylselanyl)propyl]-1 H-
benzimidazole 275, and 1-[3-(phenylselanyl)propylj-lH -benzimidazole 271 (0.455 g, ratio 1.6/ 
I respectively by GC-MS analysis) in toluene (250 ml) at reflux over 5 h. The solution was 
stirred and heated under reflux for a further 1 h. The standard work up procedure for the radical 
cyclisation of imidazoles and benzimidazoles was followed to yield a mixture of 2-deuterio-l-
propylbenzimidazole 276; mlz 161 (M+, 89%),160 (35),132 (100),131 (45) and 77 (42) and 
2,3-dihydro-1H-benzo[djpyrrolo[I,2-ajimidazole 252, as a brown oil (0.189 g, 4.0 /1.0 
respectively by GC-MS analysis). 
58) Radical cyclisation of 1·[3·(phenylselanyl)propylj.lH.benziinidazole (271) using tri·n· 
butyItin deuteride 
(X) 
~sePh 252 
271 
132 
A solution of tri-n-butyltin deuteride (1.04 ml, 3.91 mmol) and AIBN (0.268 g, 1.63 mmol) in 
toluene (50 ml) was added to the mixture of 1-[3-(phenylselanyl)propyl]-1 H-benzimidazole 271 
(1.030 g, 3.26 mmo!) in toluene (350 ml) at reflux over 5 h. The solution was stirred and heated 
under reflux for a further 1 h. The standard work up procedure for the radical cycIisation of 
imidazoles and benzimidazoles was followed to yield a mixture of 1-(3-deuteropropyl)-IH-
benzimidazole 277; mlz 161 (M+, 54%),160 (96), 132 (25),131 (lOO), 77 (57) and 2,3-dihydro-
IH-benzo[djpyrrolo[I,2-a]imidazole 252, as a brown oil (0.389 g, 3.3/1.0 respectively by GC-
MS analysis). 
5.4 Experimental for Chapter 4 
59) 1-(3-Chloropropyl)-lH-4-imidazolecarbaldehyde (288) 
OHC<~ III N 
I 
H 
• OHC'l() + 
--------~ ~N 
~CI 
278 288 289 
Imidazole-4(5)-carbaldehyde 278 (5.40 g, 56.2 mmol) was added to sodium hydride (2.02 g, 
84.3 mmol) in THF (400 m!). The mixture was stirred and heated under reflux for 1 h, and 
l-bromo-3-chloropropane (22.2 ml, 0.225 mol) was added. The mixture was stirred and heated 
under reflux for a further 2 h. The salts formed and unreacted imidazole were removed by 
filtration on a celite bed. The solution was evaporated to yield a crude slurry, which was purified 
by column chromatography using neutral alumina as absorbent with light petroleum 1 
dichloromethane followed by ethyl acetate 1 methanol as eluent to yield 1-(3-chloropropyl)-IH-
5-imidazolecarbaldehyde 289, as a yellow oil (0.34 g, 4%). Further elution using ethyl acetate 1 
methanol yielded 1-(3-chloropropyl)-IH-4-imidazolecarbaldehyde 288, as a florescent yellow 
oil (5.55 g, 58%); Vrnax 1 cm-! 2960,2751,1690 (C=O), 1539, 1497, 1452, 1349, 1327, 1163 and 
1148; OH (360.1 MHz) 2.18-2.29 (2 H, m, 2'-CH2), 3.47-3.51 (2 H, t, J 5.9, CH2CI), 4.22-4.26 
(2 H, t, J 6.6, NCH2), 7.60 (I H, s, Im-2-H), 7.65 (I H, s, Im-5-H) and 9.87 (I H, s, CHO); Oc 
33.45 (2'-CH2), 40.99 (CH2CI), 44.51 (NCH2), 124.51 (lm-2-CH), 139.27 (lm-5-CH) and 
186.67 (CHO). 
60) 1-(3-Bromopropyl)-lH -4-imidazolecarbaldehyde (290) 
________ ~. OHCt } 
~Br 
290 
133 
Imidazole-4(5)-carbaldehyde 278 (4.00 g, 41.6 mmol) was added to sodium hydride (1.50 g, 
62.4 mmol) in THF (300 ml). The mixture was stirred and heated under reflux for 1 h, and 
1,3-dibromopropane (43.0 ml, 0.424 mol) was added. The mixture was stirred and heated 
under reflux for a further 2 h. The salts formed and unreacted imidazole were removed by 
filtration on a celite bed. The solution was evaporated to yield a crude slurry, which 
was purified by column chromatography using neutral alumina as absorbent with light 
petroleum I dichloromethane followed by ethyl acetate I methanol as eluent to yield 
1-(3-bromopropyl)-lH-4-imidazolecarbaldehyde 290, as a yellow gummy oil (3.58 g, 40%) 
(Found: M+, 215.9901. C7H9N2BrO requires M, 215.9899); Urnax I cm-! 3110,2961,2824, 1682 
(C=O), 1538, 1497, 1454, 1381, 1327, 1249, 1162, 1046,979,855,780 and 627; OH 2.27-2.37 
(2 H, m, 2'-CH2), 3.30-3.36 (2 H, t, J 7.5, CH2Br), 4.20-4.26 (2 H, t, J 7.5, NCH2), 7.61 (I H, s, 
Im-2-H), 7.64 (I H, s, Im-5-H) and 9.87 (lH, s, CHO); 8c 29.13 (2'-CH2), 32.44 (CH2Br), 
45.60 (NCH2), 124.35 (lm-2-CH), 139.21 (lm-5-CH) and 186.58 (CHO); m/z 234 (M+, 36%), 
158 (47),91 (27),78 (70), 51 (45) and 41 (100). 
61) 1-(4-Bromobutyl)-IH-4-imidazolecarbaldehyde (292) 
OHC~~ 
I(J 
N 
I 
H 
278 
_____ > OHCt ) N + 
~Br 
292 293 
Imidazole-4(5)-carbaIdehyde 278 (2.000 g, 21.0 mmol) was added to sodium hydride (0.374 g, 
31.5 mmol) in THF (300 ml). The mixture was stirred and heated under reflux for 1 h, and 
1,4-bromobutane (25.1 ml, 0.210 mol) was added. The mixture was stirred and heated under 
reflux for a further 2 h. The salts formed and unreacted imidazole were removed by filtration on 
a celite bed. The solution was evaporated to yield a crude slurry, which was purified by column 
chromatography using neutral aIumina as absorbent with light petroleum I dichloromethane 
followed by ethyl acetate I methanol as eluent to yield 1-(4-bromobutyl)-lH-5-
imidazolecarbaldehyde 293, as a yellow oil (0.290 g, 6%), (Found: M+, 230.0055 CgH !!N2Br 
requires M, 230.0055); urnax I cm-! 2196, 1668 (C=O), 1536, 1489, 1348 and 1124; OH 1.84-
2.00 (4 H, m, 2' and 3'-CH2), 3.38-3.43 (2 H, t, J 6.2, CH2Br), 4.31-4.36 (2 H, t, 17.0, NCH2), 
7.68 (I H, s, Im-2-H), 7.81 (I H, s, Im-5-H) and 9.75 (I H, s, CHO); Oc 29.32 (3'-CH2), 29.44 
(2'-CH2), 32.32 (CH2Br), 46.25 (NCH2), 143.43 (Im-CH), 144.05 (lm-CH) and 179.10 (CHO); 
Further elution with ethyl acetate I methanol yielded 1-(4-bromobutyl)-lH-4-
imidazolecarbaldehyde 292, as a yellow oil (2.70 g, 56%); Urnax I cm-! 2945, 1686(C=O), 1541, 
1497,1450, 1349 and 1160; OH 1.82-1.93 (2 H, m, 3'-CH2), 2.00-2.09 (2 H, m, 2'-CH2), 3.39-
3.44 (2 H, t, J 6.2, CH2Br), 4.03-4.09 (2 H, t, J 7.0, NCH2), 7.58 (I H, s, Im-2-H), 7.64 (1 H, s, 
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Im-5-H) and 9.88 (1 H, s, CHO); Bc 29.16 (3'-CH2), 29.32 (2'-CH2), 32.02 (CH2Br), 46.80 
(NCH2), 123.83 (Im-2-CH), 138.47 (Im-5-CH) and 186.19 (CHO); mJz 232 (11),230 (M+, 
10%),151(100), 123 (54),109 (22), 95 (38), 55 (98) and 41 (29). 
62) l-(S-Bromopentyl)-lH -4-imidazolecarbaldehyde (294) 
OHC<' l/ N 
I 
H 
OHCy~ 
------. l" 
N 
~Br 
278 294 
Imidazole-4(5)-carbaldehyde 278 (1.417 g, 14.7 mmol) was added to sodium hydride (0.530 g, 
22.1 mmol) in THF (300 ml). The mixture was stirred and heated under reflux for 1 h and 
1,5-dibromopentane (20.0 ml, 0.147 mol) was added. The mixture was stirred and heated under 
reflux for a further 2 h. The salts formed and unreacted imidazole were removed by filtration on 
a celite bed. The solution was evaporated to yield a crude slurry, which was purified by column 
chromatography using neutral alumina as absorbent with light petroleum I dichloromethane 
followed by ethyl acetate I methanol as eluent to yield 1-(5-bromopentyl)-lH-4-
imidazolecarbaldehyde 294, as a tan oil (2.241 g, 63%) (Found: MH+, 245.0289. C9H13N2BrO 
+ H requires M, 244.0290); vrnax I cm-! 2862, 1683 (C=O), 1539, 1497, 1356, 1144, 1048 and 
979; BH 1.43-1.55 (2 H, m, 3'-CH2), 1.80-2.08 (4 H, m, 2' and 4'-CH2), 3.40-3.45 (2 H, t, J 5.8, 
CH2Br), 4.00-4.06 (2 H, t, J7.1, NCH2), 7.57 (1 H, s, Im-2-H), 7.64 (I H, s, Im-5-H) and 9.88 
(I H, s, CHO); Bc 24.95 (3'-CH2), 29.99 (4'-CH2), 31.78 (2'-CH2), 32.85 (CH2Br), 47.43 
(NCH2), 124.07 (Im-2-CH), 138.57 (lm-5-CH) and 186.19 (CHO); mJz 247 (83), 245 (MW, 
82%),219 (38), 217 (37),165 (100),137 (94) and 86 (15). 
63) 1-(6-Bromohexyl)-lH-4-imidazolecarbaldehyde (296) 
OHC<~ 
1(/ 
N 
I 
H 
278 
____ • OHCl ) N 
Y.Br 
296 
Imidazole-4(5)-carbaldehyde 278 (2.018 g, 21.0 mmol) was added to sodium hydride (0.756 g, 
3 1.5 mmol) in THF (400 ml). The mixture was stirred and heated under reflux for 1 hand 
1,6-dibromohexane (10.2 ml, 63.0 mmol) was added. The mixture was stirred and heated under 
reflux for a further 2 h. The salts formed and unreacted imidazole were removed by filtration on 
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a celite bed. The solution was evaporated to yield a crude slurry, which was purified by column 
chromatography using neutral alumina as absorbent with light petroleum I dichloromethane 
followed by ethyl acetate I methanol as eluent to yield 1-(6-bromohexyl)- I H-4-
imidazolecarbaldehyde 296, as a yellow oil (4.877 g, 60%); BR 1.34-1.56 (4 H, m, 3' and 4'-
CH2), 1.80-1.91 (4 H, m, 2' and 5'-CH2), 3.38-3.43 (2 H, t, J 6.5, CH2Br), 3.99-4.04 (2 H, t, 
17.1, NCH2), 7.56 (1 H, s, Im-2-H), 7.63 (1 H, s, Im-5-H) and 9.88 (1 H, s, CHO); Bc 25.99 (4'-
CH2), 27.71, 31.05, 32.58, 34.08 (CH2Br), 47.94 (NCH2), 124.56 (Im-2-CH), 139.04 
(Im-5-CH), 142.94 (q-C, Im-4-C) and 185.60 (CHO). 
64) 1-(12-bromododecyl)-IH -4-imidazolecarbaldehyde (298) 
OHC<~ 
IC.' 
____ .OHCt ) N N 
I 
H ~Br 
278 298 
Imidazole-4(5)-carbaldehyde 278 (1.5 g, 15.6 mmo1) was added to sodium hydride (0.6 g, 
23.4 mmol) in THF (300 ml). The mixture was stirred and heated under reflux for 1 hand 
1,12-dodecane (51.1 g, 0.156 mol) in THF (100 ml) was added. The mixture was stirred and 
heated under reflux for a further 2 h. The salts formed and unreacted imidazole were removed by 
filtration on a celite bed. The solution was evaporated to yield a tan solid, which was purified by 
column chromatography using neutral alumina as absorbent with light petroleum I 
dichloromethane followed by ethyl acetate as eluent to yield 1-( 12-bromododecyl)-l H-4-
imidazolecarbaldehyde 298, as cream coloured needles (6.2 g, 77%), mp 41-43 °C (Found: M+, 
342.1307. C16H27N2BrO requires M, 342.1307); BR 1.26 (16 H, m, 3'-1O'-CH2), 1.80-1.88 (4 H, 
m, 2' and I l'-CH2), 3.38-3.44 (2 H, m, CH2Br), 3.96-4.02 (2 H, t, 17.1, NCH2), 7.54 (1 H, s, 
Im-2-H), 7.62 (1 H, s, Im-5-H) and 9.88 (1 H, s, CHO); Bc (62.5 MHz) 26.31, 28.02, 28.60, 
28.85,29.21,29.24,29.29,30.71,32.68,34.00 (CH2Br), 47.63 (NCH2), 124.20 (Im-2-CH), 
138.61 (Im-5-CH), 143.33 (q-C, Im-4-C) and 186.15 (CHO); mlz 342 (M+, > 1 %),263 (34), 137 
(13),110 (23), 69 (28) and 55 (100). 
65) 1-( 4-Chlorobutyl)-IH-5-imidazolecarbaldehyde (301) 
OHC-;C~ 
lC.' N • 
I 
H 
278 
136 
lmidazole-4(5)-carbaldehyde 278 (0.500 g, 5.2 mmol) and l-chloro-4"iodobutane (6.4 ml, 
52 mmol) were heated under reflux in acetonitrile (200 ml) for 18 h. The solution was 
evaporated to dryness to yield a tan residue, which was purified by column chromatography 
using neutral alumina as absorbent with light petroleum I dichloromethane followed by ethyl 
acetate I methanol as eluent to yield 1-(4-chlorobutyl)-lH-5-imidazolecarbaldehyde 300, as a 
yellow oil (0.144 g, 15%) (Found: M+, 186.0561. CSH11N2CI 0 requires M, 186.0561); 
Vrnax I cm-' 2958,2854, 1676 (C=O), 1535, 1487, 1348 and 1125; (lH (360.1 MHz) 1.76-1.82 
(2 H, m, 3'-CH2), 1.93-1.99 (2 H, m, 2'-CH2), 3.56-3.62 (2 H, t, J 6.4, CH2CI), 4.32-4.36 (2 H, 
t, J 7.1, NCH2), 7.68 (1 H, s, lm-2(4)-H), 7.81 (1 H, s, lm-2(4)-H) and 9.75 (1 H, s, CHO); 
(le (62.5 MHz) 28.23 (3'-CH2), 29.19 (2'-CH2), 43.95 (CH2CI), 46.37 (NCH2), 143.45 (lm-CH), 
144.07 (lm-CH) and 179.10 (CHO); mlz 187 (MW, 100%), 157 (100),151 (63), 123 (88),109 
(88), 95 (55), 55 (97) and 27 (100). 
66) 1-[3-(Phenylselanyl)propyIJ.lH.5·imidazolecarbaldehyde (303) 
OHC-;:;:::-) 
lC.. N 
I 
H 
278 
__ .OHCl ) + f) N OHC N ~sePh ~sePh 
302 303 
lmidazole-4(5)-carbaldehyde 278 (1.230 g, 12.8 mmol) was added to 3-iodo-1-
(phenylselanyl)propane 233 (4.168 g, 12.8 mmol) in THF (200 ml) and the mixture was stirred 
and heated under reflux for 54 h. The solution was evaporated to yield a crude slurry, which was 
purified by column chromatography using neutral alumina as absorbent with light petroleum I 
dichloromethane followed by ethyl acetate I methanol as eluent to yield a yellow gummy oil of 
1-[3-(phenylselanyl)propylI-1H-5-imidazolecarbaldehyde 303 (0.414 g, 11 %) (Found: M+, 
294.0268. C13H ,<jN20Se requires M, 294.0271); vrnax I cm-' 3054, 1670 (C=O), 1579, 1537, 
1479, 1436, 1346, 1207, 1123 and 1022; (lH 2.01-2.20 (2 H, m, 2'-CH2), 2.79-2.84 (2 H, t, J 6.8, 
CH2SePh), 4.37-4.42 (2 H, t, J 6.8, NCH2), 7.26-7.29 (3 H, m, Ph-H), 7.47-7.50 (2 H, m, 
Ph-H), 7.61 (1 H, s, lm-2-H), 7.79 (1 H, s, lm-4-H) and 9.72 (!H, s, CHO); (le 22.81 (2'-CHv, 
28.81 (CH2SePh), 44.73 (NCH2), 125.69, 127.44 (q-C) 127.59, 129.29 (q-C), 131.40, 142.14, 
142.50 and 177.42 (CHO); mlz 294 (M+, 17%), 157 (10),137 (100),109 (13) and 100 (21). 
Further elution with ethyl acetate I methanol yielded a yellow gummy oil of 
1-[3-(phenylselanyl)propyIJ-1 H-4-imidazolecarbaldehyde 302 (0.188 g, 5%). 
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67) 1-[ 4-(Phenylselanyl)butyl]-IH-5-imidazolecarbaldehyde (305) 
OHCf) 
N 
I 
H 
278 
-----. OHCf ) 
~sePh 
305 
Imidazole-4(5)-carbaldehyde 278 (0.744 g, 8.06 mmol) was added to 4-iodo-1-
(phenylselanyl)butane 234 (2.740 g, 8.06 mmol) in THF (200 m!), and the mixture was stirred 
and heated under reflux for 54 h. The solution was evaporated to yield a crude slurry, which was 
purified by column chromatography using neutral alumina as absorbent with light petroleum I 
dichloromethane followed by ethyl acetate I methanol as eluent to yield a yellow gummy oil of 
1-[4-(phenylselanyl)butylJ-1H-5-imidazolecarbaldehyde 305 (0.323 g, 13%); vrnax I cm-! 2253, 
1675 (C=O), 1644, 1536, 1478, 1347 and 1126; IiH (400 MHz) 1.69-1.76 (2 H, m, 3'-CH2), 
1.91-1.98 (2 H, m, 2'-CH2), 2.90-2.93 (2 H, t, J 6.0, CH2SePh), 4.30-4.33 (2 H, t, 17.2, NCH2), 
7.27-7.31 (3 H, m, Ph-H), 7.48-7.51 (2 H, m, Ph-H), 7.60 (l H, s, Im-2-H), 7.82 (l H, s, Im-4-H) 
and 9.76 (lH, s, CHO); lie 27.24 (3'-CH2), 27.46 (2'-CH2), 31.11 (CH2SePh), 47.03 (NCH2), 
127.49,129.53,130.16 (q-C), 133.28, 133.39, 144.31 and 179.52 (CHO). 
68) 1-(3-Iodopropyl)-IH -4-imidazolecarbaldehyde (306) 
OHCyft. 
------. l) 
N 
~I 
288 306 
1-(3-Chloropropyl)-IH-4-imidazolecarbaldehyde 288 (3.0 g, 17.4 mmol) and sodium iodide 
(26.1 g, 0.174 mol) were added to dry acetone (250 ml) and heated under reflux for 18 h. The 
standard work up procedure for the formation of iodides was followed to give 1-(3-iodopropyl)-
IH-4-imidazolecarbaldehyde 306, as a yellow-orange solid (4.1 g, 89%); IiH (360.1 MHz) 2.23-
2.30 (2 H, m, 2'-CH2), 3.07-3.10 (2 H, t, J 6.5, CH2I), 4.16-4.20 (2 H, t, J 6.3, NCH2), 7.62 
(l H, s, Im-2-H), 7.66 (l H, s, Im-5-H) and 9.80 (1 H, s, CHO); lie 0.00 (2'-CH2I), 32.69 
(2'-CH2), 46.54 (NCH2), 122.91 (Im-2-CH), 137.90 (Im-5-CH) and 185.42 (CHO). The product 
rapidly decomposed in the dark and under inert atmospheres to give an intractable brown solid. 
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69) 6,7 -Dihydro-5H-pyrrolo[1,2-c ]imidazole-l-carbaldehyde (307) 
(from the in situ formation of iodide 306) 
• 
306 
307 
OHCYN 
+ l ~ 
N 
~ 
308 
1-(3-Chloropropyl)imidazole-4-carbaldehyde 288 (0.300 g, 1.74 mmol) and sodium iodide 
(2.600 g, 17.00 mmol) were added to dry acetonitrile (250 ml) and heated under reflux for 18 h. 
The precipitated sodium chloride was removed in darkness by filtration on a celite bed and the 
1-(3-iodopropyl)imidazole-4-carbaldehyde 306, which was formed in situ. A solution of tri-n 
butyltin hydride (0.69 rnI, 2.62 mmol) and AmN (0.140 g, 0.86 mmol) in toluene (50 rnI) was 
immediately added to the solution of 1-(3-iodopropyl)-IH-4-imidazolecarbaldehyde 306 at 
reflux over 5 h. The solution was stirred and heated under reflux for a further I h. The standard 
work up procedure for the radical cyclisation of imidazoles and benzimidazoles was followed to 
yield a tan solid, which was purified by prep-TLC using neutral alumina as absorbent with ethyl 
acetate I methanol as eluent to yield 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole-I-carbaldehyde 
307, as white needles (7 mg, 3%) and l-propyl-IH-4-imidazolecarbaldehyde 308, as a colourless 
oil (12 mg, 7%). 
70) {1-[3-(Phenylselanyl)propyl]-lH-4-imidazolyl} methanol (309) 
290 
HO~~ 
----. lJ N 
~sePh 
309 
Diphenyl diselenide (2.53 g, 8.1 mmol) was dissolved in absolute ethanol (600 ml) at ambient 
temperature. Sodium borohydride (0.67 g, 17.7 mmol) was added slowly to the stirred solution 
at 0 'C. After 30 min, 1-(3-bromopropyl)-IH-4-imidazolecarbaldehyde 290 (1.92 g, 
8.89 mmol) in absolute ethanol (100 ml) was added and the mixture was stirred at ambient 
temperature for 16 h. The solution was evaporated to dryness and 2 M hydrochloric acid 
(100 ml) added and the acidic solution was washed with light petroleum (3 x 100 m!) to remove 
selenide residues. The solution was basified to pH 8 with saturated sodium carbonate solution 
followed by the addition of 2 M sodium hydroxide solution until the aqueous solution was at pH 
14. The hydroxide solution was extracted into dichloromethane (2 x lOO ml), and the combined 
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organic extracts dried (MgS04) and evaporated to dryness to yield a brown solid, which was 
recrystaIIised with ethyl acetate to yield the {l·[3·(phenylselanyl)propyll·lH·4· 
imidazolyl}methanoI309, as yellow·orange crystals (1.08 g, 41 %) (Found: M+, 296.0437. 
C13H!6N2SeO requires M, 296.0428); vrnax I cm·! 3054, 1709, 1579, 1503, 1478, 1438, 1265 
and 1161; oH 2.08·2.15 (2 H, m, 2'-CH2), 2.78-2.84 (2 H, t, J 6.8, CH2SePh), 4.004.05 (2 H, t, 
J 6.6, NCH2), 4.58 (2 H, s, CH20H), 6.80 (1 H, s, Im·5-H), 7.24·7.29 (3 H, m, Ph·H), 7.37 (l H, 
s, Im·2·H) and 7.47-7.51 (2 H, m, Ph·H); oe 24.41 (2'·CH2), 31.28 (CH2SePh), 46.49 (NCHV, 
58.34 (CH20H), 116.47 (Im·5-CH), 127.74, 129.66, 133.57, 137.33 (Im-2·CH), 143.27 and 
(q·C, Im-4·C); miz 296 (M+' 98%),157 (49), 138 (62), 121 (72), 109 (100), 82 (97) and 41 
(81). 
71) 1 ·[3·(Pheny1se1anyl)propylj.l H.4-imidazolecarbaldehyde (302) 
____ > OHCl~ 
N 
~sePh 
302 
{H3·(Phenylselanyl)propylj-lH.4·imidazolyljmethanol 309 (0.879 g, 3.0 mmol) and activated 
manganese dioxide (2.700 g, 31.1 mmol) were stirred at ambient temperature in dry 
dichloromethane (200 mI) for 48 h. The mixture was filtered on a celite bed and the residue 
washed with dichloromethane (3 x 50 ml). The combined filtrate washings were evaporated to 
an oil, which was purified by column chromatography using neutral alumina as absorbent with 
ethyl acetate I methanol as eluent to yield 1·[3·(phenylselanyl)propyll·lH·4· 
imidazolecarbaldehyde 302, as a yellow gummy oil (0.635 g, 72%) (Found: M+, 294.0236. 
C13H!~20Se requires M, 294.0271); vrnax I cm·! 3054, 1684 (C=O), 1539, 1478, 1438, 1266, 
1160,1022 and 910; OH 2.10·2.21 (2 H, m, 2'·CH2), 2.79·2.85 (2 H, t, J 6.8, CH2SePh), 4.11-
4.16 (2 H, t, J 6.8, NCH2), 7.26-7.31 (3 H, m, Ph·H), 7.48-7.52 (3 H, m, Ph·H and Im-2·H), 
7.55 (1 H, s, Im·5-H) and 9.86 (lH, s, CHO); Bc 25.40 (2'·CH2), 32.33 (CH2SePh), 48.21 
(NCH2), 125.30, 131.02, 134.94, 140.43, 145.78 and 187.73 (CHO); miz 294 (M+, 100%), 157 
(48), 137 (38), 109 (56), 84 (67), 77 (57),49 (65) and 41 (62). 
72) 6,7.Dihydro-5H·pyrrolo[1,2-cjimidazole-l-carbaldehyde (307) (from the selenide 302) 
> 
307 308 
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A solution of tri-n-butyltin hydride (1.0 ml, 3.72 mmol) and AIBN (0.213 g, 1.30 mmol) in 
toluene (50 ml) was added to 1-[3-(phenylselanyl)propyIJ-l H-4-imidazolecarbaldehyde 302 
(0.730 g, 2.48 mmol) in acetonitrile (750 ml) at reflux over 5 h. The solution was stirred and 
heated under reflux for a further 1 h. The standard work up procedure for the radical cyclisation 
of imidazoles and benzimidazoles was followed to yield a tan solid, which was purified by 
column chromatography using neutral alumina as absorbent with ethyl acetate I methanol as 
eluent to yield 6,7-dihydro-5H-pyrrolo[I,2-cJimidazole-l-carbaldehyde 307, as white needles 
(92 mg, 27%) and 1-propyl-l H-4-imidazolecarbaldehyde 308, as a colourless oil (38 mg, 11 %). 
73) 6,7-Dihydro-5H-pyrrolo[t,2-cJimidazole-t-carbaldehyde (307) (from the bromide 290) 
OHCytt. 
+ l) 
N 
~ 
308 
A solution of tri-n-butyltin hydride (4.3 ml, 5.4 mmol) and AIDN (0.593 g, 3.6 mmol) in 
toluene (50 ml) was added to 1-(3-bromopropyl}-IH -4-imidazolecarbaldehyde 290 (1.560 g, 
7.2 mmol) in acetonitrile (750 ml) at reflux over 5 h. The solution was stirred and heated under 
reflux for a further 1 h. The standard work up procedure for the radical cycJisation of imidazoles 
and benzimidazoles was followed to yield a tan solid, which was purified by column 
chromatography using neutral alumina as absorbent with ethyl acetate I methanol as eluent to 
yield 6,7-dihydro-5H-pyrrolo[l,2climidazole-I-carbaldehyde 307, as white needles (0.411 g, 
42%), mp 137-139 °C (Found: M+, 136.0637. C7H8N20 requires M, 136.0637); Vrnax I cm-! 
3223, 1672 (C=O), 1618, 1471, 1446, 1345, 1300, 1281, 1134 and 744; IiH 2.66-2.80 (2 H, m, 
6-CH2), 3.07-3.13 (2 H, t, J7.5, 7-CH2), 4.03-4.09 (2 H, t, J7.2, NCH2), 7.48 (1 H, s, Im-3-H), 
and 9.83 (lH, s, CHO); lie 23.43 (6-CH2), 29.22 (7-CH2), 45.09 (NCH2), 132.21 (lm-3-CH), 
133.52 (q-C, Im-7a-C), 145.05 (q-C, Im-l-C) and 186.95 (CHO); m/z 136 (M+, 40%),135 (39), 
108 (36), 107 (52), 81(29), 80 (100), 79 (27), 53 (84),52 (82),41 (36) and 39 (42). Further 
elution with ethyl acetate I methanol yielded l-propyl-IH-4-imidazolecarbaldehyde 308, as a 
colourless oil (0.100 g, 10%) (Found: M+, 138.0795. C7H\ON20 requires M, 138.0793); IiH 
0.93-0.99 (3 H, t, J7.4, CH3), 1.81-1.93 (2 H, m, 2'-CH2), 3.94-3.99 (2 H, t, J7.1,NCH2), 7.55 
(1 H, s. Im-2-H), 7.62 (1 H, s, Im-5-H) and 9.87 (lH, s, CHO); lie 11.40 (CH3). 24.59 (2'-CH2), 
49.75 (NCH2), 124.49 (lm-2-CH), 139.07 (lm-5-CH), 142.92 and 186.77 (CHO); m/z 138 (M+, 
100%),121 (12), 110 (46),95 (61), 81 (13),68 (25) and 43 (47). 
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74) 5,6,7,8-Tetrahydroimidazo[1,5-a ]pyridine-l-carbaldehyde (310) 
OHCYN l~ ____ • I ~3 
OHC
8N
2 
N 
~Br 
292 
B N4 
5 
7 
6 
310 
A solution of tri-n-butyltin hydride (1.9 ml, 7.16 mmol) and AmN (0.378 g, 2.30 mmol) in 
toluene (50 ml) was added to 1-(4-bromobutyl)-lH-4-imidazolecarbaldehyde 292 (1.078 g, 
4.69 mmol) in acetonitrile (750 ml) at reflux over 5 h. The solution was stirred and heated under 
reflux for a further 1 h. The standard work up procedure for the radical cyclisation of imidazoles 
and benzimidazoles was followed to yield a tan solid, which was purified by column 
chromatography using neutral alumina as absorbent with ethyl acetate I methanol as eluent to 
yield 5,6,7,8-tetrahydroimidazo[1,5-aJpyridine-l-carbaldehyde 310, as yellow needles (0.344 g, 
49%) mp 51-53 °C, (Found: M+, 150.0793. CSHlON20 requires M, 150.0793); Vrnax I cm-! 
2957, 1672 (C=O), 1553, 1514, 1266 and 1151; OH 1.86-2.05 (4 H, m, 6 and 7-CH2), 3.07-3.12 
(2 H, t, J 6.4, 8-CH2), 4.00-4.05 (2 H, t, J 6.0, NCH2), 7.42 (1 H, s, Im-3-H) and 9.89 (!H, s, 
CHO); OC (62.5 MHz) 20.35, 22.67, 23.18 (8-CH2), 44.18 (NCH2), 137.29 (Im-3-CH) and 
187.90 (CHO); mlz 151 (MH+, 100%), 150 (M+, 69),149 (56),121 (19),94 (9) and 67 (31). 
75) 6,7,8,9-Tetrahydro-5H -imidazo[I,5-a ]azepine-l-carbaldehyde (312) 
OHCyN l~ N 
~Br 
OHCa~ 
-----_. !B I "/3 
9 N4 
B 5 
7 6 
OHCy~ 
+ l ~ 
N 
~ 
294 313 
312 
A solution oftri-n-butyltin hydride (1.20 m1, 4.50 mmol) and AffiN (0.246 g, 1.50 mmol) in 
toluene (50 ml) was added to 1-(5-bromopentyl)-1 H-4-imidazolecarbaldehyde 294, (0.726 g, 
3.00 mrnol) in acetonitrile (350 m1) at reflux over 10 h. The solution was stirred and heated 
under reflux for a further 1 h. The standard work up procedure for the radical cyclisation of 
imidazoles and benzimidazoles was followed to yield a tan solid, which was purified by column 
chromatography using neutral alumina as absorbent with ethyl acetate I methanol as eluent to 
yield 6,7,8,9-tetrahydro-5H-imidazo[ 1,5-aJazepine-l-carbaldehyde 312, as white needles 
needles (69 mg, 14%) mp 86-88 °C, (Found: M+, 164.0950. C9H12N20 requires M, 164.0950); 
Vrnax I cm-! 2857, 1666 (C=O), 1555, 1524, 1392 and 1353; OH 1.65-1.89 (6 H, m, 6,7 and 
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8-CH2), 3.20-3.22 (2 H, m, 9-CH2), 4.01-4.05 (2 H, m, NCH2), 7.39 (I H, s, Im-3-H) and 9.92 
(!H, s, CHO); oc 24.52, 26.76, 29.07, 30.89, 48.38 (NCH2), 137.80 (q-C, Im-9a-C), 138.19 
(Im-3-CH), 141.76 (q-C, Im-1-C) and 187.95 (CHO); m/z 165 (MW, 24%), 164 (M+, 100), 163 
(45),149 (18), 135 (91), 121 (34), 107 (43) and 81 (31). Further elution with ethyl acetate I 
methanol yielded I-pentyl-lH-4-imidazolecarbaldehyde 313, as a colourless oil (40 mg, 8%), 
(Found: M+, 166.11 06. C9H 1<JN20 requires M, 166.1106); OH 0.88-0.93 (3 H, t, J 6.9, CH3), 
1.25-1.40 (4 H, m, 7 and 8-CH2), 1.77-1.88 (2 H, m, 6-CH2), 3.96-4.02 (2 H, t, 17.1, NCH2), 
7.62 (I H, s, Im-2-H), 7.63 (1 H, s, Im-5-H) and 9.88 (!H, s, CHO); oc 14.17 (CH3), 22.45 
(4'-CH2), 28.98, 30.89, 48.12 (NCH2), 124.39 (Im-2-CH), 139.00 (Im-5-CH), 142.96 (q-C, 
Im-4-C) and 186.77 (CHO); m/z 166 (M+, 24%),137 (61),110 (25), 109 (20), 95 (26), 81 (34), 
68 (16), 55 (28) and 41 (100). 
76) Attempted radical cyclisation of 1-(6-bromohexyI)-IH-4-imidazolecarbaldehyde (296) 
OHC
Y1 
~ OHC 
u... ~ • y) ~----------~ ~N 
~Br ~ 
296 315 
A solution of tri-n-butyltin hydride (0.53 ml, 2.01 mmol) and AIBN (0.110 g, 0.67 mmol) in 
toluene (50 ml) was added to 1-(6-bromohexyl)-IH-4-imidazolecarbaldehyde 296, (0.346 g, 
1.34 mmol) in acetonitrile (350 ml) at reflux over 10 h. The solution was stirred and heated 
under reflux for a further 1 h. The standard work up procedure for the radical cyclisation of 
imidazoles and benzimidazoles was followed to yield a tan solid, which was purified by prep-
TLC using neutral alumina as absorbent with ethyl acetate I methanol as eluent to yield 
l-hexyl-IH-4-imidazolecarbaldehyde 315, as a colourless oil (0.136 g, 56%); OH 0.86-0.91 (3 H, 
t, J 6.5, CH3), 1.28-1.31 (6 H, m, 3', 4', and 5'-CH2), 1.79-1.84 (2 H, m, 2'-CH2), 3.96-4.02 
(2 H, t, 17.2, NCH2), 7.55 (I H, s, Im-2-H), 7.63 (I H, s, Im-5-H) and 9.87 (!H, s, CHO); OC 
14.26 (CH 3), 22.76, 26.48, 31.08, 31.06, 48.14 (NCH2), 124.48 (Im-2-CH), 139.01 (lm-5-CH), 
142.89 (q-C, Im-4-C) and 186.72 (CHO). 
77) Attempted radical cyclisation of 1-(12-bromododecyl)-IH-4-imidazolecarbaldehyde 
(298) 
298 317 
143 
A solution oftri-n-butyltin hydride (0.58 ml, 2.19 mmol) and AmN (0.120 g, 0.73 mmol) in 
toluene (50 ml) was added to 1-(l2-bromododecyl)-IH-4-imidazolecarbaldehyde 298, 
(0.500 g, 1.46 mmol) in toluene (350 ml) at reflux over 10 h. The solution was stirred and heated 
under reflux for a further I h. The standard work up procedure for the radical cyclisation of 
imidazoles and benzimidazoles was followed to yield a yellow oil of 1-dodecyl-1H-4-
imidazolecarbaldehyde 317, as an oil (0.269 g, 70%); (Found: M+, 264.2202. CI6H28N20 
requires M, 264.2202); vrnax I cm-I 2854, 1689 (C=O), 1540, 1466, 1378, 1158 and 910; oH 
0.85-0.91 (3 H, t, J 6.6, CH3), 1.25-1.38 (18 H, m, 3'-11 '-CH2), 1.79-1.82 (2 H, m, 2'-CH2), 
3.96-4.02 (2 H, t, J 7.1, NCH2), 7.54-7.55 (1 H, d, J 0.9, Im-2-H), 7.63 (1 H, d, J 0.9, Im-5-H) 
and 9.88 (lH, s, CHO); OC 14.45 (CH 3), 23.02, 26.80, 29.32, 29.66, 29.77, 29.83, 29.92, 31.18, 
31.31,32.24,48.10 (NCH2), 124.52 (lm-2-CH), 139.03 (lm-5-CH), 142.88 (q-C, Im-4-C) and 
186.65 (CHO);mlz 264 (M+, 57%), 235 (44), 221 (23),207 (29), 151 (36), 137 (37), 110 (81), 
97 (48), 55 (73), 55 (73) and 41 (100) [which required no further purification]. 
78) 1-(3-Bromopropyl)-5-methyl-lH-4-imidazolecarbaldehyde (318) 
____ • OHC)C) 
I-IJ N ~Br 
318 
4-Methylimidazole-4-carbaldehyde (2.000 g, 18.2 mmol) was added to sodium hydride 
(0.655 g, 27.3 mmol) in THF (300 ml). The mixture was stirred and heated under reflux for 1 h 
and 1,3-dibromopropane (18.5 ml, 0.182 mol) was added. The mixture was stirred and heated 
under reflux for a further 2 h. The salts formed and unreacted imidazole were removed by 
filtration on a celite bed. The solution was evaporated to yield a crude slurry, which was purified 
by column chromatography using neutral alumina as absorbent with light petroleum I 
dichloromethane followed by ethyl acetate I methanol as eluent to yield 1-( 3-bromopropyl)-5-
methyl-1H-4-imidazolecarbaldehyde 318, as a yellow gummy oil (1.428 g, 34%) (Found: M+, 
230.0062. C8HIIN2BrO requires M, 230.0055); vrnax I cm-I 3081, 1668 (C=O), 1556, 1510, 
1407, 1382, 1310, 1272, 1234, 1213, 1102 and 806; OH 2.24-2.35 (2 H, m, 2'-CH2), 2.58 (3 H, s, 
CH3), 3.35-3.39 (2 H, t, J 6.0, CH2Br), 4.11-4.17 (2 H, t, J 6.8, NCH2), 7.59 (1 H, s, Im-2-H) 
and 9.96 (lH, s, CHO) ; Oc 9.75 (CH3), 29.23 (2'-CH2), 32.98 (CH2Br), 42.77 (NCH2), 135.25 
(q-C, Im-5-C), 137.95 (Im-2-CH), 138.42 (q-C, Im-4-C) and 187.88 (CHO); mlz 232 (27), 230 
CM+, 27%), 151 (100), 124 (35), 109 (14), 96 (24) and 41 (54). 
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79) Attempted radical cyclisation of 1-(3-Bromopropyl)-5-methyl-lH4-
imidazolecarbaldehyde (318) 
OHCy ) 
H:J~N ~Br 
318 
• 
OHCy ) 
H:J~N ~ 
319 
A solution oftri-n-butyltin hydride (0.88 ml, 3.32 mmol) and AmN (0.181 g, 1.10 mmol) in 
toluene (50 ml) was added to 1-(3-bromopropyl)-5-methyl-l H-4-imidazolecarbaldehyde 318 
(0.540 g, 2.35 mmol) in acetonitrile (350 ml) at reflux over 5 h. The solution was stirred and 
heated under reflux for a further 1 h. The standard work up procedure for the radical cyclisation 
of imidazoles and benzimidazoles was followed to yield a yellow-orange oil of 
5-methyl-l-propyl-1 H-4-imidazolecarbaldehyde 319 (0.154 g, 46%); Vmax I cm-! 3111, 2876, 
1674 (C=O), 1557, 1510, 1456, 1381, 1259, 1209, 1170 and 1109; OH 0.90-0.99 (3 H, t, J7.4, 
CH3), 1.74-1.83 (2 H, m, 2'-CH2), 2.53 (3 H, s, Im-CH3), 3.82-3.88 (2 H, t, J7.2, NCH2), 7.44 
(1 H, s, Im-2-H) and 9.92 (lH, s, CHO); oc (62.5 MHz) 9.34 (lm-CH3), 11.06 (CH3), 23.72 
(2'-CH2), 46.24 (NCH2), 137.53 (Im-2-CH) and 187.54 (CHO) [which required no further 
purification]. 
80) 1-(3-Bromopropyl)-2-methyl-lH-4-imidazolecarbaldehyde (320) 
OHC 
l}-CH3 
N 
I 
H 
OHC 
__ . l}-CH3 
N 
~Br 
320 
2-Methylimidazole-4-carbaldehyde (1.000 g, 9.08 mmol) was added to sodium hydride (0.327 g, 
13.63 mmol) in THF (150 ml). The mixture was stirred and heated under reflux for 1 hand 
1,3-dibromopropane (9.2 ml, 90.80 mmol) was added. The mixture was stirred and heated under 
reflux for a further 2 h. The salts formed and unreacted imidazole were removed by filtration on 
a celite bed. The solution was evaporated to yield a crude slurry, which was purified by column 
chromatography using neutral alumina as absorbent with light petroleum I dichloromethane 
followed by ethyl acetate I methanol as eluent to yield 1-(3-bromopropyl)-2-methyl-lH-4-
imidazolecarbaldehyde 320, as a yellow gummy oil (0.948 g, 45%) (Found: M+, 230.0055. 
CgH l1N2BrO requires M, 230.0055); v max I cm'! 3125, 1678 (C=O), 1547, 1418, 1351, 1254, 
1163, 1102,991 and 812; OH 2.28-2.33 (2 H, rn, 2'-CH2), 2.48 (3 H, s, CH3), 3.35-3.39 (2 H, t, 
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J 6.0, CHzBr), 4.11-4.17 (2 H, t, J 6.7, NCHz), 7.59 (l H, s, Im-5-H) and 9.81 (lH, s, CHO) ; Oc 
13.53 (CH3), 29.21 (2'-CHz), 33.05 (CHzBr), 44.83 (NCHz), 125.81 (Im-5-CH), 141.13 (q-C, 
Im-2-C), 147.34 (q-C, Im-4-C) and 185.94 (CHO); mlz 232 (30), 231 (19),230 (M+, 23%),150 
(48),149 (48), 121 (44),81 (35),79 (28) and 41 (lOO). 
81) (E)-4-(3-methyl-6,7·dihydro·SH.pyrrolo[I,2·c]imidazol·l·yl)·3·buten·2·one (322) 
f1lCOC 
OHCy~ ll. )-CH3 
N • 
• 
~Br 
320 322 
A solution oftri-n-butyltin hydride (1.04 ml, 3.9 mmol) and AmN (0.213 g, 1.3 mmol) in 
toluene (50 ml) was added to 1-(3-bromopropyl)-2-methyl-l H-4-imidazolecarbaldehyde 320 
(0.600 g, 2.6 mmol) in acetonitrile (350 ml) at reflux over 5 h. The solution was stirred and 
heated under reflux for a further 1 h. After cooling to room temperature, the solution was 
evaporated to dryness, 2 M hydrochloric acid solution (50 ml), and a trace of acetone was added, 
and the acidic solution was washed with light petroleum (l2 x 50 ml). The solution was basified 
to pH 8 with saturated sodium carbonate solution followed by the addition of 2 M sodium 
hydroxide solution until the aqueous solution was at pH 14. The hydroxide solution was 
extracted into dichloromethane (2 x 100 ml) and the combined organic extracts dried (MgS04), 
and evaporated to dryness to yield a tan solid, which was purified by column chromatography 
using neutral alumina as absorbent with ethyl acetate / methanol as eluent to yield 
(E)-4-(3-methyl-6, 7-dihydro-5H-pyrrolo[ 1,2-climidazol-I-yl)-3-buten-2-one 322, as yellow oil 
(0.494 g, 75%) (Found: M+, 190.1106. Cl1HI~ZO requires M, 190.1106); v max / cm- l 2961, 
1661 (C=O), 1422, 1363 and 1254; OH (400 MHz) 2.28 (3 H, s, CH3), 2.88 (3 H, s, Im-CH3), 
2.64-2.69 (2 H, m, 6-CHz), 2.91-2.94 (2 H, t, 17.4, 7-CHz), 3.86-3.89 (2 H, t, 17.1, NCHz), 
6.58-6.62 (I H, d, J 15.8, l'-trans-H) and 7.36-7.40 (l H, d, J 15.8, 2'-trans-H); lie 13.51 
(Im-CH3), 23.32 (6-CHZ), 28.28 (CH3), 29.58 (7-CHZ), 44.28 (NCHz), 123.02 (I'-CH), 127.81 
(q-C), 135.83 (2'-CH), 141.32 (q-C, Im-3-C) and 198.92 (CHO); rn/z 190 (M+, 86%),175 (lOO), 
147 (88), 106 (34) and 77 (59). 
146 
82) 1-(2-Bromobenzyl)-IH-4-imidazolecarbaldehyde (323) 
OHC<~ l? N 
I 
H 
278 
OHCYN l~ 
--------_.  
323 
Imidazole-4(5)-carbaldehyde 278 (0.600 g, 6.24 mmol) was added to sodium hydride (0.225 g, 
9.36 mmol) in THF (300 ml). The mixture was stirred and heated under reflux for 1 h, and 
2-bromobenzyl bromide (5.23 ml, 28.70 mmol) was added. The mixture was stirred and heated 
under reflux for a further 2 h. The salts formed and unreacted imidazole were removed by 
filtration on a celite bed. The solution was evaporated to yield a brown slurry, which was 
purified by column chromatography using neutral alumina as absorbent with light petroleum I 
dichloromethane followed by ethyl acetate as eluent to yield 1-(2-bromobenzyl)-lH-4-
imidazolecarbaldehyde 323, as a yellow oil (0.739 g, 45%); (Found: M+, 263.9898. 
Cl1H9N2BrO requires M, 263.9899); Vrnax I cm-l 2251, 2229, 1688 (C=O), 1539, 1442, 1152, 
1030 and 909; OH 5.26 (2 H, s, NCH2), 7.09-7.12 (1 H, m, Ar-CH), 7.22-7.37 (2 H, m, Ar-CH), 
7.60-7.62 (1 H, m, Ar-CH), 7.64 (1 H, s, Im-2(5)-H), 7.65 (1 H, s, Im-2(5)-H) and 9.85 (1 H, s, 
CHO); oe (62.5 MHz) 51.37 (NCH2), 123.59 (q-C, Ar-CBr), 124.68, 128.27, 129.88, 130.58, 
133.43, 134.00 (q-C), 139.04, 142.39 (q-C, Im-2-C) and 186.04 (CHO); m/z 266 (13%), 264 
(M+, 13%), 263 (6),185 (34), 171 (lOO), 169 (98), 157 (46), 90 (73), 89 (76) and 63 (32). 
83) Attempted radical cyclisation of 1-(2-bromobenzyl)-lH-4-imidazolecarbaldehyde (323) 
323 324 
A solution oftri-n-butyltin hydride (0.57 ml, 2.14 mmol) and AmN (0.117 g, 0.72 mmol) in 
toluene (50 ml) was added to 1-(2-bromobenzyl)-lH -4-imidazolecarbaldehyde 323 (0.377 g, 
1.43 mmol) in toluene (350 ml) at reflux over 5 h. The solution was stirred and heated under 
reflux for a further 1 h. The standard work up procedure for the radical cyclisation of 
imidazoles and benzimidazoles was followed to yield a brown oil, which was purified by prep-
TLC using neutral alumina as absorbent with ethyl acetate I methanol as eluent to yield 
147 
1·(2·bromobenzyl)·IH·4·imidazolecarbaldehyde 324, as a yellow oil (0.136 g, 51%); (Found: 
M+, 186.0793. Cl1HlON2BrO requires M, 186.0793); OH 5.17 (2 H, s, NCH2), 7.19·7.22 (2 H, 
m, Ar·CH), 7.38·7.41 (3 H, m, Ar·CH), 7.61·7.62 (2 H, m, Im·2(5)·H) and 9.88 Cl H, s, CHO); 
oe (62.5 MHz) 51.96 (NCH2), 124.75, 128.09, 129.35, 129.73, 134.92 (q.C), 139.15, 134.00 
(q.C), and 186.04 (CHO);mlz 186 (100%),149 (38), 91 (38) and 65 (59). 
84) Attempted radical cyclisation of 1-[3·(Phenylselanyl)propyl).IH. 5 
.imidazolecarbaldehyde (303) 
N f~ • r(N Jl~ 
OHC N ~sePh 
303 
OHC N ~ 
331 
A solution of tri·n·butyltin hydride (0.18 ml, 0.68 mmol) and AIBN (37 mg, 0.23 mmol) in 
toluene (50 ml) was added to H3·(phenylselanyl)propyl)· 1 H·5·imidazolecarbaldehyde 303 
(0.140 g, 0.45 mmol) in acetonitrile (100 ml) at reflux over 5 h. The solution was stirred and 
heated under reflux for a further 1 h. The standard work up procedure for the radical cyclisation 
of imidazoles and benzimidazoles was followed to yield a tan solid, which was purified by prep· 
TLC using neutral alumina as absorbent with ethyl acetate / methanol as eluent to yield 
l·propyl.1H·5·imidazolecarbaldehyde 331, as a yellow oil (45 mg, 73%); (Found: M+, 
138.0793. C7HlON20 requires M, 138.0793); vrnax / cm·! 1676 (C=O), 1466, 1383, 1347 and 
1214; OH 0.89·096 (3 H, t, CH3), 1.76·1.82 (2 H, m, 2'·CH2), 4.23·4.29 (2 H, t, 17.2, NCH2), 
7.79 (1 H, s, Im·2(4)·H), 7.80 (1 H, s, Im·2(4)·H) and 9.87 (1H, s, CHO) ; mlz 139 (MW, 
100%),121 (30),97 (34) and41 (38). 
85) 5,6,7,8-Tetrahydroimidazo[1,2-a)pyridine-3-carbaldehyde (332) 
f) -----. ;et) 
OHC N OHC47 ~sePh 5 6 
305 332 
A solution of tri·n·butyltin hydride (0.38 ml, 1.44 mmol) andAIBN (79 mg, 0.48 mmol) in 
toluene (50 ml) was added to 1·[4.(phenylselanyl)butyl).IH.5·imidazolecarbaldehyde 305 
(0.295 g, 0.96 mmol) in acetonitrile (150 ml) at reflux over 5 h. The solution was stirred and 
heated under reflux for a further 1 h. The standard work up procedure for the radical cyclisation 
of imidazoles and benzimidazoles was followed to yield a tan solid, which was purified by 
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column chromatography using neutral alumina as absorbent with ethyl acetate I methanol as 
eluent to yield 5,6,7,8-tetrahydroimidazo[l,2-a]pyridine-3-carbaldehyde 332, as yellow oil 
(76 mg, 53%) (Found: M+, 150.0793. CSHloN20 requires M, 150.0793); vrnax I cm-l 1686 
(C=O), 1637, 1489, 1406, 1364, 1265; OH 1.92-2.03 (4 H, m, 6 and 7-CH2), 2.95-3.00 (2 H, t, 
J 6.2, CCH2), 4.31-4.35 (2 H, t, J 5.7, NCH2), 7.75 (1 H, s, Im-2-H) and 9.66 (1H, s, CHO); oc 
20.04 (7-CH2), 22.76 (6-CH2), 25.20 (CCH2), 46.08 (NCH2), 142.62 (lm-2-H) and 179.11 
(CHO); mlz 150 (M+, 100), 149 (60),135 (16), 122 (25) and 84 (62) 
86) 1-(Triphenylmethyl)-IH-2-imidazolecarbaldehyde (335) 107 
N (~ 
N 
I 
CPh 3 
217 
• 
N 
( }-CHO 
N 
I 
CPh 3 
335 
1-(Trityl)imidazole 217 (10.0 g, 32.2 mmol) was dissolved in THF (200 ml) and a solution of 
n-butyllithium (14 ml, 35.2 mmol) added dropwise to the stirred solution at -78°C. The solution 
which gradually turned red was stirred at 0 °C for a further 20 min and DMF (5.4 ml, 
64.4 mmol) added dropwise. The solution was stirred overnight at ambient temperature and 
evaporated to dryness. Saturated ammonium chloride (50 m!) and water (100 ml) was added to 
the residue. The aqueous mixture was extracted with dichloromethane (3 x 50 ml) and the 
organic extracts were washed with brine (2 x 100 m!). The organic extracts were evaporated to 
dryness to yield yellow crystals, which were recrystallised with ethyl acetate to give pale yellow 
needles of the 1-(triphenylmethyl)-IH-2-imidazolecarbaldehyde 335 (8.0 g, 74%), mp 184°C 
(lit. 107, mp 189-190 0C); (Found: C, 81.9; H, 5.1; N, 8.3. C23HISN20 requires C, 81.7; H, 5.3; 
N,8.3%). 
87) Imidazole-1H-2-carbaldehyde (181)135 
N 
( }-CHO 
N 
I 
CPh 3 
335 
N 
( }-CHO 
N 
I 
H 
181 
The general procedure for the removal of the protective trityl group was followed. 
1-(Trityl)-IH -2-imidazolecarbaldehyde 335 (8.00 g, 23.6 mmol) gave a cream coloured 
precipitate ofimidazole-lH-2-carbaldehyde 181 (0.58 g, 26%), mp 208-212 °C (lit. 135, mp 204-
205°C); vrnax I cm- i 1692 (C=O), 1424, 1411, 1342 and 1136; OH ([2H6J Me2S0)7.44 (2 H, bs, 
Im-4(5)-H) and 9.66 (1 H, s, CHO). 
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88) Attempted alkylation of imidazole-lH -2-carbaldehyde (181) 
(}-CHO 
N x 
I 
H 
181 
• ()-CHO 
N 
~sePh 
338 
Imidazole-1H-2-carbaldehyde 181 (0.500 g, 20.3 rnmol) was added to sodium hydride (0.732 g, 
30.5 mmol) in THF (300 ml). The mixture was stirred and heated under reflux for 1 hand 
3-iodol-(3-phenylselanyl)propane 233 (9.914 g, 30.4 mmol) was added. The mixture was 
stirred and heated under reflux for a further 2 h. The salts formed were removed by filtration on 
a celite bed and the solution was evaporated to dryness to yield an intractable mixture of 
unidentifiable products. 
89) 1-[3-(Phenylselanyl)propyIJimidazole (339) 
() 
N 
I 
H 
204 
() 
N 
~sePh 
339 
Imidazole 204 (0.500 g, 7.34 mmol) was added to sodium hydride (0.260 g, 11.02 mmol) in 
THF (300 ml). The mixture was stirred and heated under reflux for 1 hand 3-iodo-l-(3-
phenylselanyl)propane 233 (2.390 g, 7.34 mmol) was added. The mixture was stirred and heated 
under reflux for a further 2 h. The salts formed were removed by filtration on a celite bed and 
the solution was evaporated to dryness to yield a tan solid. The crude product was purified by 
column chromatography using silica gel as absorbent with light petroleum / dichloromethane 
followed by ethyl acetate / methanol as eluent to yield 1-[3-(phenylselanyl)propylJimidazole 
339, as a yellow oil (0.787 g, 41 %), (Found: M+, 266.0328. C12H!<tN2Se requires M, 
266.0322); vmax / cm-! 3424,2089,1644,1579, 1509,1478,1438,1229 and 1080; oH 2.04-2.13 
(2 H, m, 2'-CH2), 2.76-2.82 (2 H, t, J 6.9, CH2SePh), 4.02-4.08 (2 H, t, J 6.8, NCH2), 6.86 (1 H, 
s, Im-5-H), 7.06 (1 H, s, Im-4-H), 7.25-7.29 (3 H, m, Ph-H), 7.44-7.48 (2 H, m, Ph-H) and 7.49 
(l H, s, Im-2-H); Oc (62.5 MHz) 23.93 (2'-CH2), 30.90 (CH2SePh), 45.97 (NCH2), 127.34 
(Ar-CH), 129.21 (Ar-CH), 129.47 (Ar-CH) and 133.06 (Ar-CH); mlz 266 (M+, 89%),185 (26). 
157 (28),109 (72) and 81 (100). 
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90) 1,3-Di[3-(phenylselanyl)propyll-lH-imidazol-3-ium iodide (340) 
• 
~sePh 
tt<±l () r 
N 
~sePh 
340 
Imidazole 204 (0.716 g, 10.52 mmol) was added to sodium hydride (0.379 g, 15.78 mmol) in 
THF (300 ml). The mixture was stirred and heated under reflux for 1 hand 3-iodo-l-(3-
phenylselanyl)-propane 233 (6.853 g, 21.03 mmol) was added. The mixture was stirred and 
heated under reflux for a further 2 h. The salts formed were removed by filtration on a celite bed 
and the solution was evaporated to dryness to yield a tan residue, which was purified by column 
chromatography using neutral alumina as absorbent with light petroleum I dichloromethane 
followed by ethyl acetate I methanol as eluent to yield 1,3-di[3-(phenylselanyl)propyl)-lH-
imidazol-3-ium iodide 340, as a yellow oil (0.973 g, 20%); Vrnax I cm-! 3071, 1578, 1561, 1478, 
1437, 1166 and 918; OH 2.27-2.32 (4 H, m, 2'-CH2), 2.89-2.95 (4 H, t, J 6.8, CH2SePh), 4.43-
4.49 (4 H, t, J7.0, NCH2), 6.89 (I H, s, Im-4(5)-H), 7.10 (I H, s, Im-4(5)-H), 7.25-7.29 (6 H, m, 
Ph-H), 7.47-7.50 (4 H, m, Ph-H) and 10.08 (1 H, s, Im-2-H) ; Oe 23.98 (2'-CH2), 30.50 
(CH2SePh), 49.87 (NCH2), 122.67, 127.97, 129.17 (q-C), 129.72, 129.87 and 137.27. 
91) Attempted preparation of 1-[3-(Phenylselanyl)propyll-1H-2-imidazolecarbaldehyde 
(338) (from 1-[3-(phenylselanyl)propyllimidazole 339) 
() X 
N 
~sePh 
339 
· (}-CHO 
N 
~sePh 
338 
1-[3-(Phenylselanyl)propyllimidazole 339 (0.309 g, 1.16 mmol) was dissolved in THF (lOO ml) 
and a solution of n-butyllithium (0.70 ml, 1.76 mmol) added dropwise to the stirred solution at 
-78°C. The solution was stirred at 0 °C for a further 40 min and DMF (0.23 ml, 3.48 mmol) 
added dropwise. The solution was stirred overnight at ambient temperature and evaporated to 
dryness. Saturated ammonium chloride (50 ml) and water (100 ml) was added to the residue. 
The aqueous mixture was extracted with dichloromethane (3 x 50 ml) and the organic extracts 
washed with brine (2 x 50 ml). The organic extracts were evaporated to dryness, but only the 
starting 1-[3-(phenylselanyl)propyllimidazole 339 was recovered. 
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92) 2-(Diethoxymethyl)imidazole (181) 
(}-CHO 
N 
I 
H 
181 
• ( }-CH(OEt)2 
N 
I 
H 
341 
Imidazole-1H-2-carbaldehyde 181 (0.80 g, 3.7 mmol) was dissolved in dry ethanol (150 ml), and 
concentrated sulfuric acid (0.5 ml, H2S04 >96%) added. The solution was stirred and heated 
under reflux for 4 h. The solution was cooled and neutralised with solid sodium carbonate and 
filtered. The filtrate was evaporated to dryness and the crude product purified by column 
chromatography using neutral alumina as absorbent with ethyl acetate as the eluent to yield 
white needles of2-(diethoxymethyl)imidazole 341 (1.22 g, 86%); mp 114-116 °C (\it.!37, mp 
lIS-116°C); OH 1.22-1.28 (6 H, t, 17.5, CH3), 3.58-3.73 (4 H, m, CH2), 5.61 (1 H, s, 
CH(OEth) and 7.05 (2 H, brs, Im-H); Oc 15.10 (CH3), 62.00 (CH2), 96.71 (CH(OEth), 115.22 
(Im-CH), 128.94 (lm-CH) and 145.80 (2-C). 
93) 2-Diethoxymethyl-l-[3-(phenylselanyl)propylj-lH -imidazole (342) 
()-CH(OEt)2 
N 
I 
H 
341 
()-CH(OEt)2 
N 
~sePh 
342 
2-(Diethoxymethyl)imidazole 341 (0.781 g, 2.1 mmol) was added to sodium hydride (78 mg, 
3.2 mmol) in THF (200 ml). The mixture was stirred and heated under reflux for 1 hand 
3-iodo-l-(3-phenylselanyl)-propane 233 (0.711 g, 2.1 mmol) was added. The mixture was 
stirred and heated under reflux for a further 2 h. The salts formed were removed by filtration on 
a celite bed and the solution was evaporated to dryness to yield a tan solid. The crude product 
was purified by column chromatography using neutral a1umina as absorbent with 
dichloromethane I light petroleum followed by ethyl acetate as eluent to give 
2-diethoxymethyl-J-[3-(phenylselanyl)propylJ-JH-imidazole 342, as a colourless oil (0.498 g, 
64%), (Found: M+, 368.1003. C17H2<tN202Se requires M, 368.1002); vrnax I cm-! 2978,2246, 
1579, 1498, 1478, 1438, 1105, 1060,910 and 732; OH 1.17-1.23 (6 H, t, J7.0, CH3), 2.11-2.23 
(2 H, m, 2'-CH2), 2.85-2.90 (2 H, t, J 7.3, CH2SePh), 3.46-3.58 (2 H, m, diastereotopic-
CH2CH3), 3.68-3.77 (2 H, m, diastereotopic-CH2CH3), 4.23-4.29 (2 H, t, 17.0, NCH2), 5.57 
[1 H, s, CH(OEthj, 6.68 (1 H, s, Im-H), 6.97 (1 H, s, Im-H), 7.26-7.28 (3 H, m, Ph-H) and 7.47-
7.51 (2 H, m, Ph-H); Oc 15.39 (CH3), 24.65 (2'-CH2), 31.64 (CH2SePh), 46.12 (NCH2), 63.55 
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(CH2CH3), 99.29 (CH(OEth), 121.22, 127.45, 127.63, 129.49, 129.90 (q-C), 133.28 (Ph-CH) 
and 145.10 (q-C); mJz 368 (M+, 7%), 295 (21),199 (60),157 (68),137 (54),121 (100), 109 
(59),77 (71),47 (70) and 41 (61). 
94) 1·[3·(Phenylselanyl)propyll·lH·2·imidazolecarbaldehyde (338) 
()-CH(OEtb 
N 
~sePh 
342 
• (~CHO 
N 
~sePh 
338 
2-(Diethoxymethyl)-I-[3-(phenylselanyl)propyll-lH-imidazole 342 (0.444 g, 1.21 mmol) was 
dissolved in ethanol (300 ml), concentrated hydrochloric acid (5 rnl, 31-34% w/w solution) and 
water (100 ml) added. The solution was heated under reflux for 2 h. The solution was cooled, 
and neutralised with solid sodium carbonate and filtered. The filtrate was evaporated to leave 
approximately 100 ml of solution, which was extracted with dichlorornethane (2 x 50 ml). The 
combined organic extracts dried (MgS04), and evaporated to dryness to yield 
1-[3-(phenylselanyl)propyl]-lH-2-imidazolecarbaldehyde 338, as a yellow oil (0.207 g, 58%), 
(Found: M+, 294.0271. C13H !<tN20Se requires M, 294.0271); v max I cm-! 2936, 1684 (C=O), 
1475,1437,1335, 1157,771 and 737; oH 2.03-2.11 (2 H, rn, 2'-CH2), 2.72-2.77 (2 H, t, 17.1, 
CH2SePh), 4.37-4.43 (2 H, t, J 6.9, NCH2), 7.05 (1 H, s, Im-H), 7.17-7.19 (4 H, rn, Im-H and 
Ph-H) and 7.37-7.41 (2 H, m, Ph-H) ; Oc (62.5 MHz) 23.73 (2'-CH2), 30.80 (CH2SePh), 47.01 
(NCH2), 126.47, 127.19, 129.13, 131.50, 132.93, 137.08 (q-C) 143.14 (q-C) and 181.75 (CHO); 
mJz 294 (M+, 16%),265 (5),157 (29), 137 (100),109 (39) and 77 (66). 
95) Attempted radical cycIisation of 1·[3·(phenylselanyl)propyll·lH. 
2·imidazolecarbaldehyde (338) 
(~CHO 
N 
~sePh 
• (} 
~sePh 
338 339 
A solution of tri-n-butyltin hydride (0.23 ml, 0.87 rnmol) and AIBN (47 rng, 0.29 mrnol) in 
toluene (50 ml) was added to 1-[3-(phenylselanyl)propyll-lH-2-irnidazolecarbaldehyde 338 
(0.170 g, 0.58 mrnol) in acetonitrile (lOO ml) at reflux over 5 h. The solution was stirred and 
heated under reflux for a further 1 h. The standard work up procedure for the radical cyclisation 
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of imidazoles and benzimidazoles was followed to yield a tan solid, which was purified by prep-
TLC using neutral alumina as absorbent with ethyl acetate as eluent to yield 
1-[3-(phenylselanyl)propyIJimidazole 339, as a yellow oil (34 mg, 22%). Spectra identical with 
that previously recorded. 
96) 1-(3-Bromopropyl)-4-phenyl-1H-imidazole (344) 
_____ . Phl~ 
N 
~Br 
344 
4-Phenyl-IH -imidazole 343 (1.500 g, 10.40 mmol) was added to sodium hydride (0.374 g, 15.6 
mmol) in THF (300 ml). The mixture was stirred and heated under reflux for 1 h and 
1,3-dibromopropane (10.6 m1, 0.104 mol) was added. The mixture was stirred and heated 
under reflux for a further 2 h. The salts formed and unreacted imidazole were removed by 
filtration on a celite bed. The solution was evaporated to yield a crude oil, which 
was purified by column chromatography using neutral alumina with light petroleum I 
dichloromethane followed by ethyl acetate as eluent to yield 1-(3-bromopropyl)-4-phenyl-1H-
imidazole 344, as a colourless oil (1.350 g, 49%); (Found: M+, 264.0262. Cl2H 13N 2Br requires 
M,264.0263); vmax I cm-1 1605, 1482, 1368, 1280, 1195, 1067, 1046 and 941; BH 2.26.2.37 
(2 H, m, 2'-CH2), 3.33-3.38 (2 H, t, J 6.1, CH2Br), 4.14-4.20 (2 H, t, J 6.5, NCH2), 7.22 (1 H, s, 
Im-5-H), 7.23-7.27 (I H, m, Ph-H), 7.35-7.41 (2 H, m, Ph-H), 7.56 (lH, s, Im-2-H) and 7.76-
7.79 (2 H, m, Ph-H); Bc (62.5 MHz) 29.36 (2'-CH2), 33.28 (CH2Br), 44.67 (NCH2), 114.47, 
124.70, 126.70, 126.83, 128.55 and 137.44; m/z 266 (22%), 264 (M+, 23), 184 (10), 158 (32), 
157 (50), 143 (33), 130 (97), 103 (93), 102 (70),89 (100), 77 (35),51 (45) and 41 (100). 
97) 1-(4-Bromobutyl)-4-phenyl-1H-imidazole (345) 
• 
345 
4-Phenyl-1H-imidazole 343 (1.838 g, 12.74 mmol) was added to sodium hydride (0.459 g, 
19.11 mmol) in THF (300 m1). The mixture was stirred and heated under reflux for 1 h, and 
1,4-dibromobutane (15.2 ml, 0.127 mol) was added. The mixture was stirred and heated under 
reflux for a further 2 h. The salts formed and unreacted imidazole were removed by filtration on 
a celite bed. The solution was evaporated to yield a crude slurry, which was purified by column 
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chromatography using neutral alumina as absorbent with light petroleum I dichloromethane 
followed by ethyl acetate as eluent to yield 1-(4-bromobutyl)-4-phenyl-lH-imidazole 345, as a 
colourless oil (1.417 g, 40%); (Found: M+, 278.0419. C13H 15N2Br requires M, 278.0419); 
Vmax I cm-1 1606,1554, 1501, 1483, 1444, 1195 and 1068; OH 1.81-1.88 (2 H, m, 2' (3')-CH2), 
1.94-2.01 (2 H, m, 2' (3')-CH2), 3.36-3.41 (2 H, t, J 6.2, CH2Br), 3.93-3.99 (2 H, t, J 6.7, 
NCH2), 7.19-7.21 (1 H, m, Im-5-H), 7.24-7.28 (1 H, m, Ph-H), 7.34-7.41 (2 H, m, Ph-H), 7.48-
7.49 (lH, m, Im-2-H) and 7.75-7.79 (2 H, m, Ph-H); CC 28.97, 29.92, 32.92 (CH2Br), 48.68 
(NCH2), 116.81, 127.02, 129.13, 130.93, 131.58, 131.90, 136.37 (q-C), 139.55 and 144.69 
(q-C); m/z 280 (47%), 278 (M+, 42), 199 (100), 145 (39), 133 (33), 89 (88), 77 (31) and 55 (78). 
98) 1-(4-Bromobutyl)-4-nitro-IH-imidazole (346) 
O:!N:("~ (» 
N 
I 
H 
343 
___ I O:!{) 
N 
~Br 
346 
4 (5)-Nitro-lH-imidazole 171 (1.622 g, 14.3 mmol) was added to sodium hydride (0.528 g, 22.0 
mmol) in THF (300 rnl). The mixture was stirred and heated under reflux for 1 hand 
1,4-dibromobutane (17.0 rnl, 0.143 mmol) was added. The mixture was stirred and heated under 
reflux for a further 2 h. The salts formed and unreacted imidazole were removed by filtration on 
a celite bed. The solution was evaporated to yield a crude slurry, which was purified by column 
chromatography using silica gel as absorbent with light petroleum I dichloromethane followed 
by ethyl acetate as eluent to yield brown needles of 1-(4-bromobutyl)-4-nitro-lH-midazole 346 
(1.55 g, 44%), mp 34-35 °C (Found: M+, 246. 9957. C7HloN2Br02 requires M, 246.9957); 
Vrnax I cm-1 2949, 1638, 1544 (N02), 1490, 1403, 1383 and 1335; OH 1.87-1.95 (2 H, m, 
3'-CH2), 2.00-2.09 (2 H, m, 2'-CH2), 3.41-3.46 (2 H, t, J 6.1, CH2Br), 4.06-4.12 (2 H, t, 17.0, 
NCHv, 7.45-7.46 (1 H, d, J 1.6, Im-2-H) and 7.79-7.80 (lH, d, J 1.6, Im-5-H); Cc 29.54, 29.68, 
32.48 (CH2Br), 47.99 (NCH2), 119.49 (2-CH), 136.32 (5-CH) and 148.64 (q-C, 4-C); m/z 248 
(M+, 9%),168 (100), 137 (14),135 (13),122 (36) and 55 (91). 
99) I-Phenyl-6, 7-dihydro-5H-pyrrolo[l,2-c ]imidazole (347) 
• 
344 
155 
PhZSN2 
"I -,3 
7 N4 
5 
6 
347 
+ 
348 
A solution oftri-n-butyltin hydride (0.66 ml, 2.50 mmol) and AIBN (0.137 g, 0.84 mmol) in 
toluene (50 ml) was added to 1-(3-bromopropyl)-4-phenyl-1H-imidazole 344 (0.440 g, 
1.67 mmol) in toluene (350 rnl) at reflux over 5 h. The solution was stirred and heated under 
reflux for a further 1 h. The standard work up procedure for the radical cyclisation of imidazoles 
and benzirnidazoles was followed to yield a mixture of I-phenyl-6,7-dihydro-5H-pyrrolo 
[1,2-c]imidazole 347 and I-propyl-4-phenylimidazole 348, as a tan solid (0.169 g, 1.0/1.1 
respectively by lH NMR spectroscopic analysis ofrelative peak areas); 347: OH 2.71-2.79 (2 H, 
m, 6-CH2), 3.06-3.12 (2 H, t, 17.2, CCH2), 4.05-4.10 (2 H, t, 17.2, NCH2), 7.18-7.21 (1 H, m, 
Ph-H), 7.36-7.42 (2 H, m, Ph-H), 7.62 (lH, rn, Im-3-H) and 7.73-7.76 (2 H, m, Ph-H); 348: OH 
0.95-1.01 (3 H, t, 17.4, CH3), 1.83-1.91 (2 H, rn, 2'-CH2), 3.92-3.97 (2 H, t, 17.0, NCH2), 7.21 
OH, s, Im-5-H), 7.25-7.27 (I H, m, Ph-H), 7.35-7.41 (2 H, m, Ph-H), 7.60 (lH, s, Im-2-H) and 
7.77-7.80 (2 H, m, Ph-H). 
100) Radical CycIisation of 1-(4-bromobutyl)-4-phenyl-lH-imidazole (345) 
• 
Pt~8 
+ 3 4~V7 
5 6 
345 350 
A solution of tri-n-butyltin hydride (0.76 ml, 2.85 mmo!) and AIBN (0.156 g, 0.95 mmol) in 
toluene (50 m!) was added to 1-(4-bromobutyl)-4-phenyl-IH-imidazole 345 (0.530 g, 
1.90 mmol) in toluene (350 ml) at reflux over 5 h. The solution was stirred and heated 
under reflux for a further 1 h. The standard work up procedure for the radical cyclisation of 
imidazoles and benzimidazoles was followed to yield a yellow oil mixture of I-phenyl-5,6, 7,8-
tetrahydroimidazo[ 1,5-aJpyridine 349 and 2-phenyl-5,6, 7,8-tetrahydroimidazo[ 1 ,2-aJpyridine 
350 (0.185 g, 2.5 /1.0 respectively by GC-MS analysis); 349: OH 1.92-2.01 (4 H, m, 6 and 7-
CH2), 2.98-3.03 (2 H, t, J 6.4, CCH2), 4.01-4.06 (2 H, t, J 5.6, NCH2), 7.24-7.76 (5 H, m, Ph-H) 
and 7.48 (I H, s, Im-3-H); mlz 198 (M+, 74%),197 (100),170 (34),169 (58),157 (22),115 (31), 
103 (24) and 77 (22); 350: IiH 1.87-1.90 (4 H, m, 6 and 7-CH2), 2.93-2.98 (2 H, t, J 5.7, CCH2), 
3.95-4.01 (2 H, t, J 6.1, NCH2), 7.06 (I H, s, Im-3-H) and 7.24-7.76 (5 H, rn, Ph-H); mlz 198 
(M+, 100%), 197 (39),170 (20),169 (20),130 (24),104 (26) and 77 (27); (Found: M+, 
198.1157. C13H 1~2 requires M, 198.1157). 
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101) Attempted radical cyclisation of 1-(4-Bromobutyl)-4-nitro-1H-imidazole (346) 
A solution of tri-n-butyltin hydride (0.45 ml, 1.68 mmol) and AIBN (92 mg, 0.56 mmol) in 
toluene (50 ml) was added to 1-(4-bromobutyl)-4-nitro-lH-imidazole 346 (0.259 g, 1.12 
mmol) in toluene (250 ml) at reflux over 5 h. The solution was stirred and heated under reflux 
for a further 1 h. The reaction solution was cooled to ambient temperature and the solvent was 
evaporated to dryness to yield a tan residue. Ethyl acetate (50 ml) and saturated potassium 
fluoride solution (50 ml) were added and the mixture agitated vigorously for 2 h. The organic 
phase was extracted, dried (MgS04), and evaporated to dryness to yield a yellow residue, which 
was purified by column chromatography using silica gel as absorbent with light petroleum 
followed by ethyl acetate as eluent, but only unidentifiable products were isolated. 
102) l-(Phenylsulfonyl)-lH-pyrrole (352) 
Q • 
I 
H 
351 
Pyrrole 351 (9.02 ml, 0.13 mol) and sodium hydride (4.68 g, 0.195 mol) in THF (450 ml) were 
stirred, and heated under reflux 3.5 h. Benzenesulfonyl chloride (34.24 ml, 0.27 mol) was added 
dropwise, and the mixture heated under reflux for a further 2 h. The residual salts were removed 
by filtration on a celite bed, and the solution was evaporated to dryness to yield a black residue, 
which was purified by column chromatography using silica gel as absorbent with light petroleum 
I dichloromethane as eluent to yield 1-(phenylsulphonyl)-1 H-pyrrole 352, as colourless needles 
(18.43 g, 66%), mp 88-90 °C (1it. 141, mp 89-89.5 0C); OH 6.30-6.32 (2 H, m, pyrrole-H), 7.16-
7.18 (2 H, m, pyrrole-H), 7.48-7.61 (3 H, m, Ph-H) and 7.84-7.88 (2 H, m, Ph-H) .. 
103) t-(lH-3-Pyrrolyl)-t-ethanone [3-acetylpyrrole, 353] 
COCH3 
OCOCH3 Q • 0 • I I S02Ph S02 Ph I H 
352 354 353 
Acetic anhydride (7 ml) was added a to a suspension of anhydrous aluminium chloride (20.00 g, 
0.150 mol) in 1,2-dichloroethane (50 ml). The mixture was stirred at ambient temperature for 10 
min and a solution of I-(phenylsulfonyl)-IH-pyrrole 352 (4.91 g, 22.2 mmol) in 
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1,2-dichloroethane (50 ml) added. The reaction mixture was stirred for 2 h, quenched with water 
(50 ml) and extracted with dichloromethane (2 x 50 ml). The combined organic extracts were 
evaporated to dryness to yield red-brown crystals of 1-[I-(phenylsulfonyl)-1 H-3-pyrrolylj-l-
ethanone 354 (4.52 g, 17.2 mmol), which were added to dioxane (75 ml). Sodium hydroxide 
solution (75 ml, 5 M) was added, and the solution stirred for 36 h. The hydroxide solution was 
extracted with ethyl acetate (3 x 50 ml), and the combined organic extracts dried (MgS04) and 
evaporated to dryness to yield brown crystals of 3-acetylpyrrole (1.99 g, 82%), mp 106-107 °C 
(lit. 141, mp 105-107 0C); OH 2.36 (3 H, s, CH3), 6.59-6.60 (1 H, m, pyrrole-5-H), 6.70-6.73 (1 H, 
m, pyrrole-4-H) and 7.35-7.37 (1 H, m, pyrrole-2-H); Bc 28.99 (CH3), 110.67 (pyrrole-5-CH), 
121.25 (pyrrole-4-CH), 125.20 (pyrrole-2-CH), 128.08 (pyrrole-3-C) and 195.82 (CO). 
General Procedure for the alkylation ofpyrroles 
104) 1-[1-(3-Bromopropyl).IH ·3-pyrrolylj·l·ethanone (356) 
COCH3 Q 
I 
H 
riCOCH3 () 
B~ 
353 356 
3-Acetylpyrrole 353 (0.310 g, 2.84 mmol) was added to sodium hydride (0.136 mg, 5.68 mmol) 
in THF (150 ml). The mixture was stirred for 30 min at ambient temperature and 
1,3-dibromopropane (2.89 ml, 28.40 mol) was added. The mixture was stirred and refluxed for 
2 h. The residual salts formed were removed by filtration on a celite bed and the solution was 
evaporated to dryness to yield a brown slurry, which was purified by column chromatography 
using silica gel as absorbent with light petroleum I dichloromethane as eluent to yield 
1-[1-(3-bromopropyl)-lH-3-pyrrolyl}-1-ethanone 356 , as a yellow oil (0.332 g, 51 %); (Found: 
M+, 229.0103. C9H !2NBrO requires M, 229.0103); Urn.x I cm-! 1652 (C=O), 1530 and 1255; OH 
2.23-2.33 (2 H, m, 2'-CH2), 2.40 (3 H, s, CH3), 3.29-3.34 (2 H, t, J 6.1, CH2Br), 4.08-4.13 (2 H, 
t, J 6.4, CH2N), 6.58-6.60 (1 H, m, pyrrole-4,5-H), 6.64-6.66 (1 H, m, pyrrole-2-H) and 7.29-
7.31(1 H, m, pyrrole-H); oc 27.45 (CH3), 29.93 (2'-CH2), 33.99 (CH2Br), 48.00 (NCH2), 110.11 
(pyrrole-CH), 122.73 (pyrrole-CH), 126.13 (pyrrole-CH), 126.77 (pyrrole-3-C) and 193.75 
(CO); m/z 232 (MH2+, 96%), 217 (100),150 (97),135 (98),121 (19), 106 (54), 94 (72) and 80 
(21). 
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105) 1-[1-( 4-Brornobutyl)-IH -3-pyrrolyll-l-ethanone (357) 
riCOCH3 
() -----. 
I 
H 
353 357 
The general procedure for the alkylation of pyrroles was followed. 
3-Acetylpyrrole 353 (0.620 g, 5.69 mmol), sodium hydride (0.273 mg, 11.38 mmol) and 
1,4-dibromobutane (6.75 ml, 56.90 mol) in THF (150 ml) gave a tan residue, which was purified 
by column chromatography using silica gel as absorbent with light petroleum I dichloromethane 
as eluent to yield 1-[l-(4-bromobutyl)-lH-3-pyrrolyl]-1-ethanone 357, as a yellow oil (0.744 g, 
56%); (Found: M+, 243.0246. ClOH!4NBrO requires M, 243.0259); Vrnax I cm-! 1654 (C=O), 
1530,1201 and 933; oH 1.81-1.86 (2 H, rn, 3'-CH2), 1.94-2.00 (2 H, m, 2'-CH2), 2.39 (3 H, s, 
CH3), 3.37-3.42 (2 H, t, J 6.6, CH2Br), 3_90-3.96 (2 H, t, J 6.7, CH2N), 6.58-6.62 (2 H, m, 
pyrrole-4,5-H) and 7.26-7.27 (I H, m, pyrrole-2-H); Oc (62.5 MHz) 28.98 (CH3), 29.41 (3'-
CH2),29.54 (2'-CH2), 32.54 (CH2Br), 49.19 (NCH2), 109.51 (pyrrole-CH), 121.98 (pyrrole-
CH) and 125.44 (pyrrole-CH); m/z 245 (MH2+, 39%), 228 (88), 164 (100), 135 (25), 122 (57), 
109 (14), 94 (75) and 80 (23). 
106) 1-[I-(5-Bromopentyl)-IH -3-pyrrolyll-l-ethanone (358) 
riCOCH3 () ---.-. 
I 
H 
353 358 
The general procedure for the alkylation of pyrroles was followed. 
3-Acetylpyrrole 353 (0.500 g, 4.59 mmol), sodium hydride (0.220 mg, 9.17 mmol) and 
1,5-dibromopentane (6.25 ml, 45.90 mol) in THF (150 ml) gave a tan residue, which was 
purified by column chromatography using silica gel as absorbent with light petroleum I 
dichloromethane as eluent to yield 1-[l-(5-bromopentyl)-lH-3-pyrrolyl]-1-ethanone 358, as a 
yellow oil (0.743 g, 63%); Vrnax I cm-! 1652 (C=O), 1531, 1453,1386, 1251, 1103 and 933; OH 
1.45-1.50 (2 H, m, 3'-CH2), 1.79-1.91 (4 H, m, 2' and 4'-CH2), 2.39 (3 H, s, CH 3), 3.37-3.42 (2 
H, t, J 6.6, CH2Br), 3.88-3.93 (2 H, t, 17.0, CH2N), 6.57-6.62 (2 H, m, pyrrole-4,5-H) and 7.26-
7.28 (I H, m, pyrrole-2-H); Oc (62.5 MHz) 25.09, 26.98 (CH3), 30.25, 32.01 (2'-CH2)' 33.10 
(CH2Br), 49.81 (NCH2), 109.31 (pyrrole-CH), 122.02 (pyrrole-CH), 125.48 (pyrrole-CH) and 
193.35 (CO). 
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107) 1-(3-Bromopropyl)-lH -2-pyrrolecarbaldebyde (359) 
n 
"'rCHO I 
H 
177 
• 
n ~NP-CHO 
B~ 
359 
The general procedure for the alkylation of pyrroles was followed. 
Pyrrole-2-carbaldehyde 177 (1.50 g, 15.8 mmol), sodium hydride (0.76 g, 31.7 mmol) and 
1,3-dibromopropane (16.0 ml, 0.16 mol) in THF (150 ml) gave a brown slurry, which was 
purified by column chromatography using silica gel as absorbent with light petroleum I 
dichloromethane as eluent to yieldl-(3-bromopropyl)-IH-2-pyrrolecarbaldehyde 359, as a 
yellow oil (2.43 g, 71 %), (Found: M+, 214.9946. CgHIONBrO requires M, 214.9946); Vrnax I 
cm-I 2805, 1526, 1661 (C=O), 1369 and 885; OH 2.19-2.29 (2 H, m, 2'-CH2), 3.20-3.25 (2 H, t J 
6.2, CH2Br), 4.37-4.42 (2 H, t, J 6.4, NCH2), 6.15-6.18 (1 H, m, pyrrole-4-H), 6.68-6.90 (1 H, 
m, pyrrole-5-H), 6.97 (1 H, m, pyrrole-3-H) and 9.45 (1 H, s, CHO); Oc 30.57 (2'-CH2), 33.78, 
(CH2Br), 47.45 (NCH2), 110.09 (pyrrole-5-CH), 125.66 (pyrrole-4-CH), 131.56 (pyrrole-3-CH), 
132.38 (pyrrole-2-C) and 179.63 (CHO); mlz 215 (M+, 18%), 186 (11), 136 (100), 108(92),94 
(89) and 80 (100). 
108) 1-(4-Bromobutyl)-lH-2-pyrrolecarbaldebyde (360) 
n 
"'rCHO I 
H 
177 
n ~NP-CHO 
Br~ 
360 
The general procedure for the alkylation of pyrroles was followed. 
Pyrrole-2-carbaldehyde 177 (1.65 g, 17.3 mmol), sodium hydride (0.83 g, 34.6 mmol) and 
1,4-dibromobutane (19.1 ml, 0.16 mol) in THF (150 ml) gave a tan residue, which was purified 
by column chromatography using silica gel as absorbent with light petroleum I dichloromethane 
as eluent to yield 1-(4-bromobutyl)-lH-2-pyrrolecarbaldehyde 360, as a yellow oil (2.46 g, 
62%); (Found: M+, 228.9991. CgH!2NBrO requires M, 229.0103); vrnax I cm-! 2800, 1603 
(C=O), 1525, 1444, and 609; OH 1.85-1.92 (4 H, m, 2' and 3'-CH2), 3.37-3.42 (2 H, t, J 6.2, 
CH2Br), 4.33-4.38 (2 H, t, J 6.6, CH2N), 6.22-6.25 (1 H, m, pyrrole-4-H), 6.93-6.95 (2 H, m, 
pyrrole-3 and 5-H) and 9.53 (1 H, s, CHO); Oc 29.33 (3'-CH2), 29.37 (2'-CH2), 32.58 (CH2Br), 
47.82 (NCH2), 109.52 (pyrrole-5-CH), 124.71 (pyrrole-4-CH), 13087 (pyrrole-3-CH), 131.08 
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(q-C, pyrrole-2-C) and 179.06 (CHO); m/z 229 (M+, 73%), 202 (27),150 (92),122 (100),108 
(66), 94 (56) and 80 (85). 
109) 1-(5-Bromopentyl)-IH-2-pyrrolecarbaldehyde (361) 
Ill. 
"rCHO I 
• 
n 
I(.N>-CHO 
H B~ 
177 361 
The general procedure for the alkylation of pyrroles was followed. 
Pyrrole-2-carbaldehyde 177 (1.67 g, 17.6 mmol), sodium hydride (0.84 g, 35.2 mmol) and 
1,5-dibromopentane (21.5 ml, 0.16 mol) in THF (150 ml) gave a tan residue, which was purified 
by column chromatography using silica gel as absorbent with light petroleum! dichloromethane 
as eluent to yield 1-(5-bromopentyl)-lH-2-pyrrolecarbaldehyde 361, as a yellow oil (2.11 g, 
45%);vrnax !cm-) 2805, 1660 (C=O), 1572, 1321,885,838 and 763; OH 1.38-1.48 (2 H, m, 3'-
CH2), 1.72-1.93 (4 H, m, 2' and 4'-CH2), 3.36-3.42 (2 H, t, J 6.7, CH2Br), 4.28-4.43 (2 H, t, 
J7.2, NCH2), 6.21-6.23 (1 H, m, pyrrole-4-H), 6.92-6.94 (2 H, m, pyrrole-3 and 5-H) and 9.52 
(l H, s, CHO); Oc 24.25 (3'-CH2), 30.49 (4'-CH2), 32.13 (2'-CH2), 33.52 (CH2Br), 48.24 
(NCH2), 109.36 (pyrrole-5-CH), 109.93 (pyrrole-4-CH), 124.95 (pyrrole-3-CH), 131.31 (q-C, 
pyrrole-2-C) and 179.28 (CHO); m/z 245 (M+, 89%),229 (17), 217 (22), 165 (60), 137 (lOO), 
123 (38), 109 (59),95 (32) and 81 (52). 
General procedure for the radical cyclisation of pyrroles. 
110) 1-(2,3-Dihydro-1H-7 -pyrrolizinyl)-l-ethanone (362) 
~=-• 5 V ~ 7a 
4 1 
3 2 
356 362 
COCH3 Q + 
~ 
363 
A solution of tri-n-butyltin hydride (0.45 ml, 1.68 mmol) and AmN (63 mg, 0.38 mmol) in 
toluene (50 ml) was added to 1-[I-(3-bromopropyl)-IH-3-pyrrolyIJ-l-ethanone 356 (0.175 g, 
0.76 mmol) in toluene (200 ml) at reflux over 5 h. The reaction solution was cooled to ambient 
temperature and the solvent was evaporated to dryness to yield a tan residue. Ethyl acetate 
(50 ml) and saturated potassium fluoride solution (50 ml) were added and the mixture agitated 
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vigorously for 2 h. The organic phase was extracted, dried (MgS04) and evaporated to dryness 
to yield a yellow residue, which was purified by column chromatography using silica gel as 
absorbent with light petroleum I dichloromethane as eluent to yield I-propyl-lH-3-pyrrolyl-l-
ethanone 363, as a yellow oil (12 mg, 10%); (Found: M+, 151.0995. C9H13NO requires M, 
151.0997); vrnax/cm-1 1651 (C=O), 1531, 1199 and 1102; OH 0.90-0.95 (3 H, t, 17.4, CH3), 
1.77-1.86 (2 H, m, 2-CH2), 2.40 (3 H, s, CaCHj), 3.82-3.88 (2 H, t, 17.1, NCH2), 6.57-6.62 (2 
H, m, pyrrole-H) and 7.27-7.28 (1 H, m, pyrrole-H); oc (62.5 MHz) 11.05 (CH3), 24.37 
(2'-CH2), 26.98 (COCHJ), 51.76 (NCH2), 109.17 (pyrrole-CH), 122.07 (pyrrole-CH) and 125.59 
(pyrrole-CH); m/z 151 (M+, 45%), 136 (100), 94 (48) and 43 (21). Further elution with light 
petroleum I dichloromethane yielded 1-(2,3-dihydro-lH-7-pyrrolizinyl)-1-ethanone 362, as a 
yellow oil (52 mg, 46%); (Found: M+, 149.0841. C9Hl1NO requires M, 149.0841); vrnax I cm-1 
1646 (C=O), 1535, 1430, 1371, 1294, 1245 and 1206; OH 2.37 (3 H, s, COCHj), 2.48-2.62 (2 H, 
m, 2-CH2), 3.07-3.13 (2 H, t, 17.5, CCH2), 3.95-4.00 (2 H, t, 17.2, NCH2), 6.55-6.56 (1 H, m, 
pyrrole-5-H) and 6.61-6.62 (1 H, s, pyrrole-6-H); Cc (62.5 MHz) 23.55 (2-CH2), 26.09 (1-CH2), 
27.08 (COCHJ), 46.63 (NCH2), 113.29 (pyrrole-5-CH) and 114.82 (pyrrole-6-CH); m/z 149 
(M+,43%), 134 (100), 106 (IS), 77 (7), 51 (7) and 43 (9). 
111) 1-(5,6,7 ,S-Tetrahydro-1-indolizinyl)-l-ethanone (364) 
• 
357 
A solution oftri-n-butyltin hydride (0.74 ml, 2.78 mmol) and AIDN (0.114 mg, 0.69 mmol) in 
toluene (50 ml) was added to 1-[1-(4-bromobutyl)-IH-3-pyrrolyl]-I-ethanone 357 (0.338 g, 
1.39 mmol) in toluene (350 ml) at reflux over 5 h. The standard work up procedure for the 
radical cyclisation of pyrroles was followed to yield a yellow residue, which was purified by 
column chromatography using silica gel as absorbent with light petroleum I dichloromethane as 
eluent to yield 1-(5,6, 7, 8-tetrahydro-1-indolizinyl)-1-ethanone 364, as a yellow oil (0.102 g, 
45%); (Found: M+, 163.0997. CIOH13NO requires M, 163.1000); Vrnax I cm-1 1647 (C=O), 
1535,1504,1319,1228 and 1206; IiH 1.78-1.88 (2 H, m, 7-CH2), 1.86-1.99 (2 H, In, 6-CH2), 
2.37 (3 H, s, COCHj), 3.07-3.12 (2 H, t, J 6.4, 8-CH2), 3.91-3.95 (2 H, t, J 5.9, NCH2), 6.43-
6.44 (1 H, d, J 3.1, pyrrole-3-H) and 6.49-6.50 (1 H, d, J 3.1, pyrrole-2-H); Oc 20.53, 23.88, 
24.66 (8-CH2), 28.46 (COCHj), 46.02 (NCH2), 110.43 (pyrrole-3-CH), 119.56 (pyrrole-2-CH), 
120.47 (pyrrole-8a-C), 136.74 (pyrrole-l-C) and 194.63 (CO); m/z 164 (M+, 17%),163 (48), 
149 (21), 148 Cl 00), 122 (22), 120 (30) and 43 (39). 
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112) 6,7,8,9-Tetrahydro-5H -pyrrolo[1,2-a ]azepine-3-carbaldehyde (366) 
QCOCH_3 ____ > 
+ 
COCH3 d N 8 B~ 
6 7 
366 
~ 
358 367 
A solution of tri-n-butyitin hydride (0.45 ml, 1.68 mmol) and AIDN (64 mg, 0.39 mmol) in 
toluene (50 ml) was added to 1-[I-(5-bromopentyl)-IH-3-pyrrolyl]-I-ethanone 358 (0.200 g, 
0.78 mmol) in toluene (300 ml) at reflux over 7 h. The standard work up procedure for the 
radical cyclisation of pyrroles was followed to yield a yellow residue, which was purified by 
column chromatography using silica gel as absorbent with light petroleum / dichloromethane as 
eluent to yield I-pentyl-l H-3-pyrrolyl-l-ethanone 367, as a yellow oil (25 mg, 18%); (Found: 
M+,179.131O.CllH17NOrequiresM,179.131O); vrnax /cm-!1652(C=O),1531,1454, 1439, 
1386,1348 and 1251; liH 0.87-0.92 (3 H, t, J 6.2, CH3), 1.23-1.36 (4 H, m, 7 and 8-CH2), 1.72-
1.84 (2 H, m, 6-CH2), 2.39 (3 H, s, COCH3), 3.84-3.90 (2 H, t, 17.1, NCH2), 6.56-6.58 (I H, m, 
pyrrole-H), 6.59-6.61 (1 H, m, pyrrole-H) and 7.25-7.27 (1 H, m, pyrro!e-H); lie 14.27 (CH3), 
22.99 (4'-CH2), 27.85 (COCH3), 29.06 (3'-CH2), 31.23 (2'-CH2), 50.75 (NCH2), 109.57· 
(pyrro!e-CH), 122.53 (pyrro!e-CH), 126.25 (pyrro!e-CH) and 193.92 (CO); m/z 179 (M+, 19%), 
164 (49), 136 (15),134 (10), 94 (36), 80 (28) and 43 (lOO). Further elution with light petroleum / 
dichloromethane yielded 6,7,8,9-tetrahydro-5H-pyrrolo[l,2-aJazepine-3-carbaldehyde 366, as a 
yellow oil (75 mg, 54%); (Found: M+, 177.1154. CIOH!SNO requires M, 177.1154); vrnax / cm-! 
1648 (C=O), 1535,1501,1438, 1347, 1260, 1251 and 1221; liH 1.55-1.85 (6 H, m, 6, 7 and 8-
CH2), 2.40 (3 H, s, COCH3), 3.28-3.32 (2 H, m, 9-CH2), 3.91-3.95 (2 H, m, NCH2), 6.38-6.39 
(I H, d, J 3.0, pyrro!e-3-H) and 6.42-6.43 (1 H, J 3.0, pyrrole-2-H); lic 22.79, 24.54, 25.87 
(COCH3), 28.02 (6-CH2), 30.42 (9-CH2), 46.02 (NCH2), 108.50 (pyrrole-3-CH), 119.86 
(pyrrole-2-CH), 120.11 (pyrrole-9a-C) and 194.80 (CO); mlz 177 (M+, 14%), 162 (26),134 
(15),55 (16) and 43 (100). 
113) 2,3-Dihydro-1H-5-pyrrolizinecarbaldehyde (368) 
n 
"t/"'CHO 
B~ 
----> t/~ 1 CHO 
4 
2 3 
359 368 
A solution oftri-n-butyltin hydride (1.21 ml, 4.56 mmol) and AIDN (0.188 g, 1.14 mmol) in 
163 
toluene (50 mI) was added to 1-(3-bromopropyl)-IH-2-pyrrolecarbaldehyde 359 (0.491 g, 
2.28 mmol) in toluene (300 m!) at reflux over 5 h. The standard work up procedure for the 
radical cyclisation of pyrroles was followed to yield a yellow residue, which was purified by 
column chromatography using silica gel as absorbent with light petroleum I dichloromethane as 
eluent to yield a 2,3-dihydro-lH-5-pyrrolizinecarbaldehyde 368, as a yellow oil, (86 mg, 28%); 
(Found: M+, 135.0683. CgH9NO requires M, 135.0684); Vrnax I cm-! 1652 (C=O), 1472 and 804; 
OH 2.24-2.60 (2 H, rn, 2-CH2), 2.82-2.88 (2 H, t, 17.4, l-CH2), 4.26-4.32 (2 H, t, J 7.2, NCH2), 
5.97-5.98 (l H, d, J3.8, pyrrole-7-H), 6.93-6.94 (1 H, d, 13.8, pyrrole-6-H) and 9.40 
(1 H, s, CHO); Oc (62.5 MHz) 24.43 (2-CH2), 27.54 (l-CH2), 47.90 (NCH2), 103.50 (pyrrole-7-
CH), 128.68 (pyrrole-6-CH) and 178.49 (CHO); miz 135 (M+, 100%), 120 (17),106 (55), 79 
(51) and 65 (16). 
114) 5,6,7,8-Tetrahydro-3-indolizinecarbaldehyde (369) 
n "~CHQ 
Br~ &2 • Bar ~.3 8 CHQ 4 7 5 
6 
360 369 
A solution of tri-n-butyltin hydride (1.15 rnl, 4.34 mmol) and AIBN (0.178 g, 1.09 mrnol) in 
toluene (50 ml) was added to 1-(4-bromobutyl)-IH-2-pyrrolecarbaldehyde 360 (0.494 g, 2.17 
mmol) in toluene (350 ml) at reflux over 5 h. The standard work up procedure for the radical 
cycIisation of pyrroles was followed to yield a yellow residue, which was purified by column 
chromatography using silica gel as absorbent with light petroleum I dichloromethane as eluent to 
yield 5,6,7,8-tetrahydro-3-indoIizinecarbaldehyde 369, as a yellow oil (0.178 g, 55%); (Found: 
M+, 149.0841. C9Hl1NO requires M, 149.0841); vmax I cm-! 1652 (C=O), 1573 and 1301; OH 
1.63-1.85 (2 H, m, 7-CH2), 1.95-1.97 (2 H, m, 6-CH2), 2.81-2.86 (2 H,t, J 6.3, 8-CH2), 4.35-
4.40 (2 H, t, J 6.1, NCH2), 5.97-5.98 (1 H, d, 13.8, pyrrole-l-H), 6.86-6.88 (1 H, d, J 3.8, 
pyrrole-2-H) and 9.41 (1 H, s, CHO); Oc 19.77 (7-CH2), 22.92 (6-CH2), 23.75 (8-CH2), 45.60 
(NCH2), 107.93 (pyrrole-l-CH), 124.01 (pyrrole-2-CH), 131.13 (pyrrole-8a-C), 133.40 (pyrrole-
3-C) and 178.17 (CHO); miz 149 (M+, 100%), 134 (18),120 (52), 108 (34),93 (24), 80 (10) and 
65 (12). 
164 
115) 6,7,8,9-Tetrahydro-5H -pyrrolo[1,2-a lazepine-3-carbaldehyde (370) 
Q-CHO 
B~ 
361 
.(}~ 
7 6 
370 
A solution of tri-n-butyltin hydride (1.28 ml, 4.84 mmol) and AIBN (0.178 g, 1.21 mmol) in 
toluene (50 ml) was added to 1-(5-bromopentyl)-IH-2-pyrrolecarbaldehyde (0.591 g, 
2.42 mmol) in toluene (400 ml) at reflux over 5 h. The standard work up procedure for the 
radical cyclisation of pyrroles was followed to yield a yellow residue, which was purified by 
column chromatography using silica gel as absorbent with light petroleum / dichloromethane as 
eluent to yield 6,7,8,9-tetrahydro-5H-pyrrolo[1,2-alazepine-3-carbaldehyde 370, as a yellow oil 
(0.157 g, 40%); (Found: M+, 163.0997. CIOH13NO requires M, 163.0994); Vrnax / cm-! 1649 
(C=O), 1573 and 1472; OH 1.62-1.83 (6 H, m, 6, 7 and 8-CH2), 2.73-2.78 (2 H, m, 9-CH2), 4.66 
(2 H, m, NCH2), 5.98-5.99 (l H, d, J 3.9, pyrrole-l-H), 6.75-6.77 (l H, d, J 3.9, pyrrole-2-H) 
and 9.39 (1 H, s, CHO); oe 27.28 (7-CH2), 28.58 (8-CH2), 29.00 (6-CH2), 31.48 (9-CH2), 46.73 
(NCH2), 109.66 (pyrrole-l-CH), 125.46 (pyrrole-2-CH), 131.77 (pyrrole-9a-C), 148.01 (pyrrole-
3-C) and 179.32 (CHO); mlz 163 (M+, 100%), 155 (6),146 (20), 135 (61), 120 (11),106 (25), 
93 (9) and 80 (9). 
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APPENDIX 
X-ray Crystallography Data for 6,7-Dihydro-SH -pyrrolo[1,2-c ]imidazole 
carbaldehyde (307) 
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Empirical Fonnula 
Fonnula Weight 
Crystal Color, Habit 
Crystal Dimensions 
Crystal System 
Lattice Type 
Cell Detennination (26 range) 
Experimental Details 
A. Crystal Data 
C7H 8N20 
136.15 
clear, block 
0.10 X 0.10 X 0.10 mm 
orthorhombic 
Primitive 
Omega Scan Peak Wideth at Half Height 
23 (56.8-68.6") 
0.39° 
Lattice Parameters 
Space Groups 
Zvalue 
Deale 
F 
000 
fl(CuKo:) 
Diffractometer 
Radiation 
Attenuator 
Take off angle 
Detector Aperture 
Crystal to Detector Distance 
Voltage, Current 
Temperature 
Scan Type 
Scan Rate 
Scan Width 
26max 
a= 9.014(3) °A 
b=6.722(4) °A 
c = 10.767 (3) ° A 
V = 652.4 (8) ° A3 
Pnma(62) 
4 
1.386 glcm3 
288.00 
7.48 cm'! 
B. Intensity Measurements 
Rigaku AFC7S 
CuKo: (A. = 1.54178 °A) 
graphite monochromate 
Ni foil (factor = 9.42) 
6.0° 
9.0 mm horizontal 
13 mm vertical 
400 mm 
OkV,OmA 
20.0°C 
0) 
16.0 o/min (in 0» (up to 4 scans) 
(1.15 + 0.35 tan 6r 
120.2 ° 
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No. of Reflections Measured 
Corrections 
Total: 610 
Lorentz-polarization 
Absorption 
(trans. factor: 0.7686 - 1.0000) 
Decay (0.09% decline) 
Secondary Extinction 
(coefficient: 5.10: 5.10448e-05) 
c. Structure Solution and Refinement 
Structure Solution 
Refinement 
Function Minimized 
p-factor 
Anomalous Dispersion 
No. Observations (I>3.00cr(1) 
No. Variables 
ReflectionlParameter 
Residual R; Rw 
Godness of fit 
Max Shift I Error in Final Cycle 
Maximum in Final Diff. Map 
Minimium peak in final Diff. Map 
Direct Methods (SIR92) 
Full-matrix least-squares 
!.ro(/FoI-lFcfP 
0.0040 
All non-hydrogen atoms 
393 
62 
6.34 
0.039 ; 0.038 
3.03 
0.23 
0.15 e- 10 A3 
-0.13 e- 1 0 A3 
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